


CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2001



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

21ST EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

RM
301.45
.A66
2001
Sept.
suppl.

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

SUBSCRIBE NOW!

Available in March 2002

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION
2002

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate *in vivo* Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

21ST EDITION

Cumulative Supplement 9

September 2001

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition.....	vi
1.4 Report of Counts for the Prescription Drug Product List	viii
1.5 Cumulative Supplement Change Legend.....	x
1.6 Change of a Therapeutic Equivalent Code for a Drug Entity.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

21ST EDITION

**CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2001**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
BAXTER PHARMACEUTICAL PRODUCTS INC (BAXTER PHARM PROD)	BAXTER HEALTHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
CIBA VISION CORP DIV NOVARTIS CO (CIBA)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
CIBA VISION OPHTHALMICS (CIBA VISION OPHTHLMC)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
DEY LABORATORIES INC (DEY)	DEY LP (DEY)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
LOTUS BIOCHEMICAL CORPORATION (LOTUS BIOCHEM)	NEW RIVER PHARMACEUTICALS INC (NEW RIVER)
MARSAM PHARMACEUTICALS INC (MARSAM PHARMS)	MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)

APPLICANT NAME CHANGES

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
OHMEDA PHARMACEUTICAL PRODUCTS DIV (OHMEDA)	BAXTER HEATHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ZENITH GOLDLINE (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder/orange/21bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:

<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.html>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2000</u>	<u>MAR 2001</u>	<u>JUN 2001</u>	<u>SEP 2001</u>
DRUG PRODUCTS LISTED	10360	10372	10155	10094
SINGLE SOURCE	2682 (25.9%)	2696 (26.0%)	2665 (26.2%)	2643 (26.2%)
MULTISOURCE	7568 (73.1%)	7566 (72.9%)	7380 (72.7%)	7341 (72.7%)
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7263 (70.0%)	7078 (69.7%)	7050 (69.8%)
NOT THERAPEUTICALLY	311 (3.0%)	303 (2.9%)	302 (3.0%)	291 (2.9%)
EQUIVALENT EXCEPTIONS ¹	110 (1.1%)	110 (1.1%)	110 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	2	6	3	4
NUMBER OF APPLICANTS	594	582	579	572

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone tablets were reviewed in the Drug Efficacy Study Implementation program. FDA published a Federal Register notice on August 15, 1974 (39 FR 29396) finding metaxalone tablets to be effective in the treatment of discomfort associated with acute, painful musculo-skeletal conditions. The Federal Register notice did not require the conduct of a bioavailability/bioequivalence study as a condition of marketing.

On March 6, 2001, URL Mutual Pharmaceutical Co. Inc submitted a citizen petition (Docket No. 01P-0117/CP1) asking FDA to reclassify the drug product metaxalone tablets from one not presenting bioequivalence problems to one that requires an in vivo demonstration of bioequivalence as a condition of approval for an ANDA. To support these assertions, the petition included results of two in vivo bioequivalence fasting studies and three separate in vitro dissolution tests. After a careful review of the data submitted by Mutual, the agency agreed that the firm has demonstrated a lack of correlation between in vitro dissolution and in vivo bioequivalence data of oral metaxalone tablets in two bioequivalence studies. The failure of both Mutual formulations to meet the 90% confidence intervals further supports the lack of in vitro/in vivo correlations.

Therefore, in accordance with our policy as enunciated in Section 1.9 of the Introduction to the 21st Edition of the Orange Book, we are providing a 60 day period in which interested parties may submit comments. The closing date for the comments will be November 30, 2001. The comments should be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. These comments should include scientific data either supporting or disagreeing with our proposal to change the therapeutic equivalence category for metaxalone tablets from a "non bioproblem" to a "bioproblem" drug.

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

@ MIKART 150MG;180MG;15MG
@ 150MG;180MG;60MG

N81095 001 OCT 26, 1990 MAY DISC
N81097 001 OCT 26, 1990 MAY DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

@ DUNHALL 325MG;50MG

N89268 001 JUL 02, 1987 FEB WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

@ ROBERTS AND HAUCK 325MG;50MG;40MG

N87628 001 OCT 01, 1986 FEB WDRP

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB ABLE 325MG;50MG;40MG
AB 500MG;50MG;40MG

N40390 001 JUL 23, 2001 JUL NEWA
N40394 001 JUL 23, 2001 JUL NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

AB WEST WARD 325MG;50MG;40MG;30MG
AB + FIORICET W/ CODEINE 325MG;50MG;40MG;30MG
AB + NOVARTIS 325MG;50MG;40MG;30MG
AB PHRENILIN WITH CAFFEINE AND CODEINE 325MG;50MG;40MG;30MG
AB AMARIN PHARMS 325MG;50MG;40MG;30MG

N75618 001 MAR 23, 2001 MAR NEWA
N20232 001 JUL 30, 1992 MAR CFTG
N74911 001 AUG 22, 2001 AUG NEWA

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

+ MIKART 712.8MG;60MG;32MG

N40316 001 APR 28, 1999 JAN CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA MALLINCKRODT 300MG;15MG
AA 300MG;30MG
AA 300MG;60MG
AA CAPITAL WITH CODEINE 325MG;30MG
@ CARNICK 325MG;30MG

N40419 001 MAY 31, 2001 MAY NEWA
N40419 002 MAY 31, 2001 MAY NEWA
N40419 003 MAY 31, 2001 MAY NEWA
N83643 001 MAY 31, 1974 FEB WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA MALLINCKRODT 500MG/15ML;7.5MG/15ML
AA + MIKART 500MG/15ML;7.5MG/15ML
+ 500MG/15ML;5MG/15ML
AA PHARM ASSOC 500MG/15ML;5MG/15ML
500MG/15ML;7.5MG/15ML

N40418 001 JUN 27, 2001 JUN NEWA
N81051 001 AUG 28, 1992 JUN CDFR
N81226 001 OCT 27, 1992 JUN CDFR
N89557 001 APR 29, 1992 JUN CDFR
N40182 001 MAR 13, 1998 JUN CDFR

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	ENDO PHARMS	400MG;5MG	N40288 001	NOV 27, 1998	SEP	CTEC
>D>		400MG;7.5MG	N40288 002	NOV 27, 1998	SEP	CTEC
>D>		400MG;10MG	N40288 003	NOV 27, 1998	SEP	CTEC
>A>	+	400MG;5MG	N40288 001	NOV 27, 1998	SEP	CTEC
>A>	+	400MG;7.5MG	N40288 002	NOV 27, 1998	SEP	CTEC
>A>	+	400MG;10MG	N40288 003	NOV 27, 1998	SEP	CTEC
	+ WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000	JUL	DISC
	@	325MG;7.5MG	N40248 001	APR 28, 2000	AUG	DISC
	+	750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA
	LORTAB					
AA	+ WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN
	NORCO					
AA	WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA
AA	+	325MG;7.5MG	N40148 003	SEP 12, 2000	JUL	CRLD

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	ABLE	650MG;100MG	N75838 001	JUL 11, 2001	JUL	NEWA
	@ HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC
	@	650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
AB	MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
AB	VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ULTRACET

+	JOHNSON RW	325MG;37.5MG
---	------------	--------------

N21123 001 AUG 15, 2001 AUG NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML
----	---------------------	-----------------

N75627 001 MAR 28, 2001 MAR NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

AB	ARMSTRONG PHARMS	0.09MG/INH
----	------------------	------------

N72273 001 AUG 14, 1996 JUN CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

VENTOLIN HFA

+	GLAXO	EQ 0.09MG BASE/INH
---	-------	--------------------

N20983 001 APR 19, 2001 APR NEWA

CAPSULE; INHALATION

VENTOLIN ROTACAPS

@ GLAXO WELLCOME

SOLUTION; INHALATION	EQ 0.2MG BASE
----------------------	---------------

N19489 001 MAY 04, 1988 JUL DISC

ACCUNEB

+

DEY

EQ 0.021% BASE

N20949 002 APR 30, 2001 APR NEWA

+

EQ 0.042% BASE

N20949 001 APR 30, 2001 APR NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001	JUN	NEWA
AN	ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA
	VENTOLIN					
@	GLAXO WELLCOME	EQ 0.083% BASE	N19773 001	APR 23, 1992	JUL	DISC
@		EQ 0.5% BASE	N19269 002	JAN 16, 1987	JUL	DISC
	TABLET; ORAL					
@	GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC
@		EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

DUONEB

+ DEY

EQ 0.083% BASE;0.017%

N20950 001 MAR 21, 2001 MAR

NEWA

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM

AB	PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN
AB	+	300MG	N16084 002	JAN 14, 1974	MAY	CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

PHARMACIA AND UPJOHN

EQ 6.25MG BASE

N21001 001 MAY 07, 2001 MAY

NEWA

+

EQ 12.5MG BASE

N21001 002 MAY 07, 2001 MAY

NEWA

ALPRAZOLAM

>D> SOLUTION; ORAL

>D> ALPRAZOLAM

>D> + ROXANE

0.5MG/5ML

N74314 001 OCT 31, 1993 SEP

DISC

>A> @

0.5MG/5ML

N74314 001 OCT 31, 1993 SEP

DISC

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ ABBOTT

EQ 250MG BASE/ML

N63265 001 NOV 30, 1994 APR

DISC

@

EQ 250MG BASE/ML

N63266 001 OCT 31, 1994 APR

DISC

@

EQ 250MG BASE/ML

N64099 001 JUN 20, 1995 MAY

DISC

@ ELKINS SINK

EQ 250MG BASE/ML

N63275 001 MAY 18, 1992 APR

DISC

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

AB	+	IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG
		AMINOCAPROIC					
AB		MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
AMIODARONE HCL

AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA
AB	TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
@ TEVA

		75MG	N85030 001	NOV 22, 1976	JUL	DISC
--	--	------	------------	--------------	-----	------

AMLEXANOX

PASTE; DENTAL
APHTHASOL

>D>	+ BLOCK DRUG	5%	N20511 001	DEC 17, 1996	SEP	CAHN
>A>	+ GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	SEP	CAHN

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

@	LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
@		500MG	N62528 002	AUG 07, 1985	FEB	WDRP
@	MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC
@		500MG	N62067 002	AUG 14, 1980	APR	DISC
@	TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC
@		500MG	N63031 001	FEB 28, 1989	APR	DISC
TRIMOX						
@	APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC
@		500MG	N63099 002	MAR 20, 1992	APR	DISC
@	WYMOX					
@	WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC
@		500MG	N62120 002	APR 28, 1978	APR	DISC
FOR SUSPENSION; ORAL						
TRIMOX						
@	APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC
@		125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC
@		250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AUGMENTIN ES-600

+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA
-------------------	---------------------------------	------------	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
ADDERALL 7.5

SHIRE LABS	1.875MG;1.875MG;1.875MG;1. 875MG	N11522 011	AUG 31, 2000	APR	CTEC
------------	-------------------------------------	------------	--------------	-----	------

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

⑧ ABBOTT 50MG/VIAL

N64141 001 DEC 23, 1996 MAY DISC

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+ INTERMUNE PHARMS 50MG/VIAL
+ 100MG/VIALN50729 001 NOV 22, 1996 FEB CAHN
N50729 002 NOV 22, 1996 FEB CAHNAMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

⑧ ELKINS SINK EQ 125MG BASE/VIAL

N62692 001 JUN 24, 1986 MAY DISC

⑧ EQ 250MG BASE/VIAL

N62692 002 JUN 24, 1986 MAY DISC

⑧ EQ 500MG BASE/VIAL

N62692 003 JUN 24, 1986 MAY DISC

⑧ EQ 1GM BASE/VIAL

N62692 004 JUN 24, 1986 MAY DISC

⑧ EQ 2GM BASE/VIAL

N62692 005 JUN 24, 1986 MAY DISC

⑧ EQ 10GM BASE/VIAL

N62692 006 JUN 24, 1986 MAY DISC

⑧ HANFORD GC EQ 125MG BASE/VIAL

N63143 001 APR 15, 1993 APR DISC

⑧ EQ 250MG BASE/VIAL

N63145 001 APR 15, 1993 APR DISC

⑧ EQ 500MG BASE/VIAL

N63146 001 APR 15, 1993 APR DISC

⑧ EQ 500MG BASE/VIAL

N63147 001 APR 15, 1993 APR DISC

⑧ EQ 1GM BASE/VIAL

N62772 001 APR 15, 1993 MAY DISC

⑧ EQ 1GM BASE/VIAL

N63139 001 APR 15, 1993 APR DISC

⑧ EQ 2GM BASE/VIAL

N63140 001 APR 15, 1993 APR DISC

⑧ EQ 2GM BASE/VIAL

N63141 001 APR 15, 1993 APR DISC

⑧ EQ 10GM BASE/VIAL

N63142 001 APR 15, 1993 APR DISC

⑧ IBI EQ 125MG BASE/VIAL

N62797 001 JUL 12, 1993 MAY DISC

⑧ EQ 2GM BASE/VIAL

N62797 002 JUL 12, 1993 MAY DISC

⑧ MARSAM EQ 10GM BASE/VIAL

N62994 001 SEP 15, 1988 JUL DISC

OMNIPEN-N

⑧ WYETH AYERST EQ 125MG BASE/VIAL

N62718 001 DEC 16, 1986 MAY DISC

⑧ EQ 250MG BASE/VIAL

N62718 002 DEC 16, 1986 MAY DISC

⑧ EQ 500MG BASE/VIAL

N62718 003 DEC 16, 1986 MAY DISC

⑧ EQ 1GM BASE/VIAL

N62718 004 DEC 16, 1986 MAY DISC

⑧ EQ 2GM BASE/VIAL

N62718 005 DEC 16, 1986 MAY DISC

TOTACILLIN-N

SMITHKLINE BEECHAM EQ 10GM BASE/VIAL

N60677 006 MAY 04, 1976 JUL CTEC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

⑧ BIOCHEMIE EQ 250MG BASE

N64082 001 AUG 29, 1995 MAY DISC

⑧ EQ 500MG BASE

N64082 002 AUG 29, 1995 MAY DISC

FOR SUSPENSION; ORAL

⑧ MYLAN EQ 125MG BASE/5ML

N61829 002 JUL 29, 1974 MAY DISC

⑧ EQ 250MG BASE/5ML

N61829 001 JUL 29, 1974 MAY DISC

TOTACILLIN

⑧ SMITHKLINE BEECHAM EQ 125MG BASE/5ML

N60666 001 MAY 07, 1970 FEB WDRP

⑧ EQ 250MG BASE/5ML

N60666 002 MAY 07, 1970 FEB WDRP

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN

@ TEVA

EQ 3.5GM BASE/BOT;1GM/BOT

N61741 001 OCT 10, 1973 MAY DISC

AR BUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

@ GENSIA AUTOMEDICS

0.05MG/ML

N20420 001 SEP 12, 1997 MAR DISC

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

@ PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML

N20227 002 MAY 23, 1997 JUL CAHN

@

10,000 UNITS/0.5ML

N20227 001 MAY 23, 1997 JUL CAHN

@ WYETH AYERST

5,000 UNITS/0.5ML

N20227 002 MAY 23, 1997 MAY DISC

@

10,000 UNITS/0.5ML

N20227 001 MAY 23, 1997 MAY DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SABEX

80MG/VIAL;0.02MG/VIAL;400

IU/VIAL;0.001MG/VIAL;5MG/V

IAL;0.14MG/VIAL;17MG/VIAL;

1MG/VIAL;1.4MG/VIAL;1.2MG/

VIAL;7 IU/VIAL;2,300

IU/VIAL;0.2MG/VIAL

N21265 001 FEB 21, 2001 FEB NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ ASTRazeneca

80MG/VIAL;0.02MG/VIAL;0.00

1MG/VIAL;5MG/VIAL;0.01MG/V

IAL;0.14MG/VIAL;17MG/VIAL;

0.2MG/VIAL;1MG/VIAL;1.4MG/

VIAL;EQ 1.2MG

BASE/VIAL;0.7MG/VIAL;7MG/V

IAL

N18920 001 SEP 21, 2000 FEB NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

>D> MVC PLUS

>D> AP + STERIS

10MG/ML;0.006MG/ML;0.5UGM/

ML;1.5MG/ML;20

IU/ML;0.04MG/ML;4MG/ML;0.4

MG/ML;0.36MG/ML;0.3MG/ML;3

30 UNITS/ML;1 IU/ML

N18439 002 AUG 08, 1985 SEP DISC

>A> @ 10MG/ML;0.006MG/ML;0.5UGM/
ML;1.5MG/ML;20
IU/ML;0.04MG/ML;4MG/ML;0.4
MG/ML;0.36MG/ML;0.3MG/ML;3
30 UNITS/ML;1 IU/ML N18439 002 AUG 08, 1985 SEP DISC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
LANORINAL
@ LANNETT 325MG;50MG;40MG N86986 002 OCT 18, 1985 JUL DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
INVAGESIC
AB GENEVA PHARMS TECH 385MG;30MG;25MG N74817 001 NOV 27, 1996 JAN CAHN
INVAGESIC FORTE
AB GENEVA PHARMS TECH 770MG;60MG;50MG N74817 002 NOV 27, 1996 JAN CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65
@ EON 389MG;32.4MG;65MG N80044 002 SEP 16, 1983 MAY DISC
PROPOXYPHENE COMPOUND-65
@ GENEVA PHARMS 389MG;32.4MG;65MG N83101 002 JUN 24, 1985 MAY DISC

ATENOLOL

TABLET; ORAL
ATENOLOL
@ GENPHARM 25MG N74126 003 AUG 26, 1998 JUL DISC
@ 50MG N74126 001 MAR 23, 1994 JUL DISC
@ 100MG N74126 002 MAR 23, 1994 JUL DISC

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR
PFIZER EQ 10MG BASE N20702 001 DEC 17, 1996 MAR CAHN
EQ 20MG BASE N20702 002 DEC 17, 1996 MAR CAHN
EQ 40MG BASE N20702 003 DEC 17, 1996 MAR CAHN
+ EQ 80MG BASE N20702 004 APR 07, 2000 MAR CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR PLASTIC SYRINGE
ABBOTT 0.05MG/ML N21146 002 JUL 09, 2001 JUL NEWA
+ 0.1MG/ML N21146 001 JUL 09, 2001 JUL NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
@ INWOOD LABS 0.025MG;2.5MG N85509 001 MAR 09, 1978 FEB WDRP
AA LANNETT 0.025MG;2.5MG N85372 001 FEB 21, 1978 AUG CMFD
@ R AND S PHARMA 0.025MG;2.5MG N85035 001 JUL 05, 1977 MAY DISC
@ WEST WARD 0.025MG;2.5MG N87765 001 MAR 15, 1982 JUL DISC

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	EON	0.025MG;2.5MG	N86173 001 AUG 28, 1981 AUG CMFD
	@ PVT FORM	0.025MG;2.5MG	N85766 001 DEC 22, 1978 MAY DISC

AURANOFIN

CAPSULE; ORAL

RIDAURA

+ PROMETHEUS LABS

3MG

N18689 001 MAY 24, 1985 MAY CAHN

AZATHIOPRINE

TABLET; ORAL

IMURAN

AB	@ PROMETHEUS LABS	25MG	N16324 002 MAR 21, 1980 MAY CAHN
+		50MG	N16324 001 MAR 20, 1968 MAY CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION; TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

@ PFIZER

EQ 1GM BASE;EQ 100MG BASE

N50762 001 DEC 18, 1998 MAY DISC

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

@ PHARMA TEK

500,000 UNITS/BOT

N61737 001 APR 26, 1973 MAY DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEO-POLYCIN

@ DOW PHARM

500 UNITS/GM;EQ 3.5MG

BASE/GM;10,000 UNITS/GM

N60647 001 APR 19, 1954 FEB WDRP

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

KING PHARMS

5MG;40MG

N18647 001 MAY 25, 1983 AUG CAHN

+

5MG;80MG

N18647 002 MAY 25, 1983 AUG CAHN

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

+ PFIZER

EQ 50MG BASE/VIAL

N16820 001 MAR 20, 1974 MAY CAHN

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

@ CLAY PARK

EQ 0.05% BASE

N74579 001 NOV 26, 1997 APR DISC

DISC; TOPICAL

DIPROSONE

@ SCHERING

EQ 0.1% BASE

N17829 001 MAY 24, 1977 AUG DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001	JUN	NEWA
AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001	MAY	NEWA
	LOTRISONE					
AB +	SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HCL

AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA
----	-----------------	--------------	------------	--------------	-----	------

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

@	SIDMAK LABS	5MG/ML	N06536 001	OCT 12, 1948	AUG	CAHN
---	-------------	--------	------------	--------------	-----	------

TABLET; ORAL

DUVOID

@	WELLSPRING PHARM	10MG	N86262 001	MAR 22, 1978	JUN	CAHN
@		25MG	N86263 001	MAR 22, 1978	JUN	CAHN
@		50MG	N85882 003	MAR 22, 1978	JUN	CAHN

URECHOLINE

@	SIDMAK LABS	5MG	N06536 003	FEB 03, 1949	AUG	CAHN
@		10MG	N06536 002	OCT 12, 1948	AUG	CAHN
@		25MG	N06536 004	OCT 12, 1948	AUG	CAHN
@		50MG	N06536 005	JUN 24, 1980	AUG	CAHN

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

+ +	ALLERGAN	0.03%	N21275 001	MAR 16, 2001	MAR	NEWA
-----	----------	-------	------------	--------------	-----	------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HEЛИДАК

+ +	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC
+ +		262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	JUN	DISC

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA
AB		10MG	N75644 002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
@		5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
@		10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA

AB	5MG;6.25MG	N75686 002 JAN 19, 2001 JAN NEWA
AB	10MG;6.25MG	N75686 003 JAN 19, 2001 JAN NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

© ALLERGAN

0.5%

N20490 001 MAR 13, 1997 APR DISC

ALPHAGAN P

+ ALLERGAN

0.15%

N21262 001 MAR 16, 2001 MAR NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL

MARCaine

AP + ABBOTT

0.75%

N18692 001 MAY 04, 1984 JUN CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

AP + RECKITT BENCKISER

EQ 0.3MG BASE/ML

N18401 001 DEC 29, 1981 JUL CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

GLAXO WELLCOME

50MG

N20358 001 OCT 04, 1996 APR CTEC

100MG

N20358 002 OCT 04, 1996 APR CTEC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

AB BRISTOL MYERS SQUIBB

5MG

N18731 001 SEP 29, 1986 MAR CFTG

AB 10MG

N18731 002 SEP 29, 1986 MAR CFTG

AB 15MG

N18731 003 APR 22, 1996 MAR NEWA

AB + 30MG

N18731 004 APR 22, 1996 JUN CFTG

BUSPIRONE HCL

AB DANBURY PHARMA

5MG

N74253 001 MAR 28, 2001 MAR NEWA

AB 10MG

N74253 002 MAR 28, 2001 MAR NEWA

AB MYLAN

15MG

N75272 003 MAR 28, 2001 MAR NEWA

AB MYLAN TECHNOLOGIES

30MG

N76008 001 JUN 28, 2001 JUN NEWA

AB PAR PHARM

7.5MG

N75467 002 MAR 28, 2001 MAR NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

+ WALLACE LABS

15MG

N00793 002 JUN 05, 1939 MAY CTEC

SODIUM BUTABARBITAL

15MG

N85849 001 AUG 21, 1978 MAY DISC

© LANNETT

30MG

N85866 001 JUL 20, 1978 MAY DISC

©

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

>D> FEMSTAT ONE

2%

N19881 001 FEB 07, 1997 SEP CTNA

>D> + KV PHARM

2%

N19881 001 FEB 07, 1997 SEP CTNA

>A> GYNAZOLE-1

2%

N19881 001 FEB 07, 1997 SEP CTNA

>A> + KV PHARM

2%

N19881 001 FEB 07, 1997 SEP CTNA

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB	MYLAN	1MG/SPRAY	N75759 001	AUG 08, 2001	AUG NEWA
	STADOL				
AB	+ BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	DEC 12, 1991	AUG CFTG

CALCITONIN, SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

@ ASTRazeneca

200 IU/ML	N73690 001	APR 14, 1995	JUN DISC
-----------	------------	--------------	----------

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

BRAINTREE

EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	APR NEWA
-------------------	------------	--------------	----------

@

EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG DISC
-------------------	------------	--------------	----------

+

EQ 169MG CALCIUM	N21160 002	APR 02, 2001	APR NEWA
------------------	------------	--------------	----------

+ @

EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG DISC
------------------	------------	--------------	----------

PHOSLO GELCAPS

+ BRAINTREE

EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG NEWA
------------------	------------	--------------	----------

CAPTOPRIL

TABLET; ORAL

Captopril

AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN CAHN
AB		25MG	N74481 002	FEB 13, 1996	JAN CAHN
AB		50MG	N74481 003	FEB 13, 1996	JAN CAHN
AB		100MG	N74481 004	FEB 13, 1996	JAN CAHN

CARBACHOL

SOLUTION; INTRAOCULAR

CARBASTAT

AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB CAHN
----	----------	-------	------------	--------------	----------

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	CARACO	100MG	N75712 001	JUL 05, 2001	JUL NEWA
	TABLET, EXTENDED RELEASE; ORAL				
	TEGRETOL-XR				
	NOVARTIS	100MG	N20234 001	MAR 25, 1996	JUL CRLD
		200MG	N20234 002	MAR 25, 1996	JUL CRLD

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

@ SCS	10MG;100MG	N74080 001	MAR 25, 1994	FEB WDRP
@	25MG;100MG	N74080 002	MAR 25, 1994	FEB WDRP
@	25MG;250MG	N74080 003	MAR 25, 1994	FEB WDRP

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA ABLE 350MG N40421 001 JUN 21, 2001 JUN NEWA

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+ MERCK RES 50MG/VIAL N21227 001 JAN 26, 2001 JAN NEWA
+ 70MG/VIAL N21227 002 JAN 26, 2001 JAN NEWACEFACLOR

CAPSULE; ORAL

CECLOR

AB CEPH INTL EQ 250MG BASE N62205 001 JUL 28, 1979 JUN CAHN
AB EQ 500MG BASE N62205 002 JUL 28, 1979 JUN CAHN

FOR SUSPENSION; ORAL

CEFACLOR

@ ZENITH GOLDLINE EQ 125MG BASE/5ML N64087 001 APR 28, 1995 MAY DISC
@ EQ 187MG BASE/5ML N64086 001 APR 28, 1995 MAY DISC
@ EQ 250MG BASE/5ML N64085 001 APR 28, 1995 MAY DISC

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

LILLY EQ 375MG BASE N50673 001 JUN 28, 1996 APR CTEC
AB + EQ 500MG BASE N50673 002 JUN 28, 1996 JAN CFTG

CEFACLOR

AB ZENITH GOLDLINE EQ 500MG BASE N65057 001 JAN 05, 2001 JAN NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL

CEFADROXIL

@ ZENITH GOLDLINE EQ 1GM BASE N62774 001 APR 08, 1987 MAY DISC

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

@ LILLY EQ 1GM BASE/VIAL N62560 001 SEP 10, 1985 MAY DISC
@ EQ 2GM BASE/VIAL N62560 002 SEP 10, 1985 MAY DISCCEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

>A> AP HIKMA EQ 500MG BASE/VIAL N65047 001 SEP 18, 2001 SEP NEWA
>A> AP EQ 1GM BASE/VIAL N65047 002 SEP 18, 2001 SEP NEWA
@ TEVA EQ 250MG BASE/VIAL N63016 001 MAR 14, 1989 APR DISC
@ EQ 500MG BASE/VIAL N63016 002 MAR 14, 1989 APR DISC
@ EQ 1GM BASE/VIAL N63016 003 MAR 14, 1989 APR DISC
KEFZOL
@ LILLY EQ 500MG BASE/VIAL N62557 001 SEP 10, 1985 MAY DISC
@ EQ 1GM BASE/VIAL N62557 002 SEP 10, 1985 MAY DISC

CEFDITOREN PIVOXIL

TABLET; ORAL
 SPECTRACEF
 + TAP PHARM 200MG N21222 001 AUG 29, 2001 AUG NEWA

CEFONICID SODIUM

INJECTABLE; INJECTION
 MONOCID
 + @ SMITHKLINE BEECHAM EQ 500MG BASE/VIAL N50579 001 MAY 23, 1984 AUG DISC
 + @ EQ 1GM BASE/VIAL N50579 002 MAY 23, 1984 AUG DISC
 @ EQ 1GM BASE/VIAL N63295 001 JUL 26, 1993 APR DISC
 @ EQ 10GM BASE/VIAL N50579 004 MAY 23, 1984 AUG DISC

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
 CEFOBID
 @ PFIZER EQ 1GM BASE/VIAL N63333 001 MAR 31, 1995 MAY DISC
 @ EQ 2GM BASE/VIAL N63333 002 MAR 31, 1995 MAY DISC

CEFORANIDE

INJECTABLE; INJECTION
 PRECEF
 @ APOTHECON 500MG/VIAL N62579 001 NOV 26, 1984 MAY DISC
 @ 1GM/VIAL N62579 002 NOV 26, 1984 MAY DISC
 @ 2GM/VIAL N62579 003 NOV 26, 1984 MAY DISC
 @ 10GM/VIAL N62579 004 NOV 26, 1984 MAY DISC
 @ 20GM/VIAL N62579 005 NOV 26, 1984 MAY DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION
 MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ MERCK EQ 20MG BASE/ML N50581 003 SEP 20, 1984 JUL DISC
 @ EQ 40MG BASE/ML N50581 004 SEP 20, 1984 JUL DISC

CEFTAZIDIME

INJECTABLE; INJECTION
 TAZICEF
 AP ABBOTT 500MG/VIAL N62662 001 MAR 06, 1986 JAN CAHN
 AP 1GM/VIAL N62662 002 MAR 06, 1986 JAN CAHN
 AP 1GM/VIAL N64032 001 OCT 31, 1993 JAN CAHN
 AP 2GM/VIAL N62662 003 MAR 06, 1986 JAN CAHN
 AP 2GM/VIAL N64032 002 OCT 31, 1993 JAN CAHN
 AP 6GM/VIAL N62662 004 MAR 06, 1986 JAN CAHN
 TAZIDIME IN PLASTIC CONTAINER
 @ LILLY 1GM/VIAL N62739 001 JUL 10, 1986 MAY DISC
 @ 2GM/VIAL N62739 002 JUL 10, 1986 MAY DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV
 CEFUROXIME
 AB AM PHARM PARTNERS EQ 750MG BASE/VIAL N65001 001 MAY 30, 2001 MAY NEWA
 AB TEVA EQ 750MG BASE/VIAL N64192 002 APR 16, 1998 MAY CDFR

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR
	KEFUROX					
AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR
	ZINACEF					
AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR
	INJECTABLE; INJECTION					
	CEFUROXIME					
AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA
	CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER					
+ B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA	
+	EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA	
	KEFUROX IN PLASTIC CONTAINER					
@ LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC	
	INJECTABLE; INTRAVENOUS					
@ LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC	

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@ STEVENS J

EQ 500MG BASE

N62869 001 MAR 17, 1988 JUL DISC

@ TEVA

EQ 500MG BASE

N62823 001 FEB 05, 1988 MAY DISC

KEFLEX

AB CEPH INTL

EQ 250MG BASE

N62118 001 MAR 27, 1978 JUN CAHN

AB

EQ 500MG BASE

N62118 002 MAR 27, 1978 JUN CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

@ BARR

EQ 125MG BASE/5ML

N62778 001 AUG 06, 1987 MAY DISC

AB RANBAXY

EQ 125MG BASE/5ML

N65081 001 JUL 27, 2001 JUL NEWA

AB

EQ 250MG BASE/5ML

N65081 002 JUL 27, 2001 JUL NEWA

KEFLEX

+ CEPH INTL

EQ 100MG BASE/ML

N62117 001 MAR 27, 1978 JUN CAHN

AB

EQ 125MG BASE/5ML

N62117 002 MAR 27, 1978 JUN CAHN

AB +

EQ 250MG BASE/5ML

N62117 003 MAR 27, 1978 JUN CAHN

TABLET; ORAL

KEFLET

@ LILLY

EQ 250MG BASE

N62745 001 DEC 01, 1986 JUL DISC

@

EQ 500MG BASE

N62745 002 DEC 01, 1986 JUL DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

KEFLIN IN PLASTIC CONTAINER

@ LILLY

EQ 1GM BASE/VIAL

N62549 001 SEP 10, 1985 APR DISC

@

EQ 2GM BASE/VIAL

N62549 002 SEP 10, 1985 APR DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHENDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ZYRTEC-D 12 HOUR

+ PFIZER

5MG;120MG

N21150 001 AUG 10, 2001 AUG NEWA

CHLORAMPHENICOL

CAPSULE; ORAL

CHLORAMPHENICOL

@ ZENITH GOLDLINE	250MG	N62247 001	APR 28, 1980	MAY	DISC
CHLOROMYCETIN					
@ PARKEDALE	50MG	N60591 001	DEC 08, 1950	MAY	DISC
@	100MG	N60591 003	DEC 08, 1950	MAY	DISC
@	250MG	N60591 002	DEC 08, 1950	MAY	DISC
MYCHEL					
+ ARMENPHARM	250MG	N60851 001	JUN 20, 1967	MAY	CRLD
SOLUTION/DROPS; OPHTHALMIC					
CHLORAMPHENICOL					
@ AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP
@ ALCON	0.5%	N62628 001	SEP 25, 1985	MAY	DISC
CHLOROPTIC					
+ ALLERGAN	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZACHEL

@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP
CHLORDIAZEPOXIDE HCL					
@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP
@ GENEVA PHARMS	5MG	N84678 001	JUN 15, 1976	JUL	DISC
@	10MG	N84041 001	JUN 15, 1976	MAY	DISC
@	25MG	N84679 002	SEP 07, 1976	MAY	DISC
@ IMPAX LABS	5MG	N86213 001	JUL 10, 1979	JUL	DISC
@	25MG	N86212 001	JUL 10, 1979	JUL	DISC
@ ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
@	25MG	N84645 001	FEB 24, 1976	JUL	DISC

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

@ TEVA	EQ 150MG BASE	N87504 001	JAN 13, 1982	JUL	DISC
--------	---------------	------------	--------------	-----	------

CHLORTHIAZIDE

TABLET; ORAL

CHLORTHIAZIDE

@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
@ CHELSEA LABS	250MG	N86795 001	AUG 15, 1983	JUL	DISC
@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

@ STERIS	10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC
TABLET; ORAL					

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
 CHLORPHENIRAMINE MALEATE
 @ GENEVA PHARMS 4MG
 AA + ICN 4MG
 @ PHARMAVITE 4MG
 @ WEST WARD 4MG

N80961 001 DEC 20, 1972 MAY DISC
 N80598 001 FEB 11, 1972 MAY CRLD
 N85104 001 FEB 11, 1977 FEB WDRP
 N83787 001 OCT 18, 1973 FEB WDRP

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

>D CAPSULE, EXTENDED RELEASE; ORAL
 >D CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL
 >D AB GENEVA PHARMS 12MG;75MG
 >A @ 12MG;75MG
 >D DRIZE
 >D BC ASCHER 12MG;75MG
 >A @ 12MG;75MG
 >D ORNADE
 >D AB + SMITHKLINE BEECHAM 12MG;75MG
 >A @ 12MG;75MG

N88940 001 JAN 26, 1989 SEP DISC
 N88940 001 JAN 26, 1989 SEP DISC
 N88359 001 FEB 13, 1986 SEP DISC
 N88359 001 FEB 13, 1986 SEP DISC
 N12152 004 JAN 06, 1981 SEP DISC
 N12152 004 JAN 06, 1981 SEP DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 CHLORPROMAZINE HCL
 @ STERIS 25MG/ML

N80365 001 FEB 13, 1974 MAY DISC

CHLORTHALIDONE

TABLET; ORAL
 CHLORTHALIDONE
 @ GENEVA PHARMS 25MG

N87380 001 MAY 01, 1981 JUL DISC

CHLORZOXAZONE

TABLET; ORAL
 CHLORZOXAZONE
 @ DANBURY PHARMA 500MG

N81019 001 JUL 29, 1991 MAY DISC

CIMETIDINE

TABLET; ORAL
 CIMETIDINE
 AB GENEVA PHARMS TECH 200MG
 AB 300MG
 AB 400MG
 AB 800MG

N74506 001 JAN 24, 1996 JAN CAHN
 N74506 002 JAN 24, 1996 JAN CAHN
 N74506 003 JAN 24, 1996 JAN CAHN
 N74506 004 JAN 24, 1996 JAN CAHN

CINOXACIN

CAPSULE; ORAL
 CINObac
 LILLY 250MG
 + 500MG
 CINOXACIN
 @ TEVA 250MG
 @ 500MG

N18067 001 JUN 13, 1980 JUL CTEC
 N18067 002 JUN 13, 1980 JUL CTEC
 N73005 001 FEB 28, 1992 JUL DISC
 N73006 001 FEB 28, 1992 JUL DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN HCL

AB + PHARMACIA AND UPJOHN	CLINDAMYCIN HCL	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG
AB RANBAXY		EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

>A> BT GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	SEP	CAHN
>D> BT TARGET RES	EQ 1% BASE	N50782 001	NOV 27, 2000	SEP	CAHN
INJECTABLE; INJECTION					
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP + PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG
CLINDAMYCIN PHOSPHATE					
@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
@ ELKINS SINK	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
@ GENESIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA
AP	EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA
AP	EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA
SOLUTION; TOPICAL					
CLINDAMYCIN PHOSPHATE					
@ COBLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1 STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA
AB2	0.05%	N75733 001	AUG 22, 2001	AUG	NEWA

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
AB +	50MG	N19906 002	DEC 29, 1989	JUN	CAHN
AB	75MG	N19906 003	DEC 29, 1989	JUN	CAHN

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB	1MG	N75423 002	APR 27, 2001	APR	NEWA
AB	2MG	N75423 003	APR 27, 2001	APR	NEWA

<u>CLONIDINE HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
DURACLON					
>A>	+ ELAN PHARMS	0.1MG/ML		N20615 001	OCT 02, 1996 SEP CAHN
>D>	+ ROXANE	0.1MG/ML		N20615 001	OCT 02, 1996 SEP CAHN
<u>CLORAZEPATE DIPOTASSIUM</u>					
CAPSULE; ORAL					
CLORAZEPATE DIPOTASSIUM					
@ ABLE		3.75MG		N71777 001	JUL 14, 1987 JAN DISC
@		7.5MG		N71778 001	JUL 14, 1987 JAN DISC
@		15MG		N71779 001	JUL 14, 1987 JAN DISC
TABLET; ORAL					
@ GENEVA PHARMS		3.75MG		N72512 001	MAY 11, 1990 JUL DISC
<u>CORTICOTROPIN</u>					
INJECTABLE; INJECTION					
H.P. ACTHAR GEL					
BC +	QUESTCOR PHARMS	40 UNITS/ML		N08372 006	FEB 06, 1956 AUG CAHN
BC +		80 UNITS/ML		N08372 008	FEB 06, 1956 AUG CAHN
<u>CORTISONE ACETATE</u>					
TABLET; ORAL					
CORTISONE ACETATE					
@ CHELSEA LABS		25MG		N85884 001	MAY 15, 1978 MAY DISC
<u>CROMOLYN SODIUM</u>					
AEROSOL, METERED; INHALATION					
INTAL					
>A>	+ AVENTIS	0.8MG/INH		N18887 001	DEC 05, 1985 SEP CAHN
>D>	+ AVENTIS PHARMS	0.8MG/INH		N18887 001	DEC 05, 1985 SEP CAHN
SOLUTION/DROPS; OPHTHALMIC					
CROMOLYN SODIUM					
AT	NOVEX	4%		N75615 001	JAN 26, 2001 JAN NEWA
<u>CYCLACILLIN</u>					
TABLET; ORAL					
CYCLACILLIN					
@ TEVA		250MG		N62895 001	AUG 04, 1988 MAY DISC
@		500MG		N62895 002	AUG 04, 1988 MAY DISC
<u>CYPROHEPTADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
CYPROHEPTADINE HCL					
@ GENEVA PHARMS		4MG		N86808 001	FEB 24, 1981 JUL DISC
<u>DACARBAZINE</u>					
INJECTABLE; INJECTION					
DACARBAZINE					
AP	BEDFORD	200MG/VIAL		N75812 001	JUN 15, 2001 JUN NEWA

DELAVIRDINE MESYLATE

TABLET; ORAL
 DESCRIPTOR
 AGOURON 100MG N20705 001 APR 04, 1997 AUG CRLD
 + 200MG N20705 002 JUL 14, 1999 AUG NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 ORETICYL 25 N12148 001 DEC 14, 1959 MAR DISC
 @ ABBOTT 0.125MG;25MG
 ORETICYL 50 N12148 003 DEC 14, 1959 MAR DISC
 @ ABBOTT 0.125MG;50MG
 ORETICYL FORTE N12148 002 DEC 14, 1959 MAR DISC
 @ ABBOTT 0.25MG;25MG

DESONIDE

OINTMENT; TOPICAL
 DESONIDE
 AB ALTANA 0.05% N75751 001 MAR 12, 2001 MAR NEWA

DEXAMETHASONE

TABLET; ORAL
 DEXAMETHASONE N80968 001 MAY 03, 1973 MAY DISC
 @ DANBURY PHARMA 0.75MG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 DEXAMETHASONE SODIUM PHOSPHATE
 @ DELL LABS EQ 4MG PHOSPHATE/ML N83161 001 JUN 06, 1978 FEB WDRP
 @ GENESIA SICOR PHARMS EQ 4MG PHOSPHATE/ML N81125 001 AUG 31, 1990 MAY DISC
 OINTMENT; OPHTHALMIC
 DECADRON
 @ MERCK EQ 0.05% PHOSPHATE N11977 001 SEP 02, 1959 MAY DISC
 MAXIDEX
 + ALCON EQ 0.05% PHOSPHATE N83342 001 OCT 23, 1973 MAY CTEC
 SOLUTION/DROPS; OTIC
 DEXAMETHASONE SODIUM PHOSPHATE
 @ AKORN EQ 0.1% PHOSPHATE N84855 001 JUN 29, 1976 FEB WDRP

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
 NEODECADRON
 + MERCK EQ 0.1% PHOSPHATE;EQ 3.5MG N50322 001 JUL 06, 1959 MAY CTEC
 BASE/ML
 NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
 @ ALCON UNIVERSAL EQ 0.1% PHOSPHATE;EQ 3.5MG N62714 001 JUL 21, 1986 MAY DISC
 BASE/ML

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
 DEXACIDIN
 AT NOVARTIS 0.1%;EQ 3.5MG

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - SEP 2001

1-20

@	BASE/GM; 10,000 UNITS/GM 0.1%; EQ 3.5MG	N62566 001 FEB 22, 1985 FEB CAHN
SUSPENSION/DROPS; OPHTHALMIC AT NOVARTIS	BASE/GM; 10,000 UNITS/GM 0.1%; EQ 3.5MG	N62566 001 FEB 22, 1985 MAY DISC
	BASE/ML; 10,000 UNITS/ML	N62544 001 OCT 29, 1984 FEB CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA BARR	5MG	N40361 001 JAN 31, 2001 JAN NEWA
AA	10MG	N40361 002 JAN 31, 2001 JAN NEWA
DEXTROSTAT		
AA + SHIRE RICHWOOD	10MG	N84051 002 MAY 29, 1975 JAN CFTG

DIAZEPAM

GEL; RECTAL

DIASTAT

+ XCEL PHARMS

2.5MG/0.5ML
5MG/ML
10MG/2ML
15MG/3ML
20MG/4MLN20648 001 JUL 29, 1997 JUL CAHN
N20648 002 JUL 29, 1997 JUL CAHN
N20648 003 JUL 29, 1997 JUL CAHN
N20648 004 JUL 29, 1997 JUL CAHN
N20648 005 JUL 29, 1997 JUL CAHNDICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB EON	50MG	N75582 001 FEB 23, 2001 FEB NEWA
--------	------	----------------------------------

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ BIOGLAN PHARMA PLC

3%

N21005 001 OCT 16, 2000 MAR CAHN

DICLOxacillin SODIUM

CAPSULE; ORAL

DYCILL

@ SMITHKLINE BEECHAM

EQ 250MG BASE

N62238 001 DEC 31, 1979 APR DISC

@

EQ 500MG BASE

N62238 002 DEC 31, 1979 APR DISC

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

@ HALSEY

10MG

N84505 001 OCT 21, 1986 MAY DISC

INJECTABLE; INJECTION

@ STERIS

10MG/ML

N80614 001 FEB 11, 1986 JUL DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

+ AVENTIS PHARMS

75MG

N12546 001 NOV 07, 1960 JUL CTEC

TEPANIL TEN-TAB

@ 3M

75MG

N17956 001 MAY 25, 1977 JUL DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

AB2 MYLAN 120MG N75124 002 MAR 18, 1998 MAR CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

@ CHELSEA LABS 50MG N85083 001 JUN 29, 1976 MAY DISC
@ NEWTRON PHARMS 25MG N86543 001 FEB 08, 1979 FEB WDRP
@ 50MG N86544 001 FEB 08, 1979 FEB WDRP

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL PRESERVATIVE FREE
@ AM PHARM PARTNERS 50MG/ML

N80586 002 JAN 10, 1973 JUL DISC

DISULFIRAM

TABLET; ORAL

ANTABUSE

ODYSSEY PHARMS 250MG N88482 001 DEC 08, 1983 JAN CAHN
+ 500MG N88483 001 DEC 08, 1983 JAN CAHN
@ SIDMAK LABS 250MG N07883 003 NOV 03, 1970 MAR CAHN
@ 500MG N07883 002 JUN 01, 1953 MAR CAHNDOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB SIDMAK LABS EQ 1MG BASE N75750 001 JUN 08, 2001 JUN NEWA
AB EQ 2MG BASE N75750 002 JUN 08, 2001 JUN NEWA
AB EQ 4MG BASE N75750 003 JUN 08, 2001 JUN NEWA
AB EQ 8MG BASE N75750 004 JUN 08, 2001 JUN NEWA
AB TEVA EQ 1MG BASE N75353 001 JAN 12, 2001 JAN NEWA
AB EQ 2MG BASE N75353 002 JAN 12, 2001 JAN NEWA
AB EQ 4MG BASE N75353 003 JAN 12, 2001 JAN NEWA
AB EQ 8MG BASE N75353 004 JAN 12, 2001 JAN NEWADOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCHEL

@ RACHELLE EQ 25MG BASE/5ML N61720 001 JUN 18, 1973 FEB WDRP

VIBRAMYCIN

+ PFIZER EQ 25MG BASE/5ML N50006 001 DEC 06, 1967 FEB CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

@ TEVA EQ 50MG BASE N62497 001 AUG 23, 1984 APR DISC
@ EQ 100MG BASE N62497 002 JUN 15, 1984 APR DISC

DOXYCYCLINE HYCLATE

@ CHELSEA LABS EQ 50MG BASE N62142 001 AUG 12, 1981 APR DISC
@ EQ 100MG BASE N62142 002 AUG 12, 1981 APR DISCAB HALSEY EQ 50MG BASE N61717 001 JUL 17, 1973 JUN CAHN
@ EQ 50MG BASE N62418 001 JAN 28, 1983 APR DISC

AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN CAHN
@		EQ 100MG BASE	N62418 002	JAN 28, 1983	APR DISC
CAPSULE, COATED PELLETS; ORAL					
@ SIDMAK LABS NJ		EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY DISC
INJECTABLE; INJECTION					
DOXYCHEL HYCLATE					
@ RACHELLE		EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB WDRP
DOXYCYCLINE					
@ BEDFORD		EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY DISC
@		EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY DISC
@ ELKINS SINK		EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR DISC
@		EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR DISC
DOXYCYCLINE HYCLATE					
@ LEDERLE		EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY DISC
@		EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY DISC
TABLET; ORAL					
DOXY-LEMMON					
@ TEVA		EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY DISC
DOXYCYCLINE HYCLATE					
AB	HALSEY	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN CAHN
AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN CAHN
@		EQ 100MG BASE	N62391 001	SEP 30, 1982	APR DISC
DOXYCYCLINE HYLATE					
@ HALSEY		EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN CAHN
PERIOSTAT					
+ COLLAGENEX PHARMS		20MG	N50783 001	FEB 02, 2001	FEB NEWA

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION					
FENTANYL CITRATE AND DROPERIDOL					
@ ASTRazeneca		2.5MG/ML;EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989	JUL DISC

DROSPIRENONE; ETHINYL ESTRADOL

TABLET; ORAL-28					
YASMIN					
+ BERLEX LABS		3MG;0.03MG	N21098 001	MAY 11, 2001	MAY NEWA

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL					
DYCLONE					
@ ASTRazeneca		0.5%	N09925 002	JUN 13, 1974	AUG DISC
@		1%	N09925 001	AUG 03, 1955	AUG DISC

ENALAPRIL MALEATE

TABLET; ORAL					
ENALAPRIL MALEATE					
AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN NEWA
AB		5MG	N75657 002	JAN 23, 2001	JAN NEWA
AB		10MG	N75657 003	JAN 23, 2001	JAN NEWA
AB		20MG	N75657 004	JAN 23, 2001	JAN NEWA
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR NEWA
AB		5MG	N75178 001	MAR 23, 2001	MAR NEWA
AB		10MG	N75178 003	MAR 23, 2001	MAR NEWA

AB

20MG

N75178 004 MAR 23, 2001 MAR NEWA

<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>			
TABLET; ORAL			
>A>	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE		
>A> AB	EON	5MG;12.5MG	N76116 001 SEP 19, 2001 SEP NEWA
>A> AB		10MG;25MG	N76116 002 SEP 19, 2001 SEP NEWA
>A> AB	MYLAN	5MG;12.5MG	N75624 001 SEP 18, 2001 SEP NEWA
>A> AB		10MG;25MG	N75624 002 SEP 18, 2001 SEP NEWA
>A> AB	TARO PHARM IND'S	5MG;12.5MG	N75788 001 SEP 18, 2001 SEP NEWA
>A> AB		10MG;25MG	N75788 002 SEP 18, 2001 SEP NEWA
>A> AB	TEVA	5MG;12.5MG	N75727 001 SEP 18, 2001 SEP NEWA
>A> AB		10MG;25MG	N75727 002 SEP 18, 2001 SEP NEWA
>A>	VASERETIC		
>D>	MERCK	5MG;12.5MG	N19221 003 JUL 12, 1995 SEP CFTG
>D> +		10MG;25MG	N19221 001 OCT 31, 1986 SEP CFTG
>A> AB	MERCK RES LABS	5MG;12.5MG	N19221 003 JUL 12, 1995 SEP CFTG
>A> AB	+	10MG;25MG	N19221 001 OCT 31, 1986 SEP CFTG

ENFLURANE

LIQUID; INHALATION			
ENFLURANE			
AN	MINRAD	99.9%	N74396 001 JUL 29, 1994 FEB CAHN

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX			
+ AVENTIS	30MG/0.3ML	N20164 001 MAR 29, 1993 APR CAHN	
+	40MG/0.4ML	N20164 002 JAN 30, 1998 APR CAHN	
+	60MG/0.6ML	N20164 003 MAR 27, 1998 APR CAHN	
+	80MG/0.8ML	N20164 004 MAR 27, 1998 APR CAHN	
+	90MG/0.6ML	N20164 006 JUN 02, 2000 APR CAHN	
+	100MG/ML	N20164 005 MAR 27, 1998 APR CAHN	
+	120MG/0.8ML	N20164 007 JUN 02, 2000 APR CAHN	
+	150MG/ML	N20164 008 JUN 02, 2000 APR CAHN	

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST			
>A> @ ASTRazeneca	0.005MG/ML;1.5%	N17751 007 AUG 30, 1976 SEP DISC	
>D> + DENTSPLY PHARM	0.005MG/ML;1.5%	N17751 007 AUG 30, 1976 SEP DISC	
+ +	0.005MG/ML;1%	N17751 006 AUG 30, 1976 APR CAHN	
+ +	0.005MG/ML;1.5%	N17751 007 AUG 30, 1976 APR CAHN	
>A> +	0.005MG/ML;1.5%	N21384 001 AUG 30, 1976 SEP NEWA	

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE			
>A> @ ASTRazeneca	0.005MG/ML;4%	N14763 008 JUN 29, 1970 SEP DISC	
>D> + DENTSPLY PHARM	0.005MG/ML;4%	N14763 008 JUN 29, 1970 SEP DISC	
>A> +	0.005MG/ML;4%	N21383 001 JUN 29, 1970 SEP NEWA	

EPINEPHRINE; ETIDOCaine HYDROCHLORIDE

INJECTABLE; INJECTION
DURANEST
© DENTSPLY PHARM 0.005MG/ML;0.5%

N17751 004 AUG 30, 1976 APR CAHN

EPINEPHRINE; LIDOCaine HYDROCHLORIDE

INJECTABLE; AN,CNBLK EXTRADURAL, AN,PERIPHERAL NBLK
XYLOCAINE W/ EPINEPHRINE

>A> DENTSPLY PHARM 0.02MG/ML;2%
>A> INJECTABLE; AN,PERIPHERAL NBLK
+ DENTSPLY PHARM 0.01MG/ML;2%
INJECTABLE; INJECTION
LIDOCaine HCL W/ EPINEPHRINE
© INTL MEDICATION 0.01MG/ML;1%
© STERIS 0.01MG/ML;1%
© 0.01MG/ML;2%
LIDOCATON
© PHARMATON 0.02MG/ML;2%
XYLOCAINE W/ EPINEPHRINE
>A> © ASTRazeneca 0.01MG/ML;2%
>D> AP + DENTSPLY PHARM 0.01MG/ML;2%

N21381 002 NOV 19, 1948 SEP NEWA
N21381 001 NOV 19, 1948 SEP NEWA
N86402 001 FEB 04, 1980 JUL DISC
N80377 003 FEB 20, 1974 JUL DISC
N80377 004 FEB 20, 1974 JUL DISC
N84728 001 AUG 17, 1983 FEB WDRP
N06488 003 NOV 19, 1948 SEP DISC
N06488 003 NOV 19, 1948 SEP DISC

ERGOCALCIFEROL

CAPSULE; ORAL
VITAMIN D
© IMPAX LABS 50,000 IU

N80951 001 JUL 13, 1973 FEB DISC

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES
© DANBURY PHARMA 1MG
TABLET; SUBLINGUAL
© DANBURY PHARMA 1MG

N87244 001 AUG 16, 1982 JUL DISC
N87183 001 APR 16, 1981 JUL DISC

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN
© CLAY PARK 2%
AT TABLET, DELAYED RELEASE; ORAL
E-BASE 2%
© BARR 333MG
ILOTYCIN
© DISTA 250MG

N63038 001 JAN 11, 1991 APR DISC
N63038 001 JAN 11, 1991 MAY CMFD
N63028 001 MAY 15, 1990 APR DISC
N61910 001 FEB 27, 1975 MAY DISC

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
+ BARR EQ 250MG BASE
© DANBURY PHARMA EQ 250MG BASE
ILOSONE
© LILLY EQ 125MG BASE

N62162 002 JUN 15, 1981 MAY CTEC
N62087 001 JUN 14, 1979 APR DISC
N61897 001 JAN 06, 1975 MAY DISC

EQ 250MG BASE	N61897 002	JAN 06, 1975	MAY	DISC
FOR SUSPENSION; ORAL				
EQ 125MG BASE/5ML	N61893 001	JAN 06, 1975	MAY	DISC
EQ DISTA				
SUSPENSION/DROPS; ORAL				
EQ 100MG BASE/ML	N61894 003	JAN 07, 1975	APR	DISC
EQ LILLY				
TABLET; ORAL				
EQ 500MG BASE	N61896 001	JAN 03, 1975	APR	DISC
EQ LILLY				
TABLET, CHEWABLE; ORAL				
EQ 125MG BASE	N61895 001	JAN 03, 1975	MAY	DISC
EQ DISTA				
EQ 250MG BASE	N61895 002	JAN 03, 1975	MAY	DISC
EQ				

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL				
ERYTHROMYCIN ETHYLSUCCINATE				
EQ BARR	EQ 400MG BASE	N62256 001	APR 28, 1980	MAY DISC

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION				
ILOTYCIN GLUCEPTATE				
EQ DISTA	EQ 250MG BASE/VIAL	N50370 001	JUN 23, 1964	JUL DISC
EQ	EQ 500MG BASE/VIAL	N50370 002	JUN 23, 1964	JUL DISC
EQ	EQ 1GM BASE/VIAL	N50370 003	JUN 23, 1964	JUL DISC

ERYTHROMYCIN STEARATE

TABLET; ORAL				
ERYTHROMYCIN STEARATE				
EQ BARR	EQ 500MG BASE	N63179 001	MAY 15, 1990	MAY DISC
EQ ZENITH GOLDLINE	EQ 250MG BASE	N61461 001	SEP 04, 1971	MAY DISC
EQ	EQ 500MG BASE	N61461 002	APR 11, 1980	MAY DISC
WYAMYCIN S				
EQ WYETH AYERST	EQ 250MG BASE	N61675 001	OCT 06, 1972	APR DISC
EQ	EQ 500MG BASE	N61675 002	JUL 13, 1973	APR DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL				
NEXUM				
EQ 20MG BASE	N21153 001	FEB 20, 2001	FEB	NEWA
EQ 40MG BASE	N21153 002	FEB 20, 2001	FEB	NEWA
+				
ASTRAZENECA				
+				

ESTRADIOL VALERATE

INJECTABLE; INJECTION				
DELESTROGEN				
EQ KING PHARMS	10MG/ML	N09402 002	AUG 18, 1962	AUG CAHN
AO EQ	20MG/ML	N09402 004	JUN 23, 1961	AUG CAHN
AO EQ	40MG/ML	N09402 003	FEB 24, 1961	AUG CAHN

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL				
COMBIPATCH				
NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998	MAR CAHN
+	0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998	MAR CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPRO

+ WYETH AYERST

0.625MG;0.625MG;2.5MG;2.5M

G

N20527 001 NOV 17, 1995 JAN CTNA

+

0.625MG;0.625MG;5MG;5MG

N20527 003 JAN 09, 1998 JAN CTNA

PREMPRO (PREMARIN; CYCRIN)

+ WYETH AYERST

0.625MG;0.625MG;2.5MG;2.5M

G

N20303 001 DEC 30, 1994 JAN CTNA

ESTROGENS, ESTERIFIED

TABLET; ORAL

ESTRATAB

@ SOLVAY

0.3MG

N86715 001 APR 08, 1981 JUL DISC

@

0.625MG

N83209 001 JUN 17, 1977 JUL DISC

MENEST

+ MONARCH PHARMS

0.3MG

N84951 001 SEP 28, 1977 JUL CTEC

0.625MG

N84948 001 SEP 28, 1977 JUL CTEC

ESTROPIPATE

TABLET; ORAL

ORTHO-EST

AB WOMEN FIRST HLTHCARE

0.75MG

N89567 001 FEB 27, 1991 JAN CAHN

AB

1.5MG

N89582 001 JUL 17, 1991 JAN CAHN

ETHINYLEDIESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB + WYETH AYERST

0.02MG;0.1MG

N20683 001 MAR 27, 1997 APR CTEC

AVIANE-21

AB DURAMED

0.02MG;0.1MG

N75796 002 APR 30, 2001 APR NEWA

TABLET; ORAL-21, ORAL-28

ENPRESSE-21

AB DURAMED

0.03MG,0.04MG,0.03MG;0.05M

G,0.075MG,0.125MG

N75809 001 JUL 16, 2001 JUL NEWA

TABLET; ORAL-28

ALESSE

AB WYETH AYERST

0.02MG;0.1MG

N20683 002 MAR 27, 1997 APR CTEC

AVIANE-28

AB DURAMED

0.02MG;0.1MG

N75796 001 APR 30, 2001 APR NEWA

ENPRESSE-28

AB DURAMED

0.03MG,0.04MG,0.03MG;0.05M

G,0.075MG,0.125MG

N75809 002 JUL 16, 2001 JUL NEWA

ETHINYLEDIESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

AB + PARKE DAVIS

0.03MG;1.5MG

N17355 001 APR 30, 1973 FEB CFTG

LOESTRIN FE 1/20

AB + PARKE DAVIS

0.02MG;1MG

N17354 001 APR 30, 1973 FEB CFTG

MICROGESTIN FE 1.5/30

AB WATSON LABS

0.03MG;1.5MG

N75548 001 FEB 05, 2001 FEB NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

MICROGESTIN FE 1/20

AB WATSON LABS 0.02MG;1MG N75647 001 FEB 05, 2001 FEB NEWA

ETHOSUXIMIDE

SYRUP; ORAL

ZARONTIN

AA + PARKE DAVIS 250MG/5ML N80258 001 FEB 13, 1974 JAN CRLD

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@ DENTSPLY PHARM

0.5%

N17751 003 AUG 30, 1976 APR CAHN

+

1%

N17751 005 AUG 30, 1976 APR CAHN

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB TEVA 400MG N75665 003 FEB 05, 2001 FEB NEWA

ETOPOSIDE

CAPSULE; ORAL

>A> ETOPOSIDE

>A> AB GENPHARM 50MG N75635 001 SEP 19, 2001 SEP NEWA

VEPESID

>D> + BRISTOL 50MG N19557 001 DEC 30, 1986 SEP CFTG

>A> AB + 50MG N19557 001 DEC 30, 1986 SEP CFTG

INJECTABLE; INJECTION

ETOPOSIDE

>D> AP PIERRE FABRE 20MG/ML N74813 001 JUL 09, 1997 SEP WDAG

>A> @ 20MG/ML N74813 001 JUL 09, 1997 SEP WDAG

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

@ BRISTOL MYERS SQUIBB

EQ 500MG BASE/VIAL

N20906 001 FEB 27, 1998 JUN DISC

@

EQ 1GM BASE/VIAL

N20906 002 FEB 27, 1998 JUN NEWA

FAMCICLOVIR

TABLET; ORAL

FAMVIR

NOVARTIS

125MG

N20363 003 DEC 11, 1995 JAN CAHN

250MG

N20363 001 APR 26, 1996 JAN CAHN

+

500MG

N20363 002 JUN 29, 1994 JAN CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP AM PHARM PARTNERS 10MG/ML N75709 001 APR 16, 2001 APR NEWA

AP APOTHECON 10MG/ML N75707 001 APR 16, 2001 APR NEWA

@

10MG/ML N75707 001 APR 16, 2001 MAY DISC

AP BEDFORD 10MG/ML N75651 001 APR 16, 2001 APR NEWA

AP		10MG/ML	N75684 001	APR 16, 2001	APR	NEWA	
AP	ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA	
AP	FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA	
FAMOTIDINE PRESERVATIVE FREE							
AP	AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA	
AP	APOTHECON	10MG/ML	N75708 001	APR 16, 2001	APR	NEWA	
AB		10MG/ML	N75708 001	APR 16, 2001	MAY	DISC	
AP	BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA	
AP	BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA	
AP	ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA	
AP	FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA	
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER							
AP	BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001	MAY	NEWA	
PEPCID							
AP +	MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG	
AP +	MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG	
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER							
AP +	MERCK	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG	
TABLET; ORAL							
FAMOTIDINE							
AB	CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75805 002	APR 16, 2001	APR	NEWA	
AB	DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA	
AB		40MG	N75062 001	APR 16, 2001	APR	NEWA	
AB	DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75718 002	APR 16, 2001	APR	NEWA	
AB	EON	20MG	N75793 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75793 002	APR 16, 2001	APR	NEWA	
AB	GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75302 002	APR 16, 2001	APR	NEWA	
AB	GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA	
AB		40MG	N75457 002	APR 18, 2001	APR	NEWA	
AB	INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA	
AB		40MG	N75607 002	MAY 10, 2001	MAY	NEWA	
AB	MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75704 002	APR 16, 2001	APR	NEWA	
>A>	AB	PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001	SEP	NEWA
>A>	AB		40MG	N75650 002	SEP 14, 2001	SEP	NEWA
AB	TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75311 002	APR 16, 2001	APR	NEWA	
AB	TORPHARM	20MG	N75611 001	JUL 23, 2001	JUL	NEWA	
AB		40MG	N75611 002	JUL 23, 2001	JUL	NEWA	
AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75786 002	APR 16, 2001	APR	NEWA	
AB	ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA	
AB		40MG	N75511 002	APR 16, 2001	APR	NEWA	
PEPCID							
AB	MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG	
AB +		40MG	N19462 002	OCT 15, 1986	APR	CFTG	

APR NEWA
 APR NEWA
 APR NEWA
FENOFIBRATE
 TABLET; ORAL
 TRICOR
 ABBOTT 54MG N21203 001 SEP 04, 2001 AUG NEWA
 160MG N21203 003 SEP 04, 2001 SEP NEWA
 APR NEWA >A> +
 MAY DISC
 APR NEWA
FENTANYL
 FILM, EXTENDED RELEASE; TRANSDERMAL
 DURAGESIC
 ALZA 1.2MG/24HR N19813 003 AUG 07, 1990 MAY CTEC
 1.8MG/24HR N19813 002 AUG 07, 1990 MAY CTEC
 2.4MG/24HR N19813 001 AUG 07, 1990 MAY CTEC
 MAY NEWA
 APR CFTG
FENTANYL CITRATE
 INJECTABLE; INJECTION
 FENTANYL CITRATE PRESERVATIVE FREE
 @ MARSAM EQ 0.05MG BASE/ML N74917 001 FEB 03, 1998 JAN DISC
 MAY CFTG
FLECAINIDE ACETATE
 TABLET; ORAL
 FLECAINIDE ACETATE
 AB ALPHAPHARM 50MG N75442 001 JUL 31, 2001 JUL NEWA
 AB 100MG N75442 002 JUL 31, 2001 JUL NEWA
 AB 150MG N75442 003 JUL 31, 2001 JUL NEWA
 APR NEWA
 TAMBOCOR 50MG N18830 004 AUG 23, 1988 JUL CFTG
 APR NEWA AB 100MG N18830 001 OCT 31, 1985 JUL CFTG
 APR NEWA AB 150MG N18830 003 JUN 03, 1988 JUL CFTG
 APR NEWA AB +
 APR NEWA
FLOXURIDINE
 INJECTABLE; INJECTION
 FLOXURIDINE
 AP AM PHARM PARTNERS 500MG/VIAL N75837 001 FEB 22, 2001 FEB NEWA
 MAY NEWA
FLUDEOXYGLUCOSE, F-18
 INJECTABLE; INJECTION
 FLUDEOXYGLUCOSE F 18
 >A> + DOWNSTATE CLINCL 4-90mCi/ML N20306 002 SEP 25, 2001 SEP NEWA
 APR NEWA
FLUOCINOLONE ACETONIDE
 CREAM; TOPICAL
 FLUOCINOLONE ACETONIDE
 @ CLAY PARK 0.01% N86810 001 MAR 04, 1982 APR DISC
 APR NEWA @ 0.025% N86811 001 MAR 04, 1982 APR DISC
 APR NEWA
FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
 CREAM; TOPICAL
 NEO-SYNALAR
 @ MEDICIS 0.025%;EQ 3.5MG BASE/GM N60700 001 JUN 11, 1963 MAY DISC
 APR CFTG
 APR CFTG

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB NOVARTIS 0.1% N70185 001 FEB 27, 1986 FEB CAHN

FLUOROURACIL

CREAM; TOPICAL
CARAC
+ DERMIK LABS

0.5%

N20985 001 OCT 27, 2000 MAY CTNA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE

AB BARR EQ 20MG BASE N74803 001 AUG 02, 2001 AUG NEWA
AB DR REDDYS LABS LTD EQ 40MG BASE N75465 003 AUG 02, 2001 AUG NEWA
AB GENEVA PHARMS EQ 10MG BASE N75049 001 AUG 02, 2001 AUG NEWA

PROZAC

AB LILLY EQ 10MG BASE N18936 006 DEC 23, 1992 AUG CFTG
AB EQ 20MG BASE N18936 001 DEC 29, 1987 AUG CFTG
AB + EQ 40MG BASE N18936 003 JUN 15, 1999 AUG CFTG

CAPSULE, DELAYED REL PELLETS; ORAL

PROZAC WEEKLY

+ LILLY EQ 90MG BASE

SOLUTION; ORAL

FLUOXETINE

AT TEVA EQ 20MG BASE/5ML N75506 001 AUG 02, 2001 AUG NEWA
PROZAC

AT + LILLY TABLET; ORAL EQ 20MG BASE/5ML N20101 001 APR 24, 1991 AUG CFTG
FLUOXETINE HCL

AB ALPHAPHARM EQ 10MG BASE N75755 001 AUG 02, 2001 AUG NEWA
+ EQ 20MG BASE N75755 002 AUG 02, 2001 AUG NEWA

PROZAC

AB + LILLY EQ 10MG BASE N20974 001 MAR 09, 1999 AUG CFTG

FLUPHENAZINE DECANOATE

INJECTABLE; IM-SC

FLUPHENAZINE DECANOATE

AO APOTEX 25MG/ML N75918 001 AUG 17, 2001 AUG NEWA

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

@ CHELSEA LABS 15MG N72368 001 MAR 30, 1989 JUL DISC
@ PUREPAC PHARM 15MG N71927 001 SEP 09, 1987 JUL DISC
@ 30MG N71551 001 SEP 09, 1987 JUL DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

AB CARACO 50MG N75058 001 APR 27, 2001 APR NEWA
AB 100MG N75058 002 APR 27, 2001 APR NEWA

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

>A>							
>D>	+	SCHERING	125MG	N18554	001	JAN 27, 1989	SEP CFTG
>A>	AB	+	125MG	N18554	001	JAN 27, 1989	SEP CFTG
>A>		FLUTAMIDE					
>A>	AB	BARR	125MG	N75820	001	SEP 18, 2001	SEP NEWA
>A>	AB	EON	125MG	N75818	001	SEP 18, 2001	SEP NEWA
>A>	AB	TEVA	125MG	N75298	001	SEP 18, 2001	SEP NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897	001	JAN 25, 2001	JAN	NEWA
AB		50MG	N75897	002	JAN 25, 2001	JAN	NEWA
AB		100MG	N75897	003	JAN 25, 2001	JAN	NEWA
AB	INVAMED	25MG	N75887	001	JAN 05, 2001	JAN	NEWA
AB		50MG	N75887	002	JAN 05, 2001	JAN	NEWA
AB		100MG	N75887	003	JAN 05, 2001	JAN	NEWA
AB	SYNTTHON PHARMS	25MG	N75899	001	JAN 17, 2001	JAN	NEWA
AB		50MG	N75899	002	JAN 17, 2001	JAN	NEWA
AB		100MG	N75899	003	JAN 17, 2001	JAN	NEWA
AB	TORPHARM	25MG	N75902	001	MAY 07, 2001	MAY	NEWA
AB		50MG	N75902	002	MAY 07, 2001	MAY	NEWA
AB		100MG	N75902	003	MAY 07, 2001	MAY	NEWA
AB	WATSON LABS	25MG	N75894	001	APR 18, 2001	APR	NEWA
AB		50MG	N75894	002	APR 18, 2001	APR	NEWA
AB		100MG	N75894	003	APR 18, 2001	APR	NEWA
AB	ZENITH GOLDLINE	25MG	N75898	001	MAR 12, 2001	MAR	NEWA
AB		50MG	N75898	002	MAR 12, 2001	MAR	NEWA
AB		100MG	N75898	003	MAR 12, 2001	MAR	NEWA

FOLLITROPIN ALFA

INJECTABLE; INJECTION

GONAL-F

+ SERONO

1,200 IU/VIAL

N20378 004 FEB 28, 2001 AUG NEWA

FORMOTEROL FUMARATE

CAPSULE; INHALATION

FORADIL

+ NOVARTIS

0.012MG/INH

N20831 001 FEB 16, 2001 FEB NEWA

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

PFIZER

100MG

N20235 001 DEC 30, 1993 MAR CAHN

300MG

N20235 002 DEC 30, 1993 MAR CAHN

400MG

N20235 003 DEC 30, 1993 MAR CAHN

+

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL

REMINYL

+ JANSSEN

4MG/ML

TABLET; ORAL

JANSSEN

N21224 001 JUN 22, 2001 JUN NEWA

EQ 4MG BASE

N21169 001 FEB 28, 2001 FEB NEWA

EQ 8MG BASE

N21169 002 FEB 28, 2001 FEB NEWA

EQ 12MG BASE

N21169 003 FEB 28, 2001 FEB NEWA

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB GENEVA PHARMS TECH

600MG

N74615 001 SEP 29, 1995 JAN CAHN

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

@ BAUSCH AND LOMB

EQ 0.1% BASE

N64056 001 APR 29, 1994 MAY DISC

INJECTABLE; INJECTION

@ GENSIA SICOR PHARMS

EQ 10MG BASE/ML

N63149 001 NOV 21, 1991 MAY DISC

@

EQ 40MG BASE/ML

N63106 002 NOV 21, 1991 APR DISC

@ STERIS

EQ 10MG BASE/ML

N62318 002 AUG 20, 1981 APR DISC

@

EQ 40MG BASE/ML

N62318 001 JUN 02, 1981 APR DISC

U-GENCIN

EQ 10MG BASE/ML

N62248 001 MAY 02, 1980 FEB WDRP

@

EQ 40MG BASE/ML

N62248 002 MAY 02, 1980 FEB WDRP

INJECTABLE; INTRATHECAL

GARAMYCIN

EQ 2MG BASE/ML

N50505 001 OCT 01, 1979 APR DISC

@ SCHERING

OINTMENT; OPHTHALMIC

GENTACIDIN

AT NOVARTIS

EQ 0.3% BASE

N62501 001 JUL 26, 1984 FEB CAHN

@

EQ 0.3% BASE

N62501 001 JUL 26, 1984 MAY DISC

>D> GARAMYCIN

EQ 0.1% BASE

N60463 001 MAR 15, 1966 SEP DISC

>D> AT + SCHERING

EQ 0.1% BASE

N60463 001 MAR 15, 1966 SEP DISC

>A> @

EQ 0.1% BASE

N62351 001 FEB 18, 1982 SEP CTEC

GENTAMICIN

EQ 0.1% BASE

N62351 001 FEB 18, 1982 SEP CTEC

>D> AT CLAY PARK

EQ 0.1% BASE

N64054 001 APR 29, 1994 MAY DISC

>A> AT +

EQ 0.1% BASE

N62351 001 FEB 18, 1982 SEP CTEC

GENTAMICIN SULFATE

EQ 0.1% BASE

N64054 001 APR 29, 1994 MAY DISC

@ BAUSCH AND LOMB

EQ 0.1% BASE

N64054 001 APR 29, 1994 MAY DISC

SOLUTION/DROPS; OPHTHALMIC

EQ 0.1% BASE

N64054 001 APR 29, 1994 MAY DISC

GENTACIDIN

AT NOVARTIS

EQ 0.3% BASE

N62480 001 MAR 30, 1984 FEB CAHN

GENTAMICIN SULFATE

EQ 0.3% BASE

N62523 001 NOV 25, 1985 APR DISC

@ ALCON UNIVERSAL

EQ 0.3% BASE

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB GENEVA PHARMS TECH

5MG

N74542 001 JUN 20, 1995 JAN CAHN

AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN
AB	TORPHARM	5MG	N75795 001	JUN 13, 2001	JUN	NEWA
AB		10MG	N75795 002	JUN 13, 2001	JUN	NEWA

GLUTETHIMIDE

TABLET; ORAL

GLUTETHIMIDE

>D>	@ CELLTECH PHARMS	500MG	N85171 001	DEC 22, 1976	SEP	DISC
>A>	@	500MG	N85171 001	DEC 22, 1976	SEP	DISC

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

@ GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC
-----------------------	----------	------------	--------------	-----	------

TABLET; ORAL

ROBINUL

+ FIRST HORIZON	1MG	N12827 001	AUG 11, 1961	AUG	CAHN
ROBINUL FORTE					
+ FIRST HORIZON	2MG	N12827 002	AUG 11, 1961	AUG	CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

KYTRIL

+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	NEWA
---------	------------------	------------	--------------	-----	------

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

+ J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
@ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRISACTIN ULTRA

@ WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
@	250MG	N62178 002	MAR 13, 1980	APR	DISC
ULTRAGRIS-165					
@ SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC
ULTRAGRIS-330					
@ SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@ DANBURY PHARMA	1MG	N70982 001	MAR 06, 1987	JUL	DISC
@ ROXANE	0.5MG	N71128 001	FEB 17, 1987	AUG	DISC
@	1MG	N71129 001	FEB 17, 1987	AUG	DISC
@	2MG	N71130 001	FEB 17, 1987	AUG	DISC
@	5MG	N71131 001	FEB 17, 1987	AUG	DISC
@	20MG	N71133 001	MAY 12, 1987	AUG	DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL		
HALOPERIDOL INTENSOL		
© ROXANE	EQ 2MG BASE/ML	N72045 001 APR 12, 1988 AUG DISC
INJECTABLE; INJECTION		
HALOPERIDOL		
AP AM PHARM PARTNERS	EQ 5MG BASE/ML	
AP BEDFORD	EQ 5MG BASE/ML	N75689 001 MAR 09, 2001 JUN CTNA
AP GENESIA SICOR PHARMS	EQ 5MG BASE/ML	N75858 001 JUN 18, 2001 JUN NEWA
HALOPERIDOL LACTATE		N76035 001 AUG 29, 2001 AUG NEWA
AP AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001 MAR 09, 2001 MAR NEWA

HALOTHANE

LIQUID; INHALATION		
HALOTHANE		
© BH	99.99%	N84977 001 JUL 14, 1976 JAN DISC

HEPARIN SODIUM

INJECTABLE; INJECTION		
HEPARIN SODIUM		
© ABBOTT	10,000 UNITS/ML	N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE		
© PHARMA SERVE NY	1,000 UNITS/ML	N86129 001 FEB 22, 1980 FEB WDRP

HOMATROPINE METHYLBROMIDE

TABLET; ORAL		
HOMAPIN-10		
© MISSION PHARMA	10MG	N86308 001 APR 11, 1979 JUL DISC
HOMAPIN-5		
© MISSION PHARMA	5MG	N86309 001 APR 11, 1979 JUL DISC

HYALURONIDASE

INJECTABLE; INJECTION		
WYDASE		
© WYETH AYERST	150 UNITS/ML	N06343 002 MAR 22, 1950 JUL DISC
©	150 UNITS/VIAL	N06343 006 MAR 06, 1951 JUL DISC
©	1,500 UNITS/VIAL	N06343 005 MAR 06, 1951 JUL DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		
HYDRALAZINE HCL		
AP AM PHARM PARTNERS	20MG/ML	N40388 001 MAR 13, 2001 MAR NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLORTHIAZIDE; RESERPINE

TABLET; ORAL		
RESERPINE, HYDRALAZINE HCL AND HYDROCHLORTHIAZIDE		
© DANBURY PHARMA	25MG;15MG;0.1MG	N85549 001 SEP 29, 1977 MAY DISC

HYDROCHLORTHIAZIDE

TABLET; ORAL		
HYDROCHLORTHIAZIDE		
© DANBURY PHARMA	50MG	N83232 001 JAN 24, 1975 MAY DISC

© HALSEY	25MG	N83972 001	OCT 03, 1974	MAY	DISC
©	50MG	N83972 002	OCT 03, 1974	MAY	DISC
© IMPAX LABS	25MG	N84029 001	JUL 05, 1977	MAY	DISC
©	50MG	N83607 002	JUN 06, 1977	MAY	DISC
© PHARMERAL	25MG	N84325 001	JUN 24, 1976	MAY	DISC
©	50MG	N84324 001	JUN 24, 1976	MAY	DISC
© PVT FORM	50MG	N86597 001	OCT 11, 1978	JUL	DISC
© WEST WARD	50MG	N84878 001	JAN 31, 1977	MAY	DISC

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRO-RESERP

© ABC HOLDING	50MG;0.125MG	N84714 002	JUN 29, 1982	MAY	DISC
HYDROCHLOROTHIAZIDE W/ RESERPINE					
© DANBURY PHARMA	25MG;0.125MG	N84466 001	JAN 07, 1977	MAY	DISC
©	50MG;0.125MG	N84467 001	JAN 07, 1977	MAY	DISC
RESERPINE AND HYDROCHLOROTHIAZIDE-50					
© WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP

HYDROCORTISONE

CREAM; TOPICAL

>D>	DERMACORT					
>D> AT	MONARCH PHARMS	1%	N83011 002	APR 26, 1973	SEP	WDAG
>A>	©	1%	N83011 002	APR 26, 1973	SEP	WDAG
HC (HYDROCORTISONE)						
© C AND M PHARMA	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP	
©	1%	N80482 004	MAR 20, 1973	FEB	WDRP	
HYDROCORTISONE						
© TOPIDERM	1%	N89273 001	FEB 17, 1989	FEB	WDRP	
NUTRACORT						
© HEALTHPOINT	1%	N80442 003	APR 04, 1972	JUL	DISC	
PROCTOCORT						
© MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC	
LOTION; TOPICAL						
ACTICORT						
© BAKER NORTON	1%	N86535 001	FEB 04, 1981	JUL	DISC	
BETA-HC						
© BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP	
GLYCORT						
© HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP	
HYDROCORTISONE						
© MERICON	0.5%	N85282 001	JUN 05, 1978	MAY	DISC	
©	1%	N85282 002	FEB 26, 1987	MAY	DISC	
OINTMENT; TOPICAL						
HC (HYDROCORTISONE)						
© C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP	
POWDER; FOR RX COMPOUNDING						
H-CORT						
© TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP	
SOLUTION; TOPICAL						
TEXACORT						
AT + SIRIUS LABS	1%	N80425 001	DEC 22, 1971	JUN	CAHN	
+	2.5%	N81271 001	APR 17, 1992	MAY	CAHN	

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - SEP 2001

1-36

HYDROCORTISONE

TABLET; ORAL

TEXACORT

TABLET; ORAL

HYDROCORTISONE

© LANNETT

20MG

N85070 001 MAY 07, 1976 MAY DISC

HYDROCORTISONE ACETATE

CREAM; TOPICAL

MICORT-HC

FERNDALE LABS

2.5%

N40396 001 FEB 27, 2001 FEB NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF

© PHARMACIA AND UPJOHN

1%;EQ 3.5MG BASE/GM

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

© AKORN

1.5%;EQ 3.5MG BASE/ML

N60751 002 MAY 18, 1965 APR DISC

N60188 001 OCT 26, 1968 FEB WDRP

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB

ALTANA

0.2%

N75085 001 JUL 31, 2001 JUL NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEO-OTOSOL-HC

© ALCON

1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

N62423 001 AUG 25, 1983 APR DISC

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

+ MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

N50169 001 DEC 18, 1964 MAY CTEC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

© ALCON UNIVERSAL

1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

N62874 001 MAY 11, 1988 MAY DISC

SUSPENSION/DROPS; OTIC

© ALCON UNIVERSAL

1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

N62488 001 NOV 06, 1985 APR DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

© ABBOTT

50MG/ML

N86821 001 SEP 05, 1979 JUL DISC

© AM PHARM PARTNERS

25MG/ML

N88184 001 MAR 31, 1983 JUL DISC

©

50MG/ML

N88185 001 MAR 31, 1983 JUL DISC

TABLET; ORAL

25MG/ML

N85778 001 OCT 05, 1979 MAY DISC

© PAR PHARM

10MG

N87602 001 JAN 22, 1982 JUL DISC

©

25MG

N87603 001 JAN 22, 1982 JUL DISC

©

50MG

N87604 001 JAN 22, 1982 JUL DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ GENEVA PHARMS

EQ 50MG HCL

N81128 001 JUN 28, 1991 MAY DISC

@

EQ 100MG HCL

N81129 001 JUN 28, 1991 MAY DISC

@ VANGARD

EQ 50MG HCL

N88393 001 SEP 19, 1983 FEB WDRP

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS

50MG

N21335 001 MAY 10, 2001 MAY NEWA

+

100MG

N21335 002 MAY 10, 2001 MAY NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

25MG

N83799 002 AUG 05, 1977 SEP DISC

>D> AB ROXANE

25MG

N83799 002 AUG 05, 1977 SEP DISC

>A> @

50MG

N83799 003 AUG 05, 1977 SEP DISC

>D> AB

50MG

N83799 003 AUG 05, 1977 SEP DISC

>A> @

TOFRANIL

50MG

N83799 003 AUG 05, 1977 SEP DISC

AB TYCO HLTHCARE

10MG

N87844 001 MAY 22, 1984 JUN CAHN

AB

25MG

N87845 001 MAY 22, 1984 JUN CAHN

AB +

50MG

N87846 001 MAY 22, 1984 JUN CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

TYCO HLTHCARE

EQ 75MG HCL

N17090 001 MAR 15, 1973 JUN CAHN

EQ 100MG HCL

N17090 004 MAR 08, 1974 JUN CAHN

EQ 125MG HCL

N17090 003 MAR 08, 1974 JUN CAHN

+

EQ 150MG HCL

N17090 002 MAR 15, 1973 JUN CAHN

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB GENEVA PHARMS TECH

1.25MG

N74594 001 MAY 23, 1996 JAN CAHN

AB

2.5MG

N74594 002 MAY 23, 1996 JAN CAHN

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK RES LABS

EQ 100MG BASE

N20685 006 APR 19, 2000 AUG NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>A> AN ASLUNG PHARM

0.02%

N75693 001 JAN 26, 2001 JAN NEWA

AN NEPHRON

0.02%

N75562 001 SEP 27, 2001 SEP NEWA

AN NOVEX

0.02%

N75441 001 MAR 28, 2001 MAR NEWA

AN WARRICK PHARMS

0.02%

N75507 001 JAN 19, 2001 JAN NEWA

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

AN MINRAD 99.9%

N74416 001 SEP 30, 1994 FEB CAHN

ISONIAZID

SYRUP; ORAL

ISONIAZID

+ CAROLINA MEDCL

50MG/5ML

N88235 001 NOV 10, 1983 MAY CTEC

@ MIKART

50MG/5ML

N81118 001 JUL 21, 1997 MAY DISC

TABLET; ORAL

@ HALSEY

100MG

N80136 001 NOV 13, 1970 MAY DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB ZENITH GOLDLINE 30MG

N75448 002 AUG 07, 2001 AUG NEWA

AB 120MG

N75448 003 AUG 07, 2001 AUG NEWA

ISOTRETINOIN

CAPSULE; ORAL

ACCUVANE

+ HLR

20MG

N18662 004 MAR 28, 1983 APR CTEC

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

@ LOCH

EQ 75MG BASE/2ML

N63021 001 JUL 31, 1992 MAY DISC

@

EQ 500MG BASE/2ML

N63022 001 JUL 31, 1992 MAY DISC

@

EQ 1GM BASE/3ML

N63025 001 JUL 31, 1992 APR DISC

@ STERIS

EQ 1GM BASE/3ML

N62520 003 MAY 09, 1985 MAY DISC

KANTREX

+ APOTHECON

EQ 75MG BASE/2ML

N61901 003 MAR 06, 1975 MAY CTEC

+

EQ 500MG BASE/2ML

N61901 001 MAR 06, 1975 MAY CTEC

+

EQ 1GM BASE/3ML

N61901 002 MAR 06, 1975 MAY CTEC

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

AB + JANSSEN 2%

N19084 001 DEC 31, 1985 JUL CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP APOTEX 15MG/ML

N75631 002 JUN 29, 2001 JUN NEWA

AP 30MG/ML

N75626 001 JUL 24, 2001 JUL NEWA

AP

30MG/ML

N75631 001 JUN 29, 2001 JUN NEWA

@ APOTHECON

15MG/ML

N75348 001 NOV 28, 2000 MAY DISC

@

30MG/ML

N75348 002 NOV 28, 2000 MAY DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

@ APOTHECON

TRANDATE

AP + PROMETHEUS LABS

5MG/ML

N75355 001 NOV 29, 1999 MAY DISC

5MG/ML

N19425 001 DEC 31, 1985 MAY CAHN

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA VINTAGE PHARMS

10GM/15ML

N75993 001 JUL 26, 2001 JUL NEWA

SOLUTION; ORAL, RECTAL

>D> AA ROXANE

10GM/15ML

N73590 001 MAY 29, 1992 SEP DISC

>A> @

10GM/15ML

N73590 001 MAY 29, 1992 SEP DISC

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXO WELLCOME

2MG

N20764 004 SEP 08, 2000 MAR NEWA

LANSOPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; ORAL

PREVACID

TAP PHARM

15MG/PACKET

N21281 001 MAY 03, 2001 MAY NEWA

+

30MG/PACKET

N21281 002 MAY 03, 2001 MAY NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP LUITPOLD

EQ 50MG BASE/VIAL

N40338 001 JAN 31, 2001 JAN NEWA

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

AP + SIGMA TAU

200MG/ML

N20182 001 DEC 16, 1992 MAR CFTG

LEVCARNITINE

AP BEDFORD

200MG/ML

N75567 001 MAR 29, 2001 MAR NEWA

AP GENESIA SICOR PHARMS

200MG/ML

N75881 001 MAR 29, 2001 MAR NEWA

AP LUITPOLD

200MG/ML

N75861 001 JUN 22, 2001 JUN NEWA

LEVODOPA

CAPSULE; ORAL

DOPAR

@ SHIRE LABS

250MG

N16913 001 JUN 04, 1970 MAY DISC

TABLET; ORAL

@ SHIRE LABS

250MG

N16913 004 JUL 06, 1972 JUN DISC

@

500MG

N16913 005 JUL 06, 1972 JUN DISC

LARODOPA

ROCHE

250MG

N16912 003 JUN 04, 1970 JUN CRLD

+

500MG

N16912 004 JUN 04, 1970 JUN CRLD

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE W/ LEVONORDEFRIN

AP DENTSPLY PHARM 0.05MG/ML;2%

N89517 001 APR 14, 1988 JUL CAHN

LEVOHYROXINE SODIUM

TABLET; ORAL

LEVOXYL

BX +	JONES PHARMA	0.025MG	N21301 001	MAY 25, 2001	MAY	NEWA
BX		0.025MG	N21301 001	MAY 25, 2001	JUL	CRLD
BX		0.05MG	N21301 002	MAY 25, 2001	MAY	NEWA
BX		0.075MG	N21301 003	MAY 25, 2001	MAY	NEWA
BX		0.088MG	N21301 004	MAY 25, 2001	MAY	NEWA
BX		0.1MG	N21301 005	MAY 25, 2001	MAY	NEWA
BX		0.112MG	N21301 006	MAY 25, 2001	MAY	NEWA
BX		0.125MG	N21301 007	MAY 25, 2001	MAY	NEWA
BX		0.137MG	N21301 008	MAY 25, 2001	MAY	NEWA
BX		0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA
BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA
BX +		0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD
UNITHROID						
BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
BX +		0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC

LIDOCAINE HYDROCHLORIDEINJECTABLE; AN,CNBLK EXTRADURAL, AN,INFILTRATION, AN,PERIPHERAL NBLK
XYLOCAINE

>A>	AP + DENTSPLY PHARM	2%	N21380 001	NOV 19, 1948	SEP	NEWA
INJECTABLE; INJECTION						
LIDOCAINE HCL						
@ STERIS						
@						
LIDOCATON						
@ PHARMATON						
XYLOCAINE						
>A>	@ ASTRAZENECA	2%	N80377 001	FEB 20, 1974	JUL	DISC
>D>	AP + DENTSPLY PHARM	2%	N80377 002	FEB 20, 1974	JUL	DISC
N84727 001 AUG 17, 1983 FEB WDRP						
N06488 002 NOV 19, 1948 SEP DISC						
N06488 002 NOV 19, 1948 SEP DISC						

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

+ PHARMACIA AND UPJOHN

EQ 300MG BASE/ML

N50317 001 DEC 29, 1964 MAY CTEC

LINCOMYCIN HCL

@ STERIS

EQ 300MG BASE/ML

N63180 001 APR 16, 1991 MAY DISC

LISINOPRIL

TABLET; ORAL

ZESTRILO

AB ASTRazeneca

10MG

N19777 002 MAY 19, 1988 APR CTEC

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

AB SMITHKLINE BEECHAM

300MG

N16860 001 APR 06, 1970 JUN CRLD

LITHIUM CARBONATE

>A> AB ABLE

300MG

N76121 001 SEP 27, 2001 SEP NEWA

+ ROXANE

600MG

N17812 003 JAN 28, 1987 JUN CRLD

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MAXAQUIN

>D> + SEARLE

EQ 400MG BASE

N20013 001 FEB 21, 1992 SEP CAHN

>A> + UNIMED PHARMS

EQ 400MG BASE

N20013 001 FEB 21, 1992 SEP CAHN

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HCL

@ ROXANE

2MG

N73080 001 NOV 27, 1991 JUL DISC

LORATADINE

TABLET; ORAL

CLARITIN

>D> + SCHERING

10MG

N19658 001 APR 12, 1993 SEP CFTG

>A> AB +

10MG

N19658 001 APR 12, 1993 SEP CFTG

LORAZEPAM

TABLET; ORAL

LORAZEPAM

AB RANBAXY

0.5MG

N76045 001 AUG 29, 2001 AUG NEWA

AB

1MG

N76045 002 AUG 29, 2001 AUG NEWA

AB

2MG

N76045 003 AUG 29, 2001 AUG NEWA

@ WATSON LABS

0.5MG

N71086 001 MAR 23, 1987 JUL DISC

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

MERCK RES LABS

50MG

N20386 002 APR 14, 1995 AUG CRLD

+

100MG

N20386 003 OCT 13, 1998 AUG NEWA

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

>D>	AP	ASTRAZENECA	12.5GM/50ML	N89240 001	MAY 06, 1987	SEP	DISC
>A>	@		12.5GM/50ML	N89240 001	MAY 06, 1987	SEP	DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL

@ CHELSEA LABS

12.5MG

N85269 001 NOV 11, 1976 MAY DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

AB	+	BRISTOL MYERS SQUIBB	40MG/ML	N20264 001	SEP 10, 1993	JUL	CFTG
MEGESTROL ACETATE							

AB	PAR PHARM	40MG/ML	N75671 001	JUL 25, 2001	JUL	NEWA
----	-----------	---------	------------	--------------	-----	------

MELOXICAM

TABLET; ORAL

MOBIC

BOEHRINGER INGELHEIM

7.5MG

N20938 001 APR 13, 2000 JUL CRLD

+

15MG

N20938 002 AUG 23, 2000 JUL NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

@ ASTRAZENECA

@

50MG/ML

N89784 001 MAR 31, 1989 JUN DISC

100MG/ML

N89788 001 MAR 31, 1989 JUN DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HCL

@ INTL MEDICATION

POLOCAINE

AP DENTSPLY PHARM

1%

N87509 001 OCT 05, 1982 JUL DISC

3%

N88653 001 AUG 21, 1984 JUL CAHN

MEPROBAMATE

TABLET; ORAL

AMOSENE

@ FERNDALE LABS

MEPROBAMATE

@ HALSEY

@ IMPAX LABS

@

400MG

N84030 001 MAY 10, 1974 FEB WDRP

400MG

N80699 002 OCT 16, 1972 MAY DISC

200MG

N14322 002 JUL 23, 1973 AUG DISC

400MG

N14322 001 JUL 15, 1963 AUG DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ WESTWOOD SQUIBB

2%;0.01%

N20922 001 DEC 10, 1999 JUN CAHN

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

+ AXCAN SCANDIPHARM

500MG

N21252 001 JAN 05, 2001 JAN NEWA

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP AM PHARM PARTNERS

100MG/ML

N75811 001 APR 26, 2001 APR NEWA

AP GENSIA SICOR PHARMS

100MG/ML

N75764 001 APR 27, 2001 APR NEWA

MESNEX

AP + ASTA

100MG/ML

N19884 001 DEC 30, 1988 APR CFTG

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

AN NEPHRON

0.4%

N71855 001 JUL 14, 1988 AUG CAHN

AN

0.6%

N71726 001 JUL 14, 1988 AUG CAHN

AN NOVEX

0.4%

N75402 001 FEB 28, 2001 FEB NEWA

AN

0.6%

N75403 001 FEB 28, 2001 FEB NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

+ ABBOTT

5MG

N05378 002 DEC 31, 1943 JUL CTEC

METHAMPHETAMINE HCL

@ REXAR

5MG

N84931 001 JAN 19, 1976 JUL DISC

@

10MG

N84931 002 AUG 22, 1977 JUL DISC

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

@ APPLIED ANAL

25MG

N40011 001 JUL 17, 1997 MAY DISC

@

50MG

N40011 002 JUL 17, 1997 MAY DISC

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB EON

5MG

N40411 001 MAR 27, 2001 MAR NEWA

AB

10MG

N40411 002 MAR 27, 2001 MAR NEWA

+ GENPHARM

20MG

N40350 003 JUN 07, 2001 JUN NEWA

METHOTREXATE SODIUM

TABLET; ORAL

TREXALL

BARR

EQ 5MG BASE

N40385 001 MAR 21, 2001 MAR NEWA

EQ 7.5MG BASE

N40385 002 MAR 21, 2001 MAR NEWA

EQ 10MG BASE

N40385 003 MAR 21, 2001 MAR NEWA

+

EQ 15MG BASE

N40385 004 MAR 21, 2001 MAR NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - SEP 2001

1-44

<u>METHOXAMINE HYDROCHLORIDE</u>	
>D>	INJECTABLE; INJECTION
>D>	VASOXYL
>D>	+ GLAXO WELLCOME
>A>	@
	20MG/ML
	20MG/ML
	N06772 001 MAR 28, 1949 SEP WDAG
	N06772 001 MAR 28, 1949 SEP WDAG
<u>METHSCOPOLAMINE BROMIDE</u>	
	TABLET; ORAL
	METHSCOPOLAMINE BROMIDE
	@ PVT FORM
	PAMINE
	2.5MG
	N80970 001 OCT 18, 1976 MAY DISC
	+ BRADLEY PHARMS
	2.5MG
	N08848 001 APR 09, 1953 MAY CTEC
<u>METHYCLOTHIAZIDE</u>	
	TABLET; ORAL
	METHYCLOTHIAZIDE
	@ PAR PHARM
	@
	2.5MG
	5MG
	N89135 001 FEB 12, 1986 JUL DISC
	N89136 001 FEB 12, 1986 JUL DISC
<u>METHYLDOPA</u>	
	TABLET; ORAL
	METHYLDOPA
	@ LEDERLE
	125MG
	N70070 003 OCT 15, 1985 MAY DISC
<u>METHYLPHENIDATE HYDROCHLORIDE</u>	
	CAPSULE, EXTENDED RELEASE; ORAL
	METADATE CD
	+ CELLTECH PHARMS
	TABLET; ORAL
	METHYLPHENIDATE HCL
AB	ABLE
AB	5MG
AB	10MG
	20MG
	N21259 001 APR 03, 2001 APR NEWA
	N40404 001 MAR 29, 2001 MAR NEWA
	N40404 002 MAR 29, 2001 MAR NEWA
	N40404 003 MAR 29, 2001 MAR NEWA
	TABLET, EXTENDED RELEASE; ORAL
	METADATE ER
AB	CELLTECH PHARMS
	10MG
	METHYLPHENIDATE HCL
AB	ABLE
AB	20MG
	20MG
	N40306 001 OCT 20, 1999 APR CTEC
	N76032 001 MAY 09, 2001 MAY NEWA
	N40410 001 FEB 09, 2001 FEB NEWA
<u>METHYLPREDNISOLONE ACETATE</u>	
	INJECTABLE; INJECTION
	DEPO-MEDROL
	PHARMACIA AND UPJOHN
	METHYLPREDNISOLONE ACETATE
	@ STERIS
	40MG/ML
	40MG/ML
	N11757 001 APR 27, 1959 MAY CTEC
	N85600 001 MAR 14, 1979 MAY DISC
<u>METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE</u>	
	CREAM; TOPICAL
	NEO-MEDROL ACETATE
	@ PHARMACIA AND UPJOHN
	0.25%;EQ 3.5MG BASE/GM
	1%;EQ 3.5MG BASE/GM
	N60611 002 DEC 07, 1964 MAY DISC
	N60611 001 DEC 07, 1964 MAY DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

@ GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N81267 001	NOV 30, 1992	MAY	DISC
@	EQ 1GM BASE/VIAL	N81268 001	NOV 30, 1992	MAY	DISC

METHYLTESTOSTERONE

TABLET; BUCCAL

ORETON

@ SCHERING	10MG	N80281 001	AUG 03, 1979	FEB	DISC
------------	------	------------	--------------	-----	------

TABLET; BUCCAL/SUBLINGUAL

METHYLTESTOSTERONE

@ IMPAX LABS	10MG	N84287 001	JUL 16, 1974	JUL	DISC
--------------	------	------------	--------------	-----	------

@ LILLY

@ LILLY	10MG	N80256 001	DEC 22, 1971	JUL	DISC
---------	------	------------	--------------	-----	------

TABLET; ORAL

@ LILLY

25MG	N80256 002	DEC 22, 1971	JUL	DISC
------	------------	--------------	-----	------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

AT FALCON PHARMS	0.3%	N75720 001	AUG 06, 2001	AUG	NEWA
------------------	------	------------	--------------	-----	------

OPTIPRANOLOL

AT + BAUSCH AND LOMB	0.3%	N19907 001	DEC 29, 1989	AUG	CFTG
----------------------	------	------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC
----------	----------------	------------	--------------	-----	------

SOLUTION; INJECTION

METOCLOPRAMIDE

AA UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA
--------	-----------------	------------	--------------	-----	------

SOLUTION; ORAL

AA UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR
--------	-----------------	------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HCL

AB GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
-----------------------	-------------	------------	--------------	-----	------

AB	EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN
----	--------------	------------	--------------	-----	------

@ MUTUAL PHARM

EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC
-------------	------------	--------------	-----	------

@

EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC
--------------	------------	--------------	-----	------

METOCURINE IODIDE

>D INJECTABLE; INJECTION

>D METUBINE IODIDE

>D + LILLY	2MG/ML	N06632 003	FEB 15, 1952	SEP	WDAG
------------	--------	------------	--------------	-----	------

>A @

2MG/ML	N06632 003	FEB 15, 1952	SEP	WDAG
--------	------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

TOPROL-XL

+ ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA
---------------	------------------	------------	--------------	-----	------

EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD
------------------	------------	--------------	-----	------

EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD
-------------------	------------	--------------	-----	------

METRONIDAZOLE

INJECTABLE; INJECTION

METRO I.V.

@ B BRAUN

500MG/100ML

N18674 001 AUG 31, 1982 MAY DISC

METRONIDAZOLE

@ ABBOTT

500MG/100ML

N18889 001 NOV 18, 1983 MAY DISC

@ ELKINS SINK

500MG/100ML

N18907 001 MAR 30, 1984 MAY DISC

TABLET; ORAL

PROTOSTAT

@ JOHNSON RW

250MG

N18871 001 MAR 02, 1983 MAR DISC

@

500MG

N18871 002 MAR 02, 1983 MAR DISC

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

@ BAYER

EQ 1GM BASE/VIAL

N62372 005 JAN 13, 1983 MAY DISC

@

EQ 2GM BASE/VIAL

N62372 001 MAY 13, 1982 MAY DISC

@

EQ 3GM BASE/VIAL

N62372 002 MAY 13, 1982 MAY DISC

@

EQ 4GM BASE/VIAL

N62372 003 MAY 13, 1982 MAY DISC

@

EQ 20GM BASE/VIAL

N62372 004 MAR 02, 1988 MAY DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

@ APOTHECON

EQ 1MG BASE/ML

N75620 001 NOV 01, 2000 MAY DISC

@

EQ 5MG BASE/ML

N75620 002 NOV 01, 2000 MAY DISC

@

EQ 5MG BASE/ML

N75641 001 OCT 19, 2000 MAY DISC

@ ASTRazeneca

EQ 5MG BASE/ML

N75263 001 JUN 26, 2000 MAY DISC

>D> AP BEDFORD

EQ 5MG BASE/ML

N75249 001 JUN 23, 2000 SEP DISC

>A> @

EQ 5MG BASE/ML

N75249 001 JUN 23, 2000 SEP DISC

>D> AP BEN VENUE

EQ 5MG BASE/ML

N75455 001 JUN 20, 2000 SEP DISC

>A> @

EQ 5MG BASE/ML

N75455 001 JUN 20, 2000 SEP DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB LEDERLE

EQ 75MG BASE

N50649 003 FEB 12, 2001 MAR NEWA

AB +

EQ 100MG BASE

N50649 002 MAY 31, 1990 MAR CRLD

MINOCYCLINE HCL

AB DANBURY PHARMA

EQ 100MG BASE

N63065 001 DEC 30, 1991 MAR CRLD

AB IMPAX LABS

EQ 75MG BASE

N65005 003 APR 18, 2001 APR NEWA

VECTRIN

@ MEDICIS

EQ 75MG BASE

@

EQ 100MG BASE

N63067 002 SEP 15, 1999 MAY DISC

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

EQ 100MG BASE

N63067 001 JUL 31, 1990 MAY DISC

+ ORAPHARMA

EQ 1MG BASE

N50781 001 FEB 16, 2001 FEB NEWA

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

REMERON SOLTAB

+ ORGANON INC

15MG

N21208 001 JAN 12, 2001 JAN NEWA

30MG	N21208 002	JAN 12, 2001	JAN	NEWA
45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+ FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN
+	30MG	N20616 004	MAR 09, 2001	JUN	NEWA
+	50MG	N20616 002	JUL 03, 1996	JUN	CAHN
+	60MG	N20616 005	MAR 09, 2001	JUN	NEWA
+	100MG	N20616 003	JUL 03, 1996	JUN	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA
ORAMORPH SR					

>A> BC ELAN PHARMS	15MG	N19977 004	NOV 23, 1994	SEP	CAHN
>A> BC	30MG	N19977 001	AUG 15, 1991	SEP	CAHN
>A> BC	60MG	N19977 002	AUG 15, 1991	SEP	CAHN
>A> BC	100MG	N19977 003	AUG 15, 1991	SEP	CAHN
>D> BC ROXANE	15MG	N19977 004	NOV 23, 1994	SEP	CAHN
>D> BC	30MG	N19977 001	AUG 15, 1991	SEP	CAHN
>D> BC	60MG	N19977 002	AUG 15, 1991	SEP	CAHN
>D> BC	100MG	N19977 003	AUG 15, 1991	SEP	CAHN

NABUMETONE

TABLET; ORAL

NABUMETONE

>A> AB TEVA	750MG	N75189 002	SEP 24, 2001	SEP	NEWA
-------------	-------	------------	--------------	-----	------

NADOLOL

TABLET; ORAL

CORGARD

AB APOTHECON	40MG	N18063 001	DEC 10, 1979	AUG	CRLD
NADOLOL					
AB GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN
AB	40MG	N74501 002	NOV 09, 1995	JAN	CAHN
AB	80MG	N74501 003	NOV 09, 1995	JAN	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

@ APOTHECON

+	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC
+	EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD
+	EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC
+	EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC
+	EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC
+	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC
+	EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN
+	EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC
+	EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC
+	EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC
+	EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC

NALLPEN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NALLPEN

⑧ SMITHKLINE BEECHAM

⑧

⑧

⑧

UNIPEN

⑧ WYETH AYERST

⑧

⑧

⑧

⑧

⑧

⑧

UNIPEN IN PLASTIC CONTAINER

⑧ WYETH AYERST

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 10GM BASE/VIAL

N61999 001 JUL 10, 1978 MAY DISC
N61999 002 JUL 10, 1978 MAY DISC
N61999 003 JUL 10, 1978 MAY DISC
N61999 004 JUL 17, 1978 MAY DISC

EQ 500MG BASE/VIAL

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 4GM BASE/VIAL

EQ 10GM BASE/VIAL

N50320 001 JUN 23, 1970 MAY DISC
N62717 001 DEC 16, 1986 MAY DISC
N62717 002 DEC 16, 1986 MAY DISC
N50320 003 JUN 23, 1970 MAY DISC
N62717 004 DEC 16, 1986 MAY DISC
N50320 004 JUN 23, 1970 MAY DISC
N50320 005 DEC 21, 1978 MAY DISC

EQ 1GM BASE/VIAL

N50320 002 JUN 23, 1970 MAY DISC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

⑧ ASTRazeneca

⑧

10MG/ML

20MG/ML

N72070 001 APR 10, 1989 JUN DISC
N72073 001 APR 10, 1989 JUN DISCNALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

⑧ WYETH AYERST

⑧

⑧

⑧

0.02MG/ML

0.02MG/ML

0.4MG/ML

0.4MG/ML

N70188 001 SEP 24, 1986 JAN DISC
N70189 001 SEP 24, 1986 JAN DISC
N70190 001 SEP 24, 1986 JAN DISC
N70191 001 SEP 24, 1986 JAN DISCNALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HCL AND PENTAZOCINE

AB AMIDE PHARM

EQ 0.5MG BASE;EQ 50MG BASE

N75735 001 JUL 11, 2001 JUL NEWA

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

AT ALLERGAN

0.1%

N80248 001 MAR 24, 1972 JUL CRLD

AT +

0.1%

N80248 001 MAR 24, 1972 AUG CRLD

NAPHCON FORTE

⑧ ALCON

0.1%

N80229 001 MAR 06, 1974 JUL DISC

OPCON

⑧ BAUSCH AND LOMB

0.1%

N87506 001 DEC 01, 1981 JUL DISC

VASOCON

AT NOVARTIS

0.1%

N80235 002 MAR 24, 1983 FEB CAHN

NAPROXEN

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN

AB + ALPHAPHARM

375MG

N75390 001 APR 19, 2001 APR NEWA

AB +	500MG	N75390 002 APR 19, 2001 APR NEWA
<u>NAPROXEN SODIUM</u>		
TABLET; ORAL		
NAPROXEN SODIUM		
AB GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001 DEC 05, 1994 JAN CAHN
AB	EQ 500MG BASE	N74495 002 DEC 05, 1994 JAN CAHN
<u>NEDOCROMIL SODIUM</u>		
AEROSOL, METERED; INHALATION		
TILADE		
>A+ AVENTIS	1.75MG/INH	N19660 001 DEC 30, 1992 SEP CAHN
>D+ AVENTIS PHARMS	1.75MG/INH	N19660 001 DEC 30, 1992 SEP CAHN
<u>NEFAZODONE HYDROCHLORIDE</u>		
TABLET; ORAL		
SERZONE		
BRISTOL MYERS SQUIBB	50MG	N20152 001 DEC 22, 1994 APR CTEC
<u>NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>		
SOLUTION; IRRIGATION		
NEOMYCIN AND POLYMYXIN B SULFATES		
@ STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664 001 APR 08, 1986 MAY DISC
NEOSPORIN G.U. IRRIGANT		
MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001 JUN 28, 1966 MAY CTEC
SOLUTION/DROPS; OPHTHALMIC		
STATROL		
@ ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339 001 NOV 30, 1984 JUL DISC
<u>NESIRITIDE</u>		
FOR SOLUTION; INTRAVENOUS		
NATRECOR		
+ SCIOS	1.5MG/VIAL	N20920 001 AUG 10, 2001 AUG NEWA
<u>NETILMICIN SULFATE</u>		
INJECTABLE; INJECTION		
NETROMYCIN		
@ SCHERING	EQ 100MG BASE/ML	N50544 003 FEB 28, 1983 MAY DISC
<u>NIFEDIPINE</u>		
CAPSULE; ORAL		
NIFEDIPINE		
@ CHASE LABS NJ	10MG	N72409 001 JUL 04, 1990 FEB WDRP
@	20MG	N73421 001 JUN 19, 1991 FEB WDRP
TABLET, EXTENDED RELEASE; ORAL		
ADALAT CC		
AB1 BAYER	30MG	N20198 001 APR 21, 1993 APR CTEC
NIFEDIPINE		
AB2 BIOVAIL	30MG	N75289 002 FEB 06, 2001 FEB NEWA
PROCARDIA XL		

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
 PROCARDIA XL
 AB2 + PFIZER 30MG N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE

OINTMENT; TOPICAL
 NITROFURAZONE
 @ CLAY PARK 0.2% N84968 001 JAN 25, 1978 MAY DISC
 POWDER; TOPICAL
 FURACIN
 @ ROBERTS LABS 0.2% N83791 001 OCT 17, 1975 FEB WDRP
 SOLUTION; TOPICAL
 NITROFURAZONE
 @ CLAY PARK 0.2% N85130 001 NOV 02, 1978 MAY DISC
 + WENDT 0.2% N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN

AEROSOL; SUBLINGUAL
 NITROLINGUAL
 @ POHL BOSKAMP 0.4MG/SPRAY N18705 001 OCT 31, 1985 APR DISC

NOREpinephrine Bitartrate; Procaine Hydrochloride; Propoxycaine Hydrochloride

>D> INJECTABLE; INJECTION
 >D> RAVOCAIN AND NOVOCAIN W/ LEVOPHED
 >D> + EASTMAN KODAK EQ 0.033MG BASE/ML;2%;0.4% N08592 003 MAR 11, 1955 SEP WDAG
 >A> @ EQ 0.033MG BASE/ML;2%;0.4% N08592 003 MAR 11, 1955 SEP WDAG

Norethindrone Acetate

TABLET; ORAL
 NORETHINDRONE ACETATE
 AB BARR 5MG N75951 001 MAY 25, 2001 MAY NEWA

Nortriptyline Hydrochloride

CAPSULE; ORAL
 PAMELOR
 AB TYCO HLTHCARE EQ 10MG BASE N18013 001 AUG 01, 1977 JUN CAHN
 AB EQ 25MG BASE N18013 002 AUG 01, 1977 JUN CAHN
 AB + EQ 50MG BASE N18013 004 JUN 14, 1979 JUN CAHN
 SOLUTION; ORAL N18013 003 JUN 14, 1979 JUN CAHN
 AA TYCO HLTHCARE EQ 10MG BASE/5ML N18012 001 AUG 01, 1977 JUN CAHN

NYSTATIN

CREAM; TOPICAL
 NILSTAT
 @ LEDERLE 100,000 UNITS/GM N61445 001 APR 02, 1971 MAY DISC
 NYSTATIN
 @ TEVA 100,000 UNITS/GM N61966 001 MAY 25, 1976 MAY DISC
 OINTMENT; TOPICAL
 NILSTAT
 @ LEDERLE 100,000 UNITS/GM N61444 001 MAR 29, 1971 MAY DISC
 NYSTATIN

NYSTATIN

OINTMENT; TOPICAL
NYSTATIN

AT + ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY	CTEC
SUSPENSION; ORAL					
@ ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY	DISC
@ TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY	DISC
@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY	DISC
@ THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL	DISC
TABLET; ORAL					
@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC
@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC
TABLET; VAGINAL					
KOROSTATIN					
@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
MYCO-TRIACET II

@ TEVA	100,000 UNITS/GM; 0.1%	N62045 002	NOV 26, 1985	MAY	DISC
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
@ CLAY PARK	100,000 UNITS/GM; 0.1%	N62280 002	OCT 10, 1985	MAY	DISC

OLANZAPINE

TABLET; ORAL
ZYPREXA

LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD
+	20MG	N20592 006	SEP 09, 1997	JUN	CMFD

OXACILLIN SODIUM

INJECTABLE; INJECTION
BACTOCILL

@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC
OXACILLIN SODIUM					
AP + APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
AP +	EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD
@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC
@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC
@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC
@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC
@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC

OXaprozin

TABLET; ORAL
DAYPRO

AB + SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG
OXaprozin					
AB DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA
AB EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA
AB GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA
AB GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA
AB INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - SEP 2001

1-52

AB	MYLAN	600MG	N75851 001	AUG 17, 2001	AUG	NEWA
AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA

OXAZEPAM

CAPSULE; ORAL

SERAX

AB	FAULDING PHARMS	10MG	N15539 002	SEP 29, 1966	JUN	CAHN
AB		15MG	N15539 004	SEP 29, 1966	JUN	CAHN
AB +		30MG	N15539 006	SEP 29, 1966	JUN	CAHN
	TABLET; ORAL					
+ FAULDING PHARMS		15MG	N15539 008	NOV 16, 1967	JUN	CAHN

OXCARBAZEPINE

SUSPENSION; ORAL

TRILEPTAL

+ NOVARTIS

300MG/5ML

N21285 001 MAY 25, 2001 MAY NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ROXICODONE

>A>	ELAN PHARMS	15MG	N21011 001	AUG 31, 2000	SEP	CAHN
>A> +		30MG	N21011 002	AUG 31, 2000	SEP	CAHN
>D>	ROXANE	15MG	N21011 001	AUG 31, 2000	SEP	CAHN
>D> +		30MG	N21011 002	AUG 31, 2000	SEP	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	OXYCONTIN					
@ PURDUE PHARMA LP		160MG	N20553 005	MAR 15, 2000	JUN	DISC

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXYTETRACYCLINE HCL

@ IMPAX LABS

EQ 250MG BASE

N60760 001 AUG 09, 1967 FEB DISC

@ PROTER

EQ 250MG BASE

N60869 001 JAN 29, 1964 FEB WDRP

@ WEST WARD

EQ 250MG BASE

N60770 001 SEP 29, 1967 MAY DISC

TERRAMYCIN

+ PFIZER

EQ 250MG BASE

N50286 002 SEP 08, 1964 MAY CTEC

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	BEDFORD	6MG/ML	N75190 001	JUL 27, 2001	JUL	NEWA
AP	MYLAN	6MG/ML	N75278 001	JUL 23, 2001	JUL	NEWA
AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

AP +	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
AP +		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG
	PAMIDRONATE DISODIUM					
AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

@ ASTRazeneca

1MG/ML

N72210 001 MAR 31, 1988 JUL DISC

@

2MG/ML

N72211 001 MAR 31, 1988 JUL DISC

@

2MG/ML

N72213 001 MAR 31, 1988 JUL DISC

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PROTONIX IV

+ WYETH AYERST

EQ 40MG BASE/VIAL

N20988 001 MAR 22, 2001 MAR NEWA

TABLET, DELAYED RELEASE; ORAL

PROTONIX

+ WYETH AYERST

EQ 20MG BASE

N20987 002 JUN 12, 2001 JUN NEWA

PEMOLINE

TABLET; ORAL

PEMOLINE

AB MALLINCKRODT

18.75MG

N75726 003 MAR 30, 2001 MAR NEWA

AB

37.5MG

N75726 002 MAR 30, 2001 MAR NEWA

AB

75MG

N75726 001 MAR 30, 2001 MAR NEWA

AB WATSON LABS

18.75MG

N75287 001 JUN 13, 2001 JUN NEWA

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENAVIR

+ NOVARTIS

1%

N20629 001 SEP 24, 1996 JUL CAHN

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN

@ TEVA

200,000 UNITS/5ML

N60307 002 MAY 27, 1964 JUL DISC

@

400,000 UNITS/5ML

N60307 004 MAY 27, 1964 JUL DISC

PENICILLIN-2

@ TEVA

250,000 UNITS/5ML

N60307 003 MAY 27, 1964 JUL DISC

TABLET; ORAL

PENICILLIN G POTASSIUM

@ TEVA

200,000 UNITS

N60306 001 JUN 01, 1964 MAY DISC

@

250,000 UNITS

N60306 002 JUN 01, 1964 MAY DISC

@

400,000 UNITS

N60306 003 JUN 01, 1964 MAY DISC

@

500,000 UNITS

N60306 004 JUN 26, 1979 MAY DISC

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

@ PFIZER

300,000 UNITS/VIAL

N60099 001 NOV 10, 1948 MAY DISC

@

1,500,000 UNITS/VIAL

N60099 002 NOV 10, 1948 MAY DISC

PFIZERPEN-AS

@ PFIZER

300,000 UNITS/ML

N60286 001 NOV 01, 1950 MAY DISC

@

600,000 UNITS/ML

N60286 002 NOV 01, 1950 MAY DISC

WYCILLIN

+ KING PHARMS

300,000 UNITS/ML

N60101 002 APR 26, 1948 MAY CTEC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - SEP 2001

1-54

+	600,000 UNITS/ML	N60101 001 APR 26, 1948 MAY CTEC
PENICILLIN G SODIUM		
INJECTABLE; IM-IV		
PENICILLIN G SODIUM		
+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001 FEB 26, 2001 FEB NEWA
@ MARSAM	5,000,000 UNITS/VIAL	N63014 001 SEP 13, 1988 FEB DISC
PENICILLIN V POTASSIUM		
FOR SOLUTION; ORAL		
PENICILLIN V POTASSIUM		
@ MYLAN	EQ 125MG BASE/5ML	N61624 002 AUG 07, 1972 MAY DISC
@	EQ 250MG BASE/5ML	N61624 001 JUN 05, 1972 MAY DISC
V-CILLIN K		
@ LILLY	EQ 125MG BASE/5ML	N60004 001 AUG 21, 1958 MAY DISC
@	EQ 250MG BASE/5ML	N60004 002 APR 07, 1967 MAY DISC
TABLET; ORAL		
PEN-VEE K		
AB + WYETH AYERST	EQ 500MG BASE	N60006 003 JAN 13, 1958 MAY CRLD
PENICILLIN V POTASSIUM		
AB + BIOCHEMIE	EQ 500MG BASE	N64071 002 NOV 30, 1995 MAY CTEC
@ MYLAN	EQ 250MG BASE	N61530 001 NOV 18, 1971 MAY DISC
@	EQ 500MG BASE	N61530 002 MAR 20, 1972 MAY DISC
V-CILLIN K		
@ LILLY	EQ 125MG BASE	N60003 001 SEP 17, 1957 MAY DISC
@	EQ 250MG BASE	N60003 002 SEP 17, 1957 MAY DISC
@	EQ 500MG BASE	N60003 003 SEP 17, 1957 MAY DISC
PENTOBARBITAL		
ELIXIR; ORAL		
NEMBUTAL		
@ ABBOTT	18.2MG/5ML	N83244 001 JAN 08, 1975 JUL DISC
PENTOBARBITAL SODIUM		
CAPSULE; ORAL		
NEMBUTAL SODIUM		
@ ABBOTT	50MG	N84093 001 JAN 14, 1975 JUL DISC
SUPPOSITORY; RECTAL		
NEMBUTAL		
@ ABBOTT	30MG	N83247 001 JAN 25, 1982 JUL DISC
@	60MG	N83247 002 JAN 25, 1982 JUL DISC
@	120MG	N83247 003 JAN 25, 1982 JUL DISC
@	200MG	N83247 004 JAN 25, 1982 JUL DISC
PERFLUTREN		
INJECTABLE; INTRAVENOUS		
DEFINITY		
+ DUPONT PHARMS	6.52MG/ML	N21064 001 JUL 31, 2001 JUL NEWA
PERPHENAZINE		
CONCENTRATE; ORAL		
PERPHENAZINE		
+ PHARM ASSOC	16MG/5ML	N40360 001 MAY 25, 2001 MAY NEWA

PERPHENAZINE

CONCENTRATE; ORAL

TRILAFON

@ SCHERING

16MG/5ML

N11557 001 DEC 12, 1958 MAR DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HCL

+ ABLE

200MG;800MG;160MG

N21105 001 JUN 26, 2001 JUN NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE

@ EON

35MG

N85633 001 JUL 13, 1978 JUL DISC

@

35MG

N85694 001 JUN 05, 1978 MAY DISC

AA +

35MG

N85695 001 JUN 05, 1978 JUL CRLD

@

35MG

N85702 001 JUN 07, 1978 JUL DISC

CAPSULE, EXTENDED RELEASE; ORAL

BC + EON

105MG

N18074 001 APR 16, 1979 JUL CRLD

@ GENEVA PHARMS

105MG

N87378 001 NOV 03, 1981 JUL DISC

TABLET; ORAL

PHENAZINE-35

@ ABC HOLDING

35MG

N85512 001 MAY 06, 1977 MAY DISC

PHENDIMETRAZINE TARTRATE

@ EON

35MG

N85402 001 MAY 19, 1978 MAY DISC

@

35MG

N85497 001 AUG 19, 1977 MAY DISC

@ MIKART

35MG

N89452 001 OCT 30, 1991 JUL DISC

@ ROSEMONT

35MG

N84399 001 MAY 28, 1981 MAY DISC

STATOBEX

35MG

N86013 001 DEC 16, 1977 JUL DISC

@ TEVA

35MG

N86550 001 SEP 16, 1981 JUL DISC

X-TROZINE

35MG

N86551 001 SEP 16, 1981 JUL DISC

@

35MG

N86552 001 SEP 16, 1981 JUL DISC

@

35MG

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

OBY-TRIM

@ SHIRE RICHWOOD

30MG

N87764 001 MAR 18, 1982 JUL DISC

PHENTERMINE HCL

@ ABC HOLDING

30MG

N85411 001 SEP 10, 1980 MAY DISC

AA ABLE

30MG

N40403 001 AUG 30, 2001 AUG NEWA

AA

30MG

N40427 001 AUG 30, 2001 AUG NEWA

@ ROSEMONT

30MG

N84487 001 APR 09, 1982 MAY DISC

TABLET; ORAL

AA ABLE

37.5MG

N40402 001 AUG 30, 2001 AUG NEWA

+ EON

30MG

N88605 001 SEP 28, 1987 MAY CMFD

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB UDL

125MG/5ML

N40342 001 JAN 31, 2001 JAN NEWA

PIPERAZINE CITRATE

SYRUP; ORAL

PIPERAZINE CITRATE

© LANNEBT

EQ 500MG BASE/5ML

N80963 001 JUL 25, 1974 MAY DISC

TABLET; ORAL

© IMPAX LABS

EQ 250MG BASE

N80874 001 JUL 19, 1973 MAY DISC

PIPOBROMAN

TABLET; ORAL

VERCYTE

© ABBOTT

25MG

N16245 002 JUL 01, 1966 JUL DISC

>A> PORACTANT ALFA

>A> SUSPENSION; INTRATRACHEAL

>A> CUROSURF

>A> + DEY

80MG/ML

N20744 001 NOV 18, 1999 SEP CAIN

>D> PORACTANT ALPHA

>D> SUSPENSION; INTRATRACHEAL

>D> CUROSURF

>A> + DEY

80MG/ML

N20744 001 NOV 18, 1999 SEP CAIN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K-DUR 10

AB KEY PHARMS

10MEQ

N19439 002 JUN 13, 1986 APR CTEC

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL

© PUREPAC PHARM

©

©

EQ 1MG BASE

N72991 001 MAY 16, 1989 JUL DISC

EQ 2MG BASE

N72921 001 MAY 16, 1989 JUL DISC

EQ 5MG BASE

N72992 001 MAY 16, 1989 JUL DISC

PREDNICARBATE

OINTMENT; TOPICAL

DERMATOP

+ AVENTIS PHARMS

0.1%

N19568 001 SEP 23, 1991 MAR CMFD

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

© CHELSEA LABS

5MG

N85085 002 FEB 23, 1977 MAY DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

VASOCIDIN

AT NOVARTIS

0.5%;10%

N88791 001 OCT 05, 1984 FEB CAHN

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

+ SCHERING

0.5%;10%

N10210 001 FEB 24, 1956 FEB CTEC

PREDAMIDE

© AKORN

0.5%;10%

N88059 001 JUL 29, 1983 FEB WDRP

SULPHRIN

© BAUSCH AND LOMB

0.5%;10%

N88089 001 DEC 28, 1982 FEB WDRP

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC						
INFLAMASE FORTE						
AT + NOVARTIS	EQ 0.9% PHOSPHATE	N80751	002	DEC 19,	1973	FEB CAHN
INFLAMASE MILD						
AT + NOVARTIS	EQ 0.11% PHOSPHATE	N80751	001	DEC 19,	1973	FEB CAHN
PREDNISOLONE SODIUM PHOSPHATE						
@ AKORN	EQ 0.11% PHOSPHATE	N83358	001	AUG 21,	1974	FEB WDRP
@	EQ 0.9% PHOSPHATE	N83358	002	AUG 21,	1974	FEB WDRP
@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043	001	OCT 24,	1991	MAY DISC
@	EQ 0.9% PHOSPHATE	N81044	001	OCT 24,	1991	MAY DISC

PREDNISONE

TABLET; ORAL						
PREDNISONE						
@ CHELSEA LABS	5MG	N85084	002	DEC 15,	1981	MAY DISC
@ GENEVA PHARMS	5MG	N80336	002	JUL 29,	1976	MAY DISC
@ HALSEY	10MG	N86595	001	APR 10,	1979	JUL DISC
@ LANNETT	20MG	N84275	001	JUN 27,	1974	MAY DISC
AB TRIGEN	5MG	N40362	002	AUG 29,	2001	AUG NEWA
AB	10MG	N40362	001	AUG 29,	2001	AUG NEWA

PRILOCaine HYDROCHLORIDE

INJECTABLE; INJECTION						
CITANEST PLAIN						
>A@ @ ASTRAZENECA	4%	N14763	007	NOV 18,	1965	SEP DISC
>D@ + DENTSPLY PHARM	4%	N14763	007	NOV 18,	1965	SEP DISC
>A@ +	4%	N21382	001	NOV 18,	1965	SEP NEWA

PRIMIDONE

SUSPENSION; ORAL						
mysoline						
+ XCEL PHARMS	250MG/5ML	N10401	001	JUL 05,	1956	JUL CAHN
TABLET; ORAL						
AB ELAN PHARMA	50MG	N09170	003	MAR 08,	1954	MAY CFTG
AB XCEL PHARMS	50MG	N09170	003	MAR 08,	1954	JUL CAHN
AB +	250MG	N09170	002	MAR 08,	1954	JUL CAHN
PRIMIDONE						
AB LANNETT	50MG	N84903	002	MAY 24,	2001	MAY NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL						
COMPazine						
AB SMITHKLINE BEECHAM	2.5MG	N11127	003	FEB 09,	1959	JUL CFTG
AB	5MG	N11127	001	SEP 27,	1957	JUL CFTG
PROCHLORPERAZINE						
AB ABLE	2.5MG	N40407	001	JUL 11,	2001	JUL NEWA
AB	5MG	N40407	002	JUL 11,	2001	JUL NEWA
AB	25MG	N40407	003	JUL 11,	2001	JUL NEWA

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

@ WYETH AYERST

EQ 5MG BASE/ML

N86348 001 JUL 05, 1979 JUL DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB GENEVA PHARMS TECH

EQ 5MG BASE

N40101 001 JUL 19, 1996 JAN CAHN

AB EQ 10MG BASE

N40101 002 JUL 19, 1996 JAN CAHN

AB EQ 25MG BASE

N40101 003 JUL 19, 1996 JAN CAHN

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

AO AM PHARM PARTNERS

50MG/ML

N75906 001 APR 25, 2001 APR NEWA

AO + STERIS

50MG/ML

N17362 002 MAY 08, 1978 APR CFTG

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHACON

@ POLYMEDICA

50MG

N84902 001 OCT 05, 1981 MAY DISC

TABLET; ORAL

PHENERGAN

@ WYETH AYERST

12.5MG

N07935 002 MAR 29, 1951 MAY CTEC

PROMETHAZINE HCL

@ LANNETT

12.5MG

N80949 001 JUL 28, 1976 MAY DISC

@

25MG

N80949 002 JUN 28, 1976 MAY DISC

@

50MG

N80949 003 JUN 28, 1976 MAY DISC

@ PVT FORM

25MG

N83658 001 OCT 01, 1976 MAY DISC

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

@ GENEVA PHARMS

65MG

N83125 002 APR 14, 1976 MAY DISC

@ IMPAX LABS

65MG

N83317 001 OCT 23, 1973 MAY DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

WYETH AYERST LABS

60MG

N18553 004 MAR 18, 1987 AUG CRLD

80MG

N18553 002 APR 19, 1983 AUG CRLD

120MG

N18553 003 APR 19, 1983 AUG CRLD

TABLET; ORAL

PROPRANOLOL HCL

@ LEDERLE

10MG

N70125 001 JUL 30, 1985 MAY DISC

@

40MG

N70127 001 JUL 30, 1985 SEP DISC

@

40MG

N70127 001 JUL 30, 1985 SEP DISC

@ WATSON LABS

20MG

N70549 001 APR 11, 1986 MAY DISC

>D>

>A>

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HCL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	JAN	CAHN
AB		10MG	N73645 001	AUG 24, 1995	JAN	CAHN
	VIVACTIL					
AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	MAR	CTNA
AB +		10MG	N73645 001	AUG 24, 1995	MAR	CTNA
@	SIDMAK LABS	5MG	N16012 001	SEP 27, 1967	MAR	DISC
@		10MG	N16012 002	SEP 27, 1967	MAR	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRILITRON

@ NEWTRON PHARMS

30MG/5ML;1.25MG/5ML

N88474 001 FEB 12, 1985 FEB WDRP

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINAGLUTE

BX +	BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC
	QUINIDINE GLUCONATE					
BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC
@	GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@ IMPAX LABS

200MG

N83347 001 DEC 08, 1976 FEB DISC

@ MUTUAL PHARM

300MG

N81031 001 APR 14, 1989 MAY DISC

@ WEST WARD

200MG

N83862 001 SEP 02, 1976 MAY DISC

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANTAC 150

@ GLAXO WELLCOME

EQ 150MG BASE

N20095 001 MAR 08, 1994 AUG DISC

TABLET; ORAL

RANITIDINE HCL

>D>	AB	BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662 001	AUG 29, 1997	SEP	DISC
>A>	@		EQ 150MG BASE	N74662 001	AUG 29, 1997	SEP	DISC
>D>	AB		EQ 300MG BASE	N74662 002	AUG 29, 1997	SEP	DISC
>A>	@		EQ 300MG BASE	N74662 002	AUG 29, 1997	SEP	DISC

RIBAVIRIN

CAPSULE; ORAL

REBETOL

+ SCHERING PLOUGH RES

200MG

N20903 002 JUL 25, 2001 AUG NEWA

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

AB VERSAPHARM

150MG

N65028 001 MAR 14, 2001 MAR NEWA

AB	300MG	N65028 002 MAR 14, 2001 MAR NEWA
<u>RISPERIDONE</u>		
TABLET; ORAL		
RISPERDAL		
JANSSEN	0.5MG	N20272 007 JAN 27, 1999 APR CRLD
+	1MG	N20272 001 DEC 29, 1993 APR CRLD
	4MG	N20272 004 DEC 29, 1993 APR CRLD
<u>SECOBARBITAL SODIUM</u>		
CAPSULE; ORAL		
SECOBARBITAL SODIUM		
@ ICN	100MG	N85477 001 DEC 10, 1981 FEB WDRP
<u>SECRETIN</u>		
INJECTABLE; INJECTION		
SECRETIN-FERRING		
@ FERRING	75CU/VIAL	N18290 001 MAY 29, 1981 JUN DISC
<u>SILVER SULFADIAZINE</u>		
DRESSING; TOPICAL		
SILDAFLO		
@ QUESTCOR PHARMS	1%	N19608 001 NOV 30, 1989 MAY CTNA
<u>SIMVASTATIN</u>		
TABLET; ORAL		
ZOCOR		
MERCK	5MG	N19766 001 DEC 23, 1991 APR CTEC
<u>SODIUM POLYSTYRENE SULFONATE</u>		
SUSPENSION; ORAL, RECTAL		
SPS		
AA + CAROLINA MEDCL	15GM/60ML	N87859 001 DEC 08, 1982 MAY CRLD
<u>SODIUM TETRADECYL SULFATE</u>		
INJECTABLE; INJECTION		
SOTRADECOL		
@ ELKINS SINK	1%	N05970 004 AUG 13, 1946 JUL DISC
@	3%	N05970 005 AUG 13, 1946 JUL DISC
<u>SOMATROPIN RECOMBINANT</u>		
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS		
SAIZEN		
+ SERONO	8.8MG/VIAL	N19764 003 AUG 29, 2000 AUG NEWA
<u>SOTALOL HYDROCHLORIDE</u>		
TABLET; ORAL		
SORINE		
AB UPSHER SMITH	80MG	N75500 001 APR 27, 2001 APR NEWA
AB	120MG	N75500 004 APR 27, 2001 APR NEWA
AB	160MG	N75500 002 APR 27, 2001 APR NEWA
AB	240MG	N75500 003 APR 27, 2001 APR NEWA

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

AB	MYLAN	25MG	N40424 001	AUG 20, 2001	AUG	NEWA
AB		50MG	N40424 002	AUG 20, 2001	AUG	NEWA
AB		100MG	N40424 003	AUG 20, 2001	AUG	NEWA

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

@ PFIZER	EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
+ PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
BLEPH-10

@ ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC
CETAMIDE					

AT + ALCON

SODIUM SULAMYD	10%	N80021 001	SEP 27, 1972	MAY	CTEC
@ SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC

SOLUTION/DROPS; OPHTHALMIC
BLEPH-10

AT + ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD
BLEPH-30					

AT + ALLERGAN

SODIUM SULAMYD	30%	N80028 002	MAY 25, 1971	MAY	CRLD
@ SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC
@	30%	N05963 003	NOV 26, 1947	MAY	DISC

>D+ SULF-10

@ NOVARTIS	10%	N80025 001	JUN 03, 1971	SEP	CMFD
>A> AT	10%	N80025 001	JUN 03, 1971	SEP	CMFD
@	10%	N80025 001	JUN 03, 1971	FEB	CAHN

SULF-15

AT NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN
-------------	-----	------------	--------------	-----	------

SULTEN-10

@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP
-------------------	-----	------------	--------------	-----	------

SULFAMETHOXAZOLE

TABLET; ORAL
GANTANOL

+ ROCHE	500MG	N12715 002	NOV 17, 1961	MAY	CTEC
---------	-------	------------	--------------	-----	------

SULFAMETHOXAZOLE

@ GENEVA PHARMS	500MG	N85844 001	MAR 23, 1978	MAY	DISC
-----------------	-------	------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP
---------	--------------------	------------	--------------	-----	------

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ TEVA 400MG;80MG
@ 800MG;160MGN18242 001 MAY 19, 1981 MAY DISC
N18242 002 MAY 19, 1981 MAY DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

>D> AB ROXANE 800MG;160MG
>A> @ 800MG;160MGN72769 001 AUG 30, 1991 SEP DISC
N72769 001 AUG 30, 1991 SEP DISCSULFANILAMIDE

CREAM; VAGINAL

AVC

AT + NOVAVAX 15%
SUPPOSITORY; VAGINAL
+ NOVAVAX 1.05GMN06530 003 JAN 27, 1987 JAN CAHN
N06530 004 JAN 27, 1987 JAN CAHNSULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ GENEVA PHARMS 500MG

N85628 001 JUN 13, 1977 JUL DISC

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

BERLEX LABS N/A
DIATIDE RES LABS N/A
N/AN20887 001 SEP 14, 1998 MAY CAHN
N20887 001 SEP 14, 1998 APR CAHN
N20887 001 SEP 14, 1998 JUL CAHNTECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

>D> AP NYCOMED AMERSHAM N/A
>A> @ N/AN17255 001 APR 15, 1976 SEP WDAG
N17255 001 APR 15, 1976 SEP WDAGTEMAZEPM

CAPSULE; ORAL

RESTORIL

AB TYCO HLTHCARE 7.5MG
AB 15MG
AB + 30MGN18163 003 OCT 25, 1991 JUN CAHN
N18163 001 FEB 27, 1981 JUN CAHN
N18163 002 FEB 27, 1981 JUN CAHNTERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL

AB TORPHARM EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 5MG BASE
AB EQ 10MG BASE
AB ZENITH GOLDLINE EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 5MG BASE
AB EQ 10MG BASEN75498 001 APR 12, 2001 APR NEWA
N75498 002 APR 12, 2001 APR NEWA
N75498 003 APR 12, 2001 APR NEWA
N75498 004 APR 12, 2001 APR NEWA
N75614 002 JAN 30, 2001 JAN NEWA
N75614 001 JAN 30, 2001 JAN NEWA
N75614 003 JAN 30, 2001 JAN NEWA
N75614 004 JAN 30, 2001 JAN NEWA

TERBUTALINE SULFATE

TABLET; ORAL					
BRETHINE					
AB NOVARTIS	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
AB +	5MG	N17849 002	MAY 17, 1976	JUN	CFTG
TERBUTALINE SULFATE					
AB IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA
AB	5MG	N75877 002	JUN 26, 2001	JUN	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL					
PANMYCIN					
@ PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC
ROBITET					
@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
@	500MG	N61734 002	JUN 06, 1973	MAY	DISC
TETRACYCLINE HCL					
@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
@	500MG	N60768 002	NOV 07, 1977	MAY	DISC
@ WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC
@	500MG	N61685 002	DEC 11, 1972	JUL	DISC

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL					
THIORIDAZINE HCL					
@ CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC
@ TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC
@ ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC

THIOTEPANA

INJECTABLE; INJECTION					
THIOPLEX					
AP + IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG
THIOTEPANA					
>AP AP AAIPHARMA	15MG/VIAL	N75698 001	SEP 20, 2001	SEP	NEWA
AP BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
AP GENESIS SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
+ @ IMMUNEX	30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC

THYROGLOBULIN

TABLET; ORAL					
THYROGLOBULIN					
@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC

TICARCILLIN DISODIUM

INJECTABLE; INJECTION					
TICAR					
@ SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC

TOBRAMYCIN

SOLUTION; INHALATION				
TOBI				
>D> + PATHOGENESIS	300MG/5ML		N50753 001	DEC 22, 1997
>A> + CHIRON	300MG/5ML		N50753 001	DEC 22, 1997
SOLUTION/DROPS; OPHTHALMIC				
TOBRAMYCIN				
@ ALCON UNIVERSAL	0.3%		N63176 001	MAY 25, 1994
>A> AT ALTANA	0.3%		N65026 001	SEP 11, 2001
				MAY DISC
				SEP NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION				
NEBCIN				
AP + LILLY	EQ 1.2GM BASE/VIAL		N50519 001	JUN 11, 1979
TOBRAMYCIN				AUG CFTG
AP PHARMA TEK	EQ 1.2GM BASE/VIAL		N65013 001	AUG 17, 2001
TOBRAMYCIN SULFATE				AUG NEWA
@ ASTRazeneca	EQ 10MG BASE/ML		N63119 001	OCT 31, 1994
@	EQ 40MG BASE/ML		N63121 001	OCT 31, 1994
@ ELKINS SINK	EQ 10MG BASE/ML		N63128 001	NOV 27, 1991
@	EQ 40MG BASE/ML		N63127 001	NOV 27, 1991
@ LEDERLE	EQ 10MG BASE/ML		N63113 001	APR 26, 1991
				MAY DISC

TOLMETIN SODIUM

CAPSULE; ORAL				
TOLMETIN SODIUM				
@ GENEVA PHARMS	EQ 400MG BASE		N73462 001	APR 30, 1992
				JUL DISC

TOPIRAMATE

TABLET; ORAL				
TOPAMAX				
+ JOHNSON RW	25MG		N20505 004	DEC 24, 1996
	200MG		N20505 002	DEC 24, 1996
				MAR CRLD

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC				
TRAVATAN				
+ ALCON UNIVERSAL	0.004%		N21257 001	MAR 16, 2001
				MAR NEWA

TRIAMCINOLONE

TABLET; ORAL				
TRIAMCINOLONE				
@ IMPAX LABS	4MG		N84340 001	APR 22, 1975
				FEB DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION				
AZMACORT				
>A> + AVENTIS	0.1MG/INH		N18117 001	APR 23, 1982
>D> + AVENTIS PHARMS	0.1MG/INH		N18117 001	APR 23, 1982
AEROSOL, METERED; NASAL				SEP CAHN
NASACORT				
>A> + AVENTIS	0.055MG/INH		N19798 001	JUL 11, 1991
				SEP CAHN

>D>	+ AVENTIS PHARMS CREAM; TOPICAL TRIAMCINOLONE ACETONIDE @ TARO @ TOPIDERM @ @ OINTMENT; TOPICAL ARISTOCORT @ FUJISAWA HLTHCARE ARISTOCORT A @ FUJISAWA HLTHCARE TRIAMCINOLONE ACETONIDE @ G AND W LABS @ AT THAMES AT SPRAY; TOPICAL KENALOG + APOTHECON SPRAY, METERED; NASAL NASACORT AQ	0.055MG/INH 0.025% 0.025% 0.1% 0.5% 0.5% 0.5% 0.025% 0.1% 0.025% 0.5%	N19798 001 JUL 11, 1991 SEP CAHN N40038 001 OCT 26, 1994 MAY DISC N89274 001 FEB 21, 1989 FEB WDRP N89275 001 FEB 21, 1989 FEB WDRP N89276 001 FEB 21, 1989 FEB WDRP N80745 002 MAY 28, 1974 JUL DISC N80745 003 SEP 23, 1975 JUL DISC N89795 001 DEC 23, 1988 JUL DISC N89796 001 DEC 23, 1988 JUL DISC N40374 001 JUN 05, 2001 JUN NEWA N40386 001 JUN 05, 2001 JUN NEWA
>A>	+ AVENTIS	0.055MG/SPRAY	N20468 001 MAY 20, 1996 SEP CAHN
>D>	+ AVENTIS PHARMS	0.055MG/SPRAY	N20468 001 MAY 20, 1996 SEP CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL TRICHOREX @ LANNETT @	4MG 4MG	N83436 001 AUG 11, 1980 MAY DISC N85630 001 MAY 16, 1977 FEB WDRP
---	------------	--

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL TRIFLUOPERAZINE HCL @ GENEVA PHARMS TABLET; ORAL	EQ 10MG BASE/ML	N85787 001 APR 15, 1982 MAY DISC
AB GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001 OCT 25, 1996 JAN CAHN
AB	EQ 2MG BASE	N40153 002 OCT 25, 1996 JAN CAHN
AB	EQ 5MG BASE	N40153 003 OCT 25, 1996 JAN CAHN
AB	EQ 10MG BASE	N40153 004 OCT 25, 1996 JAN CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION TRIMETHOBENZAMIDE HCL @ STERIS	100MG/ML	N86577 001 OCT 19, 1982 JUL DISC
--	----------	----------------------------------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL PRIMSOL @ ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995 JUN DISC
--	------------------	----------------------------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

SIDMAK LABS

EQ 25MG BASE

N16792 001 JUN 12, 1979 AUG CAHN

EQ 50MG BASE

N16792 002 JUN 12, 1979 AUG CAHN

+

EQ 100MG BASE

N16792 003 SEP 15, 1982 AUG CAHN

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

TRIPLE SULFA

@ FOUGERA

3.7%;2.86%;3.42%

N86424 001 MAY 31, 1979 JUN DISC

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

>D>	+ DEBIO RECHERCHE	11.25MG/VIAL	N21288 001 JUN 29, 2001 SEP CAHN
	+	11.25MG/VIAL	N21288 001 JUN 29, 2001 JUN NEWA
>A>	+ PHARMACIA AND UPJOHN	11.25MG/VIAL	N21288 001 JUN 29, 2001 SEP CAHN
	TRELSTAR DEPOT		
>D>	+ DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001 JUN 15, 2000 SEP CAHN
	+	EQ 3.75MG BASE/VIAL	N20715 001 JUN 15, 2000 JUN CDFR
>A>	+ PHARMACIA AND UPJOHN	EQ 3.75MG BASE/VIAL	N20715 001 JUN 15, 2000 SEP CAHN

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

>D>	AP + LILLY	3MG/ML	N06325 001 NOV 28, 1947 SEP WDAG
>A>	@	3MG/ML	N06325 001 NOV 28, 1947 SEP WDAG

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

@ SHIRE PHARM

1MG

N12892 001 SEP 13, 1962 JUN DISC

UREA, C-13

FOR SOLUTION; ORAL

BREATHTEK UBT FOR H-PYLORI

+ MERETEK	EQ 75MG /POUCHE	N20586 002 MAY 10, 2001 AUG NEWA
MERETEK UBT KIT (W/ PRANACTIN)		

@ MERETEK 125MG/VIAL N20586 001 SEP 17, 1996 AUG DISC

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

VALCYTE

+ SYNTEX (USA) INC LLC

EQ 450MG BASE

N21304 001 MAR 29, 2001 MAR NEWA

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

@ PAR PHARM

@ SCHERER RP

250MG

N70431 001 FEB 28, 1986 MAY DISC

250MG

N70195 001 JUL 02, 1987 JUL DISC

VALSARTAN

TABLET; ORAL
 DIOVAN
 NOVARTIS 80MG N21283 001 JUL 18, 2001 JUL NEWA
 160MG N21283 002 JUL 18, 2001 JUL NEWA
 + 320MG N21283 003 JUL 18, 2001 JUL NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
 VANCOMYCIN HCL
 @ ELKINS SINK EQ 500MG BASE/VIAL N62879 001 AUG 02, 1988 MAY DISC
 @ EQ 1GM BASE/VIAL N62879 002 AUG 02, 1988 MAY DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION
 VECURONIUM BROMIDE
 >A> + ABBOTT 4MG/VIAL N75558 001 SEP 11, 2001 SEP NEWA

VINBLASTINE SULFATE

INJECTABLE; INJECTION
 VELBAN
 @ LILLY 10MG/VIAL N12665 001 MAR 06, 1961 MAY DISC
 VINBLASTINE SULFATE
 AP + BEDFORD 10MG/VIAL N89395 001 APR 09, 1987 MAY CRLD

VITAMIN A PALMITATE

CAPSULE; ORAL
 VITAMIN A
 @ WEST WARD EQ 50,000 UNITS BASE N80967 001 MAY 04, 1973 FEB WDRP
 INJECTABLE; INJECTION
 AQUASOL A
 + NEOSAN PHARMS EQ 50,000 UNITS BASE/ML N06823 001 MAY 18, 1949 AUG CAHN

WARFARIN SODIUM

TABLET; ORAL
 COUMADIN
 AB DUPONT MERCK 2.5MG N09218 018 NOV 29, 1961 JUL CRLD
 AB + 5MG N09218 007 FEB 17, 1964 JUL CRLD
 AB 5MG N09218 007 FEB 17, 1964 AUG CRLD

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
 GEODON
 PFIZER 20MG N20825 001 FEB 05, 2001 FEB NEWA
 40MG N20825 002 FEB 05, 2001 FEB NEWA
 60MG N20825 003 FEB 05, 2001 FEB NEWA
 + 80MG N20825 004 FEB 05, 2001 FEB NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)
 ZOMETA
 >A> + NOVARTIS EQ 4MG BASE/VIAL N21223 001 AUG 20, 2001 SEP CPOT

>D>	+	4.264MG/VIAL	N21223 001 AUG 20, 2001 SEP CPOT
	+	4.264MG/VIAL	N21223 001 AUG 20, 2001 AUG NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

ASTRAZENECA

2.5MG

N21231 001 FEB 13, 2001 FEB NEWA

PREScription DRUG PRODUCT LIST - 21ST EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - SEP 2001

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

>D>	ABLE	120MG	N73106 001	FEB 27, 1995	SEP	WDAG
>A>	@	120MG	N73106 001	FEB 27, 1995	SEP	WDAG
>D>		325MG	N73107 001	FEB 27, 1995	SEP	WDAG
>A>	@	325MG	N73107 001	FEB 27, 1995	SEP	WDAG
>D>		650MG	N73108 001	FEB 27, 1995	SEP	WDAG
>A>	@	650MG	N73108 001	FEB 27, 1995	SEP	WDAG
	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
+		650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA
---	----------	---------------------------	------------	--------------	-----	------

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+	3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA
---	----	--------	------------	--------------	-----	------

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BROMATAPP

@ COBLEY PHARM

12MG;75MG

N71099 001 JUL 02, 1987 JUL DISC

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

@ NOVARTIS

1.34MG;75MG

N18298 002 AUG 21, 1992 JAN DISC

@

1.34MG;75MG

N20640 001 AUG 09, 1996 JAN DISC

CLOTRIMAZOLE

CREAM; VAGINAL

TRIVAGIZOLE 3

TARO

2%

N21143 001 APR 12, 2000 JUL CRLD

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ALPHARMA

5.2MG/INH

N74800 001 JUL 26, 2001 JUL NEWA

BAUSCH AND LOMB

5.2MG/SPRAY

N75702 001 JUL 03, 2001 JUL NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

DR REDDYS LABS LTD

10MG

N75758 001 AUG 17, 2001 AUG NEWA

TEVA

10MG

N75312 001 MAY 31, 2001 MAY NEWA

ZENITH GOLDLINE 10MG

N75512 001 JUL 26, 2001 JUL NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROHM COLD AND SINUS

OHM LABS

200MG;30MG

N74567 001 APR 17, 2001 APR NEWA

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR PURIFIED PORK INSULIN

+ NOVO NORDISK

100 UNITS/ML

N18381 001 MAR 17, 1980 MAY CTEC

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN R

+ NOVO NORDISK

100 UNITS/ML

N19938 001 JUN 25, 1991 MAY CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

+ LILLY

50 UNITS/ML;50 UNITS/ML

N20100 001 APR 29, 1992 MAY CTEC

NOVOLIN 70/30

+ NOVO NORDISK

30 UNITS/ML;70 UNITS/ML

N19991 001 JUN 25, 1991 MAY CTEC

INSULIN RECOMBINANT PURIFIED HUMAN

>D> INJECTABLE; INJECTION

>D> VELOSULIN BR HUMAN

>D> + NOVO NORDISK

100 UNITS/ML

N19450 001 MAY 30, 1986 SEP WDAG

>A> @

100 UNITS/ML

N19450 001 MAY 30, 1986 SEP WDAG

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT 3 COMBINATION PACK

+ PERSONAL PRODS

2%;4%

N21261 001 FEB 02, 2001 FEB NEWA

CREAM; TOPICAL, VAGINAL

+ PERSONAL PRODS

2%;4%

N21261 001 FEB 02, 2001 MAY CDFA

CREAM; VAGINAL

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

PERRIGO

5%

N75598 001 JUN 13, 2001 JUN NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 9 AUGUST '01

NO SEPTEMBER 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
2-chloroethyl-3-sarcosinamide-1-nitrosourea <u>TN=</u>	Treatment for malignant gliomas	Lawrence Panasci, MD Professor of Medicine, McGill 3755 Cote Ste Catherine Montreal, Quebec H3T 1E2 DD= 8/3/01 MA=
2-methoxyestradiol <u>TN=Panzem</u>	Treatment of multiple myeloma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 7/10/01 MA=
3-(4'aminoisoindoline-1'-ne one)-1-piperidine-2,6-dio <u>TN=Revimid (proposed)</u>	Treatment for multiple myeloma	Celegene Corporation 7 Powder Horn Drive Warren NJ 07059 DD= 9/20/01 MA=
9-nitro-20-(S)-camptothe cin <u>TN=Camvirex</u>	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900 DD= 5/15/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX <u>TN=Coagulin-B</u>	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX <u>TN=Coagulin-B</u>	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
adenovirus-mediated herpes simplex virus-thymidine kinase TN=	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd 6 Warren Mews London W1T 6AR UK DD= 7/31/01 MA=
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
Angiotensin 1-7 TN=MARstem	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation 4041 MacArthur Boulevard, Suite Newport Beach CA 92660 DD= 8/3/01 MA=
augmerosen TN=GenaSense	Treatment of multiple myeloma	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
augmerosen TN=GenaSense	Treatment of chronic lymphocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
augmerosen TN=GenaSense	Treatment of acute myelocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	<u>Indication Designated:</u>	Sponsor & Address DD=Date Designated MA=Marketing Approval
Beclomethasone 17,21-dipropionate TN=	Prevention of gastrointestinal graft-versus-host disease	Enteron Pharmaceuticals, Inc. 1680 Michigan Ave. Suite 700 Miami FL 33139 DD= 8/28/01 MA=
Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium TN= Total Block VL SPF 75	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium dioxide, zinc oxidephotodynamic therapy	Fallien Cosmeceuticals Ltd. 677 W. Dekalb Pike King of Prussia PA 19406 DD= 8/13/01 MA=
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	SuperGen, Inc. 4140 Dublin Boulevard Dublin CA 94568 DD= 3/5/01 MA=
Coenzyme Q10 TN=	For the treatment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
DHA-paclitaxel TN=Taxoprexin	Treatment of pancreatic cancer	Protarga, Inc. 2200 Renaissance Blvd. Suite 450 King of Prussia PA 19406 DD= 9/25/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Glatiramer acetate for Injection <u>TN=Copaxone</u>	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road North Wales PA 19454 DD= 6/5/01 MA=
h5G1.1mAb <u>TN=</u>	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=
Hsp E7 <u>TN=</u>	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=
human gammaglobulin <u>TN=</u>	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747 DD= 5/25/01 MA=
humanized monoclonal antibody against Shiga-like toxin II <u>TN=</u>	To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Teijin America, Inc. 600 Alexander Park Suite 304 Princeton NJ 08540 DD= 9/12/01 MA=
Imatinib <u>TN=Gleevec</u>	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA= 5/10/01

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	<u>Indication Designated:</u>	Sponsor & Address DD=Date Designated MA=Marketing Approval
Imexon <u>TN= n/a</u>	Treatment of metastatic malignant melanoma	AmpliMed Corporation 2321 Camino La Zorrela Tucson AZ 85718 DD= 8/3/01 MA=
INH-A00021 <u>TN=</u>	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway Suite 150 Alpharetta GA 30004 DD= 6/13/01 MA=
Interferon-alfa-1b <u>TN=</u>	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Cleveland OH 44195 DD= 4/17/01 MA=
Intraoral fluoride releasing system <u>TN=IFRS</u>	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc. 1120 Win Drive Bethlehem PA 18017 DD= 7/31/01 MA=
L-glutamine <u>TN=</u>	Treatment of sickle cell disease	Orphan Drugs International, LLC PO Box 0401 Montrose CA 91021-0401 DD= 8/1/01 MA=
Latrodectus immune F(ab)2 <u>TN=Aracmyn</u>	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 6/18/01 MA=
Medroxyprogesterone acetate <u>TN=Hematrol</u>	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	Indication Designated:	Sponsor & Address DD=Date Designated <u>MA=Marketing Approval</u>
metreleptin TN=	Treatment of metabolic disorders secondary to lipodystrophy	Amgen, Inc., One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 8/22/01 MA=
metreleptin TN=	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 8/22/01 MA=
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes TN=	Treatment of children and adolescent osteosarcoma	Jenner Biotherapies, Inc. 541 Kenosa Street Walworth WI 53184 DD= 6/5/01 MA=
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=
oglufanide disodium TN=	Treatment of ovarian cancer	Cytran, Inc. 10230 NE Points Dr., NE Suite 530 Kirkland WA 98033-7869 DD= 9/24/01 MA=
p1-(uridine 5'--p4-(2'-deoxycytidin e 5') tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=
pemetrexed disodium TN=Alimta	Treatment of malignant pleural mesothelioma	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 DD= 8/28/01 MA=
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	<u>Indication Designated:</u>	Sponsor & Address DD=Date Designated MA=Marketing Approval
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=
recombinant human alpha-1 antitrypsin (rAAT) TN=	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Baxter Healthcare Corporation 550 N. Brand Blvd. Glendale CA 91203 DD= 8/28/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
recombinant human endostatin protein TN=	Treatment of neuroendocrine tumors.	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 8/13/01 MA=
Reviparin sodium TN=Clivarine	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
Reviparin sodium TN=Clivarine	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=

Orphan Products Designations and Approvals List
September 2001

Name: Generic Name <u>TN=Trade Name</u>	<u>Indication Designated:</u>	Sponsor & Address DD=Date Designated MA=Marketing Approval
squalamine lactate <u>TN=</u>	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462 DD= 5/11/01 MA=
Synthetic Human Parathyroid Hormone 1-34 <u>TN=</u>	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Thyrotropin alfa <u>TN=Thyrogen</u>	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 8/3/01 MA=
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody <u>TN=</u>	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=
Vasoactive intestinal peptide <u>TN=</u>	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin <u>TN=Virulizin</u>	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2001 ADDITIONS

PREScription AND oTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
D and PED represent Pediatric Exclusivity

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	CODE	EXCLUS CODE	EXCLUS CODE	EXPIRES
>ADD>							
>ADD>							
021205 001	ABACAVIR SULFATE; TRIZIVIR						
>ADD>							
020977 001	ABACAVIR SULFATE; ZIAGEN						
>ADD>							
020978 001	ABACAVIR SULFATE; ZIAGEN						
>ADD>							
021082 001	ACETAMINOPHEN; TAVIST ALLERGY/SINUS						
021123 001	ACETAMINOPHEN; ULTRACET	5336691	AUG 09, 2011				
020760 001	ALATROFLOXACIN MESYLATE; TROVAN PRESERVATIVE	6194429	JUL 23, 2018	NCE	DEC 18,		
020760 002	ALATROFLOXACIN MESYLATE; TROVAN PRESERVATIVE	6194429	JUL 23, 2018	NP	APR 30,		
020949 001	ALBUTEROL SULFATE; ACCUNEB	6251368	DEC 04, 2012	NP	APR 30,		
020949 002	ALBUTEROL SULFATE; DUONEB	5897031	JUN 21, 2016	NC	MAR 21,		
020950 001	ALBUTEROL SULFATE; VENTOLIN HFA	6194004	DEC 02, 2012	I-235	SEP 23,		
020983 001	ALBUTEROL SULFATE; VENTOLIN HFA	6225294	JUL 17, 2018	I-262	JUN 02,		
021074 001	ALCOHOL; AVAGARD	5565447	JUL 17, 2018	NC	JUN 07,		
020560 001	ALENDRONATE SODIUM; FOSAMAX	5565447	MAR 27, 2014	NCE	MAY 07,		
020560 004	ALENDRONATE SODIUM; FOSAMAX	5360800	MAR 27, 2014	NCE	MAY 07,		
020560 005	ALENDRONATE SODIUM; FOSAMAX	6284770	OCT 05, 2018	U-405			
021001 001	ALMOTRIPTAN MALATE; AXERT	4879303	MAR 25, 2007				
021001 002	ALMOTRIPTAN MALATE; AXERT	4572909	JUL 31, 2006				
021107 001	ALOSETRON HYDROCHLORIDE; LOTRONEX	4879303*PED	SEP 25, 2007				
>ADD>							
019787 001	AMLDIPINE BESYLATE; NORVASC	4879303*PED	JAN 31, 2007				
>ADD>							
>ADD>							
019787 002	AMLDIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007				
>ADD>							
>ADD>							
019787 003	AMLDIPINE BESYLATE; NORVASC	4572909	JUL 31, 2006				
>ADD>							
>ADD>							
020883 001	ARGATROBAN; ACOVIA	4879303*PED	SEP 25, 2007				
>ADD>							
021078 001	ATOVAQUONE; MALARONE	4572909*PED	JAN 31, 2007				
>ADD>							
021078 002	ATOVAQUONE; MALARONE PEDIATRIC	5214052	MAR 13, 2012	U-406 NC	JUL 14,		
>ADD>							
021078 003	ATOVAQUONE; MALARONE	6166046	NOV 25, 2013	NOV 25,			
>ADD>							
021078 004	ATOVAQUONE; MALARONE	5053432	OCT 01, 2008	OCT 01,			
>ADD>							
021078 005	ATOVAQUONE; MALARONE	6291488	NOV 25, 2013	NOV 25,			
>ADD>							
021078 006	ATOVAQUONE; MALARONE	5053432	OCT 01, 2008	OCT 01,			
>ADD>							
021078 007	ATOVAQUONE; MALARONE	6291488	NOV 25, 2013	NOV 25,			

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

גָּדְעָן וְעַמְּלֵךְ כָּל־יִשְׂרָאֵל

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPRES
019408 002 021056 001	BETAMETHASONE DIPROPIONATE; DIPROLENE BEVAROTENE; TARGETIN	4489070 5780676 5962731 5466861 1712251 5712251 56888819	MAY 13, 2003 JUL 14, 2015 OCT 05, 2016 NOV 14, 2012 SEP 18, 2001 SEP 18, 2001 SEP 21, 2012	ODE	DEC 29, 2006	
020498 001	BICALUTAMIDE; CASODEX					
>ADD> >ADD> >ADD>	BIMATOPROST; LUNIGAN BOSENTAN; TRACLEER					
021275 001 021290 001	BRIMONIDINE TARTRATE; ALPHAGAN	6194415 6248741 6194415*PED DEC 28, 6248741*PED DEC 28, 6194415*PED DEC 28, 5736165 APR 07, 5736165*PED OCT 07, 6248741 JUN 28, 6194415 JUN 28, 6244741*PED DEC 28, 5424078 JUN 13, 5424078*PED DEC 13, 5378703 APR 01,	JUN 28, 2015 JUN 28, 2015 JUN 28, 2015 APR 07, 2015 JUN 28, 2015 JUN 28, 2015 JUN 28, 2015 JUN 28, 2015 JUN 13, 2012 JUN 13, 2012 APR 01, 2012	U-391 U-391 U-394 U-394 U-395 U-395 U-395 U-395 U-395 U-395 U-224	NCE NCE NCE NCE NCE NCE NCE NCE NCE NCE NP	MAR 16, 2006 NOV 20, 2006 SEP 06, 2001 MAR 06, 2002 SEP 06, 2001 MAR 06,
020490 001	BRIMONIDINE TARTRATE; ALPHAGAN P					
020613 001	BRIMONIDINE TARTRATE; ALPHAGAN					
021262 001	BRIMONIDINE TARTRATE; ALPHAGAN P					
>ADD> >ADD>	BRINZOLAMIDE; AZOPT BUDESONIDE; ENTOCORT BUDESONIDE; RHINOCORT					
020816 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR					
021124 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR					
020746 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR					
020338 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR					
020358 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR					
020358 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR					
>ADD> >ADD>	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR					
>ADD> >ADD>	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR					
018731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR					
074253 001	BUSPIRONE HYDROCHLORIDE; BUSPIRONE HCL					
074253 002	BUSPIRONE HYDROCHLORIDE; BUSPIRONE HCL					
075272 003	BUSPIRONE HYDROCHLORIDE; BUSPIRONE HCL					
075467 002	BUSPIRONE HYDROCHLORIDE; BUSPIRONE HCL					
076008 001	BUSPIRONE HYDROCHLORIDE; BUSPIRONE HCL					
020524 001	BUTENAFINE HYDROCHLORIDE; MENTAX CALCITRIOL; CALCIQUEX					
>ADD> >ADD>						
018874 001						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD>	CALCITRIOL; CALCIJEX	6274169*PED 6265392*PED	FEB 02, FEB 02,	2020 2020			
018874 002		4308264 6051567 4308264*PED 6051567*PED	JAN 28, AUG 02, JUL 28, FEB 02,	2001 2019 2001 2020			
		6265392 6274169 4870105 4870105 4870105 4870105	AUG 02, AUG 02, APR 07, APR 07, APR 07, APR 07,	2019 2019 2007 2007 2007 2019			
019976 001	CALCIUM ACETATE; PHOSLO	4870105 4870105 4870105 4870105	APR 07, APR 07, APR 07, APR 07,	2007 2007 2007 2007			
021160 001	CALCIUM ACETATE; PHOSLO						U-381
021160 002	CALCIUM ACETATE; PHOSLO						U-381
021160 003	CALCIUM ACETATE; PHOSLO GELCAPS						U-381
020896 001	CAPECITABINE; XELODA						
020896 002	CAPECITABINE; XELODA						
>ADD>							
>ADD> >ADD>	CARVEDILOL; COREG	5952300 5378804 5514650	MAR 28, MAR 16, MAR 16,	2017 2013 2013			
>ADD> >ADD>	CARVEDILOL; COREG	5792746 6136783	MAR 16, MAR 28,	2013 2017			
>ADD> >ADD>	CARVEDILOL; COREG	5952300 5378804	MAR 28, MAR 16,	2017 2013			
>ADD>	CASPOFUNGIN ACETATE; CANCIDAS	5514650 5792746 6136783	MAR 16, MAY 16, MAY 28,	2013 2013 2017			
021227 002	CASPOFUNGIN ACETATE; CANCIDAS				NCE	JAN 26,	2006
020998 001	CELECOXIB; CELEBREX	4762709 5767251 4957730 4847265 6177101 4910214 5922736 5908850	AUG 09, JUN 16, SEP 18, NOV 17, JUN 11, JUL 15, DEC 04, DEC 04,	2005 2015 2007 2011 2018 2008 2015 2015		I-338 OCT 17, OCT 17, NP U-379	OCT 17, 2004 2004
020998 002	CELECOXIB; CELEBREX						
019111 001	CHLORPHENIRAMINE POLISTIREX; TUSSIONEX						
021149 001	CHORIOTONADOTROPIN ALFA; OVIDREL						
021022 001	CICLOPIROX; PENLAC						
020839 001	CLOPIDOGREL BISULFATE; PLAVIX						
020705 001	DELAVIDRINE MESYLATE; RESCRIPTOR						
>ADD>	DEXMEDETOMIDINE; PRECEDEX						
021038 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; DEXMETHYLPHENIDATE H						
>ADD>							
>ADD>							
>ADD>							
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; DEXMETHYLPHENIDATE H	6255325 5908850	DEC 04, DEC 04,	2015 2015	U-424 U-423	NOV 13,	2004
>ADD>							
>ADD>							
>ADD>							
		6255325	DEC 04,	2015	U-424 U-422		

PRESCRIPTION AND OTC DRUG PRODUCT

*PED and PED represent Pediatric Exclusivity
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT

* PED and PED represent Pediatric Exclusivity

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020623 001	DOLasetron Mesylate MONOHYDRATE ; ANZEMET	4906755	JUL 02, 2011	JUL 02,	2011		
020623 002	DOLasetron Mesylate MONOHYDRATE ; ANZEMET	4906755	JUL 02, 2011	JUL 02,	2011		
020624 001	DOLasetron Mesylate MONOHYDRATE ; ANZEMET	4906755	JUL 02, 2011	JUL 02,	2011		
020690 001	DONEpezil HYDROCHLORIDE ; ARICEPT	6140321	DEC 30, 2016	DEC 01,	2018		
020690 002	DONEpezil HYDROCHLORIDE ; ARICEPT	6245911	DEC 30, 2016	DEC 01,	2016		
		5985864	DEC 30, 2016	DEC 01,	2016		
		6140321	DEC 30, 2016	DEC 01,	2016		
		6245911	DEC 01, 2018	DEC 01,	2016		
		5985864	DEC 01, 2016	DEC 30,	2016		
		6248735	APR 17, 2011	NCE	NCE	MAY 11, 2004	
						NOV 20, 2006	
020869 001	DORZOLAMIDE HYDROCHLORIDE ; COSOPT	4430343	AUG 14, 2005	U-403			
021098 001	DROSPIRENONE ; YASMIN	5441958	DEC 08, 2013	U-404			
021319 001	DUTASTERIDE ; DUTASTERIDE	4264611	JUN 19, 2001	U-3			
>ADD>	EMEDASTINE DIFUMARATE ; EMADINE	4803081	APR 03, 2007				
020706 001	ENALAPRIL MALEATE ; LEXXEL	4264611*PED	DEC 19, 2001	U-3			
		4803081*PED	OCT 03, 2007				
		4374829	DEC 30, 2001	U-3			
		4472380	SEP 18, 2001				
		4703038	OCT 07, 2005	U-3			
		4803081	APR 03, 2007				
		4264611	JUN 19, 2001	U-3			
		4264611*PED	DEC 19, 2001	U-3			
		4803081*PED	OCT 03, 2007				
>ADD>	018998 001	ENALAPRIL MALEATE ; VASOTEC	4486420	DEC 04, 2001	U-122	FEB 13, 2004	
>ADD>	018998 002	ENALAPRIL MALEATE ; VASOTEC	4692435	DEC 24, 2004	U-123	AUG 13, 2004	
>ADD>	018998 003	ENALAPRIL MALEATE ; VASOTEC	5389618	FEB 14, 2012		FEB 13, 2004	
>ADD>	018998 005	ENALAPRIL MALEATE ; VASOTEC	4486420	DBC 04,	2001	M-7	
>ADD>	020164 002	ENOXAPARIN SODIUM ; LOVENOX	4692435	DEC 24,	2004	PED	
		5389618	4486420	DEC 04,	2001	AUG 13,	
		4486420	4692435	DBC 24,	2004		
		5389618	5389618	4486420	DEC 04,		
				4692435	DBC 24,		
				5389618	FEB 14,		
				4486420	DEC 04,		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5389618	5389618		
				4486420	4486420		
				4692435	4692435		
				5			

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPRIES
020164 006	ENOXAPARIN SODIUM; LOVENOX	4486420	DEC 04, 2001				
020164 007	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	U-123			
020164 008	ENOXAPARIN SODIUM; LOVENOX	5389618	FEB 14, 2012				
>ADD>	021268 001	4486420	DEC 04, 2001	U-122			
>ADD>	021268 002	4692435	DEC 24, 2004	U-123			
>ADD>	020718 001	5389618	FEB 14, 2012				
>ADD>	020718 002	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004	
>ADD>	019386 001	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004	
019386 002	EPTIFIBATIDE; INTEGRILIN	6310094	JAN 12, 2021				
019386 003	EPTIFIBATIDE; INTEGRILIN ESMOLOL HYDROCHLORIDE; BREVIBLOC	5017609	MAY 21, 2008				
021153 001	ESOMEPRAZOLE MAGNESIUM; NEXIUM	5017609	MAY 21, 2008				
		4593119	JUN 03, 2003				
		4255431	APR 05, 2001	U-373	NP	FEB 20, 2004	
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				
		4255431	APR 05, 2001	U-373			
		4738974	APR 19, 2005	U-373			
		4636499	MAY 30, 2005	U-373			
		5900424	MAY 04, 2016	U-373			
		4786505	APR 20, 2007	U-373			
		4853230	APR 20, 2007	U-373			
		5714504	FEB 03, 2015	U-373			
		5877192	MAY 27, 2014	U-373			
		5093342	FEB 02, 2010	U-373			
		5599794	FEB 04, 2014	U-373			
		5629305	FEB 04, 2014	U-373			
		5690960	NOV 25, 2014	U-373			
		6147103	OCT 09, 2018				
		6166213	OCT 09, 2018				
		6191148	OCT 09, 2018				
		4508905	FEB 20, 2001				

PRESCRIPTION AND OTC DRUG PRODUCT

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020870 001	ESTRADIOL; COMBIPATCH	5474783	DEC 12, 2012				
		5656286	AUG 12, 2014				
		5958446	DEC 12, 2012				
020870 002	ESTRADIOL; COMBIPATCH	6024976	JAN 07, 2014				
		5474783	DEC 12, 2012				
		5656286	AUG 12, 2014				
		5958446	DEC 12, 2012				
020538 005	ESTRADIOL; VIVELLE-DOT	6024976	JAN 07, 2014				
		5474783	DEC 12, 2012				
		5656286	AUG 12, 2014				
020538 006	ESTRADIOL; VIVELLE-DOT	5474783	DEC 12, 2012				
		5656286	AUG 12, 2014				
020538 007	ESTRADIOL; VIVELLE-DOT	5958446	DEC 12, 2012				
		6024976	JAN 07, 2014				
020538 008	ESTRADIOL; VIVELLE-DOT	5474783	DEC 12, 2012				
		5656286	AUG 12, 2014				
020130 002	ETHINYL ESTRADIOL; ESTROSTEP FE	5958446	DEC 12, 2012				
020130 001	ETHINYL ESTRADIOL; ESTROSTEP 21	5010070	APR 23, 2008				
021187 001	ETHINYL ESTRADIOL; NUVA RING	5010070	APR 23, 2008				
021180 001	ETHINYL ESTRADIOL; OTHO EVRA	6156742	DEC 05, 2020				
020946 001	ETHINYL ESTRADIOL; PREVEN EMERGENCY CON	6156742	DEC 05, 2020				
020584 001	ETODOLAC; LODINE XL	5474783	DEC 12, 2012				
020584 002	ETODOLAC; LODINE XL	5656286	AUG 12, 2014				
020584 003	ETODOLAC; LODINE XL	5958446	DEC 12, 2012				
020457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010				
020906 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008				
020906 002	ETOPOSIDE PHOSPHATE; ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010				
075312 001	FAMOTIDINE; FAMOTIDINE	5041424	AUG 20, 2008				
020902 001	FAMOTIDINE; PEPcid AC	RE35524	MAY 17, 2010				
019834 001	FELODIPINE; PLENDIL	4264611	JUN 19, 2001				
		4803081	APR 03, 2007				
		4803081*PED	OCT 03, 2007				
		4264611*PED	DEC 19, 2001				
		PC	NOV 28,				
		D-47	NOV 09,				
		PED	MAY 09,				

REBATES EXCEPT ON OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE CODE	EXCLUS EXPIRES CODE	EXCLUS EXPIRES CODE
>ADD> 020831 001	FORMOTEROL FUMARATE; FORADIL			NCE FEB 16, 2006	
021279 001	FORMOTEROL FUMARATE; FORADIL			I-342 SEP 25, 2004	
>ADD> 021006 001	FROVATRIPTAN SUCCINATE; FROVA	5464864	NOV 07, 2012	U-72 NCE	NCE FEB 16, 2006
>ADD>		5616603	APR 01, 2014	U-72	NOV 08, 2006
>ADD>		5637611	JUN 10, 2014	U-72	
>ADD>		5827871	OCT 27, 2015	U-72	
>ADD>		5962501	DEC 16, 2013	U-72	
>ADD> 021129 001	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008		
>ADD>		5084479	JAN 02, 2010	U-258	
>ADD> 021169 001	GALANTAMINE HYDROBROMIDE; REMINYL	6099863	JUN 06, 2017	NCE	FEB 28, 2006
>ADD> 021169 002	GALANTAMINE HYDROBROMIDE; REMINYL	6099863	JUN 06, 2017	NCE	FEB 28, 2006
>ADD> 021169 003	GALANTAMINE HYDROBROMIDE; REMINYL	6099863	JAN 15, 2006	NCE	FEB 28, 2006
>ADD> 021224 001	GALANTAMINE HYDROBROMIDE; REMINYL	4663318	JAN 15, 2006	NCE	FEB 28, 2006
021061 001	GATIFLOXACIN; TEQUIN	6099863	JUN 06, 2017	NCE	FEB 28, 2006
021061 002	GATIFLOXACIN; TEQUIN	4663318	JAN 15, 2006	NCE	FEB 28, 2006
021062 001	GATIFLOXACIN; TEQUIN	6099863	JUN 06, 2017	NCE	FEB 28, 2006
021062 002	GATIFLOXACIN; TEQUIN	4663318	JAN 15, 2006	NCE	FEB 28, 2006
>ADD> 021178 001	GLYBURIDE; GLUCOVANCE	6099863	JAN 15, 2006	NCE	FEB 28, 2006
>ADD> 021178 002	GLYBURIDE; GLUCOVANCE	6303146	JUL 14, 2019	D-69	OCT 12, 2004
>ADD> 021178 003	GLYBURIDE; GLUCOVANCE	6303146	JUL 14, 2019	D-69	OCT 12, 2004
>ADD> 020239 001	GRANISETRON HYDROCHLORIDE; KYTRIL	6294548	MAY 04, 2019	D-69	OCT 12, 2004
>ADD> 020239 002	GRANISETRON HYDROCHLORIDE; KYTRIL	6294548	MAY 04, 2019	D-69	OCT 12, 2004
021238 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886803	DEC 29, 2007	U-89	
020387 001	HYDROCHLOROTHIAZIDE; HYZAAR	4886803	DEC 29, 2007	U-105	I-264 JUL 27, 2002
020387 002	HYDROCHLOROTHIAZIDE; HYZAAR	5608075	MAR 04, 2014		
>ADD> 019778 001	HYDROCHLOROTHIAZIDE; PRINZIDE	5608075	MAR 04, 2014		
>ADD> 019778 002	HYDROCHLOROTHIAZIDE; PRINZIDE	4374829	DEC 29, 2001	U-3	
>ADD>		4374829*PED	JUN 29, 2002		
>ADD> 019778 003	HYDROCHLOROTHIAZIDE; PRINZIDE	4374829	DEC 29, 2001	U-3	
>ADD>		4374829*PED	JUN 29, 2002		
>ADD> 019888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC	4374829	DEC 29, 2001	U-3	
>ADD> 019888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC	4374829	DEC 29, 2001	U-3	
>ADD> 019888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC	4374829	DEC 29, 2001	U-3	
>ADD>		4374829*PED	JUN 29, 2002		
020402 002	IBUPROFEN POTASSIUM; ADVIL MIGRAINE LIQUI	6211246	JUN 10, 2019	NP	MAR 16, 2003
021128 001	IBUPROFEN; CHILDREN'S MOTRIN CO				

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
PED and PED represent Pediatric Exclusivity

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>>ADD>	021335 001	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013	NCE	MAY 10, 2006
>>ADD>	021335 002	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013	ODE	MAY 10, 2008
>>ADD>	021172 001	INSULIN ASPART RECOMBINANT; NOVOLOG MIX 70/30 INSULIN GLARGINE; LANTUS	5656722	SEP 12, 2014	I-327	OCT 27, 2003
021081 001	IPRATROPIUM BROMIDE; ATROVENT ISOTRETINOIN; ACCUTANE	5656722*PED MAR 12, 2015	4464394 AUG 07, 2001			
020394 001	ISOTRETINOIN; ACCUTANE	4464394*PED FEB 07, 2002	4464394 AUG 07, 2001			
018662 002	ISOTRETINOIN; ACCUTANE	4464394*PED FEB 07, 2002	4464394 AUG 07, 2001			
018662 003	ISOTRETINOIN; ACCUTANE	4464394*PED FEB 07, 2002	4464394 AUG 07, 2001			
018662 004	ISOTRETINOIN; ACCUTANE	4464394*PED FEB 07, 2002	4464394 AUG 07, 2001			
020657 001	ITRACONAZOLE; SPORANOX ITRACONAZOLE; SPORANOX KETOROLAC TROMETHAMINE; ACULAR	4791111 DEC 23, 2005	4791111 DEC 23, 2005			
020966 001	KETOROLAC TROMETHAMINE; ACULAR	4454151 MAR 22, 2002	4454151 MAR 22, 2002			
019700 001		5110493 MAY 05, 2009	5110493 MAY 05, 2009			
		4454151*PED SEP 22, 2002	4454151*PED SEP 22, 2002			
		5110493*PED NOV 05, 2009	5110493*PED NOV 05, 2009			
		U-75	U-75			
020811 001	KETOROLAC TROMETHAMINE; ACULAR PRESERVATIVE	4454151 MAR 22, 2002	4454151 MAR 22, 2002			
>>ADD>	020857 001	LAMIVUDINE; COMBIVIR	6180639*PED JUL 30, 2018	6180639*PED JUL 30, 2018		U-248
>>ADD>	020564 001	LAMIVUDINE; EPIVIR	6180639 JAN 30, 2018	6180639 JAN 30, 2018		U-248
>>ADD>	020596 001	LAMIVUDINE; EPIVIR	6180639*PED JUL 30, 2018	6180639*PED JUL 30, 2018		U-248
>>ADD>	021003 001	LAMIVUDINE; EPIVIR-HBV	6180639 JAN 30, 2018	6180639 JAN 30, 2018		U-248
>>ADD>	021004 001	LAMIVUDINE; EPIVIR-HBV	6180639 JAN 30, 2018	6180639 JAN 30, 2018		U-248
>>ADD>	021281 001	LANSOPRAZOLE; PREVACID	6180639 JAN 30, 2018	6180639 JAN 30, 2018		U-248
021281 002	LANSOPRAZOLE; PREVACID	I-339 AUG 16, 2004	I-339 AUG 16, 2004			
		PED FEB 16, 2005	PED FEB 16, 2005			
		M-1 JUL 06, 2002	M-1 JUL 06, 2002			
		D-42 JUL 20, 2001	D-42 JUL 20, 2001			
		I-316 NOV 30, 2003	I-316 NOV 30, 2003			
		M-1 JUL 06, 2002	M-1 JUL 06, 2002			
		D-42 JUL 20, 2001	D-42 JUL 20, 2001			
020905 001	LEFLUNOMIDE; ARAVA	4284786 DEC 13, 2001	4284786 DEC 13, 2001			
020905 002	LEFLUNOMIDE; ARAVA	4284786 DEC 13, 2001	4284786 DEC 13, 2001			
020905 003	LEFLUNOMIDE; ARAVA	4284786 DEC 13, 2001	4284786 DEC 13, 2001			
020726 001	LETROZOLE; Femara	4978672 JUN 03, 2011	4978672 JUN 03, 2011			
019732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5631021 NOV 01, 2004	5631021 NOV 01, 2004			
>>ADD>		5476663 NOV 01, 2004	5476663 NOV 01, 2004			
>>ADD>		5575987 SEP 02, 2013	5575987 SEP 02, 2013			
>>ADD>		6036976 DEC 13, 2013	6036976 DEC 13, 2013			
		U-203				

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
>ADD>	020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020 5476663	NOV 01, 2004 NOV 01, 2004		
>ADD>	020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5575987 5643607	SEP 02, 2013 JAN 02, 2013		
>ADD>			5631021	NOV 01, 2004		
>ADD>			5476663	NOV 01, 2004		
>ADD>			5814342	FEB 01, 2011		
>ADD>			6036976	DEC 13, 2016		
>ADD>	020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021 5476663	NOV 01, 2004 NOV 01, 2004		
>ADD>			5575987	SEP 02, 2013		
>ADD>			6036976	DEC 13, 2013		
>ADD>	020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT - PED	5631021 5475987	NOV 01, 2004 SEP 02, 2013		
>ADD>			5476663	NOV 01, 2004		
>ADD>			6036976	DEC 13, 2013		
>ADD>	020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT - PED	5631021 5476663	NOV 01, 2004 NOV 01, 2004		
>ADD>			5575987	SEP 02, 2013		
>ADD>			6036976	DEC 13, 2013		
>ADD>	020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT - PED	5631021 5476663	NOV 01, 2004 NOV 01, 2004		
>ADD>			5575987	SEP 02, 2013		
>ADD>			6036976	DEC 13, 2013		
>ADD>	020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT - PED	5631021 5476663	NOV 01, 2004 NOV 01, 2004		
>ADD>			5575987	SEP 02, 2013		
>ADD>	020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT - 3	5631021 5476663	NOV 01, 2004 NOV 01, 2004		
>ADD>			5643607	JAN 02, 2013		
>ADD>			5814342	FEB 01, 2011		
>ADD>			6036976	DEC 13, 2016		
>ADD>			5631021	NOV 01, 2004		
>ADD>			5476663	NOV 01, 2004		
>ADD>			5643607	JAN 02, 2013		
>ADD>			5814342	FEB 01, 2011		
>ADD>			6036976	DEC 13, 2016		
>ADD>	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712 4374829	JUN 13, 2017 DEC 29, 2001		
>ADD>	019558 001	LISINOPRIL;PRINTVIL	4374829*PED	JUN 29, 2002		
>ADD>	019558 002	LISINOPRIL;PRINTVIL	4374829	DEC 29, 2001		
>ADD>	019558 003	LISINOPRIL;PRINVIL	4374829*PED	JUN 29, 2002		
>ADD>			4374829	DEC 29, 2001		
>ADD>			4374829*PED	JUN 29, 2002		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUSIVITY EXPIRES
>ADD>	019558 004	LISINOPRIL;PRINIVIL	4374829 DEC 29, 2001			
>ADD>	019558 006	LISINOPRIL;PRINIVIL	4374829* PED JUN 29, 2002			
>ADD>	019777 001	LISINOPRIL;ZESTRIL	4374829 DEC 29, 2001			
>ADD>	019777 002	LISINOPRIL;ZESTRIL	4374829* PED JUN 29, 2002			
>ADD>	019777 003	LISINOPRIL;ZESTRIL	4374829* PED JUN 29, 2002			
>ADD>	019777 004	LISINOPRIL;ZESTRIL	4374829 DEC 29, 2001			
>ADD>	019777 005	LISINOPRIL;ZESTRIL	4374829* PED JUN 29, 2002			
>ADD>	019777 006	LISINOPRIL;ZESTRIL	4374829 DEC 29, 2001			
>ADD>	021226 001	LOPINAVIR;KALETRA	6232333 NOV 07, 2017			
021251 001	LOPINAVIR;KALETRA	6284767 FEB 14, 2016	U-401			
020386 001	LOSARTAN POTASSIUM;COZAAR	5608075 MAR 04, 2014				
020386 002	LOSARTAN POTASSIUM;COZAAR	5608075 MAR 04, 2014				
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069 AUG 11, 2009				
019643 002	LOVASTATIN;MEVACOR	5153197 OCT 06, 2009	U-3			
019643 003	LOVASTATIN;MEVACOR	5608075 MAR 04, 2014				
019643 004	LOVASTATIN;MEVACOR	4231938 JUN 15, 2001	I-250	MAR 11, 2002		
075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE	4231938* PED DEC 15, 2001		PED	SEP 11, 2002	
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	4231938 JUN 15, 2001		I-250	MAR 11, 2002	
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	4231938 JUN 15, 2001		PED	SEP 11, 2002	
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	4231938* PED DEC 15, 2001		PED	SEP 11, 2002	
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	4231938 JUN 15, 2001		I-250	MAR 11, 2002	
020357 005	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4231938* PED DEC 15, 2001		PED	SEP 11, 2002	
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337 SEP 16, 2003	U-372	PC	JAN 12, 2002	
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337 SEP 16, 2003	U-372	M-6	APR 19, 2004	
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337 SEP 16, 2003	U-372	M-6	APR 19, 2004	
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	4927640 MAY 22, 2007		NDF	APR 03, 2004	
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5246714 SEP 21, 2010		I-194	FEB 05, 2004	
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640 MAY 22, 2007				
		5246714 SEP 21, 2010				

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
021085 001 021277 001 <u>>ADD:</u> <u>>ADD:</u>	MOXIFLOXACIN HYDROCHLORIDE; AVELOX MOXIFLOXACIN HYDROCHLORIDE; AVELOX	I-329 NCE NDF	APR 27, DEC 10, NOV 30,	2004 2004 2004		
075179 001 075189 001 075189 002 019583 001	NABUMETONE; NABUMETONE NABUMETONE; NABUMETONE NABUMETONE; NABUMETONE NABUMETONE; RELAFEN	4420639 4420639 *PED 4420639 *PED RE34878	DEC 13, JUN 13, DEC 13, MAR 28,	2002 2003 2003 2006		
019583 002	NABUMETONE; RELAFEN	4420639 *PED	JUN 13,	2003		
021204 001	NATEGLINIDE; STARLIX	4420639 *PED	JUN 13,	2003		
021204 002	NATEGLINIDE; STARLIX	RE34878 5463116 5488150 RE34878 5463116 5488150 5114923 5674710 6165497 5633008 5633008 6165497 5633008 6165497	OCT 21, OCT 21, JAN 30, OCT 21, OCT 21, JAN 30, MAY 19, OCT 07, JUN 14, JUN 14, JUN 14, JUN 14, JUN 14, JUN 14,	2012 2012 2013 2006 2012 2013 2009 2014 2008 2008 2008 2008 2008 2008		
020920 001	NESTIRITIDE; NATRECOR				AUG 10,	2006
020165 004 020165 005 020165 006	NICOTINE; NICODERM CQ NICOTINE; NICODERM CQ NICOTINE; NICODERM CQ	5114923 5674710 6165497 5633008 5633008 6165497 5633008 6165497	MAY 19, OCT 07, JUN 14, JUN 14, JUN 14, JUN 14, JUN 14, JUN 14,	2009 2014 2008 2008 2008 2008 2008 U-388 U-389 U-389 U-388 U-388 U-389		
075269 002 019667 001 019667 002 019667 003 019667 004 019667 005 021008 001 021008 002 021008 003 020799 001 020592 001 020592 002 020592 003 020592 004 <u>>ADD:</u> 020592 005	NIFEDIPINE; NIFEDIPINE OCTREOTIDE ACETATE SANDOSTATIN OCTREOTIDE ACETATE SANDOSTATIN OCTREOTIDE ACETATE SANDOSTATIN OCTREOTIDE ACETATE SANDOSTATIN LAR OCTREOTIDE ACETATE SANDOSTATIN LAR OCTREOTIDE ACETATE SANDOSTATIN LAR OCTREOTIDE ACETATE SANDOSTATIN LAR OFLOXACIN; FLOXIN OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA OLANZAPINE; ZYPREXA	5753618 5753618 5753618 5753618 5753618 5753618 5753618 5753618 5753618 5753618 6251895 6251895 6251895 6251895 6251895 5401741 6251895 6251895 6251895 6251895 6251895 5229382 5605897 6251895 5229382 5605897	JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, SEP 23, SEP 23, SEP 23, SEP 23, SEP 23, MAR 27, JUL 08, JUL 08, JUL 08, JUL 08, JUL 08, APR 23, FEB 25, SEP 23, APR 23, FEB 25,	2008 2008 2008 2008 2008 2008 2008 2008 2008 2008 2017 2017 2017 2017 2017 2012 2012 2012 2012 2012 2011 2014 2017 2011 2014		
	OLANZAPINE; ZYPREXA				U-149 U-176	
	OLANZAPINE; ZYPREXA				U-149	
	OLANZAPINE; ZYPREXA				U-149	
	OLANZAPINE; ZYPREXA				U-176	
	OLANZAPINE; ZYPREXA				U-176	
	OLANZAPINE; ZYPREXA				U-176	
	OLANZAPINE; ZYPREXA				U-176	

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
021086 001	OLANZAPINE; ZYPREXA ZYDIS	6020487	SEP 23, 2017			
021086 002	OLANZAPINE; ZYPREXA ZYDIS	6251895	SEP 23, 2017			
021086 003	OLANZAPINE; ZYPREXA ZYDIS	620487	SEP 23, 2017			
021086 004	OLANZAPINE; ZYPREXA ZYDIS	6251895	SEP 23, 2017			
>ADD> 020688 001	OLOPATADINE HYDROCHLORIDE; PATANOL OMEPRAZOLE; PRILOSEC	625195	SEP 23, 2017			
>ADD> 019810 001		5641805	JUN 06, 2015	U-184	PED	DEC 29, 2001
>ADD> 019810 002	OMEПRAZOLE; PRILOSEC	4508905*PED	OCT 02, 2002	PED		
>ADD> 019810 003	OMEПRAZOLE; PRILOSEC	6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001			
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007			
		4853230*PED	OCT 20, 2007			
		5093342*PED	AUG 02, 2010			
		5599794*PED	AUG 04, 2014			
		5629305*PED	AUG 04, 2014			
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002	PED		
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001			
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007			
		4853230*PED	OCT 20, 2007			
		5093342*PED	AUG 02, 2010			
		5599794*PED	AUG 04, 2014			
		5629305*PED	AUG 04, 2014			
		6147103*PED	APR 09, 2014			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002	PED		
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001			
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007			
		4853230*PED	OCT 20, 2007			
		5093342*PED	AUG 02, 2010			
		5599794*PED	AUG 04, 2014			
		5629305*PED	AUG 04, 2014			
		6147103*PED	APR 09, 2014			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002	PED		
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
>ADD> 020781 001 021246 001	ONDANSETRON; ZOFRAN ODT OSELTAMIVIR PHOSPHATE; TAMIFLU	5599794*PED 5629305*PED 6147103*PED 6150380*PED 6166213*PED 6191148*PED	AUG 04, AUG 04, APR 09, MAY 10, APR 09, APR 09,	2014 2014 2019 2019 2018 2019	U-166 U-188		
020897 001	OXYBUTYNIN CHLORIDE; DITROPAN XL	4753789 5763483 5866601 5952375 6124355 6262115 6262115 6262115 6262115 4861598	JUN 24, DEC 27, FEB 02, FEB 02, MAY 22, MAY 22, MAY 22, MAY 22, MAY 22, AUG 29,	2006 2016 2016 2016 2015 2015 2015 2015 2006 2006	U-330 U-376 NDF NCE	NOV 17, DEC 14, OCT 27, 2003 2003 2004	
020897 002	OXYBUTYNIN CHLORIDE; DITROPAN XL	6124355 6262115 6124355 6262115 4861598	MAY 22, MAY 22, MAY 22, MAY 22, NOV 13,	2015 2015 2015 2015 2007	U-378 U-393 U-393 U-393 FEB 05,		
020897 003	OXYBUTYNIN CHLORIDE; DITROPAN XL	6124355 6262115 6262115 4861598	MAY 22, MAY 22, MAY 22, AUG 29,	2015 2015 2015 2006	U-378 U-393 U-393 FEB 05,		
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075 5266331 5549912 4861598 4970075 5266331 5549912 5508042 5656295 6096331 6150198	NOV 13, FEB 05, FEB 05, AUG 29, NOV 13, FEB 05, FEB 05, APR 16, FEB 05, FEB 22, MAY 08,	2007 2008 2008 2006 2007 2008 2008 2013 2008 2013 2011	U-380		
020553 005	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5266331 5549912 5508042 5656295 6096331 6150198	FEB 05, FEB 05, APR 16, FEB 05, FEB 05, MAY 08,	2008 2008 2008 2007 2008 2011			
020262 001	PACLITAXEL; TAXOL						
>ADD> 020036 001 020036 003	PAMIDRONATE DISODIUM; AREDIA PAMIDRONATE DISODIUM; AREDIA	4758579	JUL 19,	2005	I-330 NDF NCE	JUN 12, MAR 22, FEB 02,	
020036 004	PAMIDRONATE DISODIUM; AREDIA				PC	MAY 05,	
>ADD> 075290 001	PAMIDRONATE DISODIUM; PAMIDRONATE DISODIUM				PC	2002	
>ADD> 075290 003	PAMIDRONATE DISODIUM; PAMIDRONATE DISODIUM				PC	MAY 05,	
020987 001	PANTOPRAZOLE SODIUM; PROTONIX				I-330	2004	
020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV				NDF		
>ADD>	020819 001	PARICALCITOL; ZEMPLAR	5246925	APR 17,	2012	U-314 I-337	AUG 20, AUG 20, AUG 20, APR 13, OCT 19,
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL				D-68	2004	
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL				D-68	2004	
020031 003	PAROXETINE HYDROCHLORIDE; PAXIL				D-68	2004	
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL				PC	MAY 05,	
020031 005	PAROXETINE HYDROCHLORIDE; PAXIL				PC	2002	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS CODE EXPIRES	
020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR	4721723 4839177 5422123 5789449 5872132 5900423	DEC 29, 2006 JUN 13, 2006 JUN 06, 2012 JAN 06, 2009 MAY 19, 2015 MAY 19, 2015					
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5769080 6211205 6271243 6303640 6166042 6166043 6172090 5965584 6150383 6150384 6211205 6271243 6303640 6166042 6166043	JUL 20, 2010 JUN 19, 2016 JUN 19, 2016				U-410 U-411 U-411 U-411 U-414 U-415 U-416 U-417 U-418 U-419 U-410 U-411 U-411 U-418 U-419
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021073 002	PIOGLITAZONE HYDROCHLORIDE; ACTOS	6303640 5965584 6150383 6150384 6166043 6172090 6303640 6166042 6166043	JUN 19, 2016 JUN 19, 2016				U-416 U-417 U-416 U-417 U-418 U-419 U-410 U-411 U-425 U-414
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021073 003	PIOGLITAZONE HYDROCHLORIDE; ACTOS	6211205 6271243 6303640 6166042 6166043	JUN 19, 2016 JUN 19, 2016 JUN 19, 2016 JUN 19, 2016 JUN 19, 2016				
>ADD> >ADD> >ADD> >ADD> >ADD>	020667 005 019627 002	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX PROPOFOL; DIPRIVAN	5965584 6150383 6150384 6172090 5965584 6150383 48866812	JUN 19, 2016 JUN 19, 2016 JUN 19, 2016 JUN 19, 2016 JUN 19, 2016 JUN 19, 2016 MAR 25, 2011			I-322 FEB 20, 2004 PED AUG 20, 2004	

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5035899	APR 04, 2009	U-385		
019901 001	RAMIPRIL;ALTACE	4418068	APR 03, 2002			
019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
020903 001	RIBAVIRIN;REBETOL	5767097	JUN 23, 2016	U-235	PED	JUN 09, 2002
		5914128	DEC 22, 2017	PED	PED	DEC 03, 2001
		6051252	DEC 22, 2017			
		6063772	JAN 23, 2016	U-375		
		6172046	SEP 21, 2017	U-377		
		5767097*PED	JUL 23, 2016	U-235		
		5914128*PED	JUN 22, 2018			
		6051252*PED	JUN 22, 2018			
		6063772*PED	JUL 23, 2016	U-375		
		6172046*PED	MAR 21, 2018	U-377		
		6150337	NOV 21, 2017	U-400		
		6232333	NOV 21, 2017			
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		5691374	JUN 24, 2013	U-266		
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U-266		
		5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013	U		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

INGREDIENT NAME: TRADE NAME

卷之三

PATENT NUMBER PATENT/PED EXCL USE CODE CORD EXCLUS
NUMBER FXPRTS PED EXCL USE CODE CORD EXCLUS

020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDA	D-65	FEB 16,	2004
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDA	M-9	FEB 16,	2004
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDA	D-65	FEB 16,	2004
		M-9	FEB 16,	2004
>ADD>	021097 001 SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL SOMATROPIN RECOMBINANT;GENOTROPIN	5616346 5633352	MAY 18, MAY 27,	2013 2014
>ADD>	020280 006 SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAY 27,	2014
>ADD>	020280 007 SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAY 27,	2014
>ADD>	020280 001 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 002 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 003 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 004 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 005 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 008 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 009 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 010 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 011 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 012 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
>ADD>	020280 013 SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27,	2014
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF	4978655 4978655*PED	JUN 24, DEC 24,	2008 2008
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF	NP	FEB 22,	2003
021151 003	STAVUDINE;ZERIT	PED	PED	2003
020412 001	STAVUDINE;ZERIT	AUG 22,	AUG 22,	2003
020412 002	STAVUDINE;ZERIT	NP	FEB 22,	2003
020412 003	STAVUDINE;ZERIT	PED	PED	2003

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	EXCL CODE	EXCL EXPIRES
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008	U-94		
>ADD> 021184 002	TAZAROTENE;TAZORAC	4978655	JUN 24, 2008	U-94		
>ADD> 021356 001	TENOFOVIR;VIREAD	4978655*PED	DEC 24, 2008	U-94		
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
019964 001	TERCONAZOLE;TERAZOL 3	5977089	JUL 25, 2017	U-248	I-344	OCT 11, 2004
020898 001	THYROTROPIN ALFA;THYROID	6043230	JUL 25, 2017	U-248	NCE	OCT 26, 2006
		5935946	JUL 25, 2017	U-248		
		4808716	APR 25, 2006	U-248		
		6057305	MAY 02, 2017	U-248		
		5922695	JUL 25, 2017	U-248		
		4358449	NOV 09, 2001			
		5674711	AUG 31, 2010			
		5602006	FEB 11, 2014			
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
		4861760	SEP 25, 2006			
		4861760	SEP 25, 2006			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	5559269	NOV 05, 2013	U-318	NCE	NOV 27, 2001
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	5559269	NOV 05, 2013	U-318		
>ADD> 020397 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX					
>ADD> 020771 001	TOLTERODINE TARTRATE;DETROL					
>ADD> 020771 002	TOLTERODINE TARTRATE;DETROL					
020505 001	TOPIRAMATE;TOPAMAX	ODE	AUG 28,	2008		
020505 002	TOPIRAMATE;TOPAMAX	ODE	AUG 28,	2004		
020505 003	TOPIRAMATE;TOPAMAX	ODE	AUG 28,	2008		
020505 004	TOPIRAMATE;TOPAMAX	ODE	AUG 28,	2008		
020505 005	TOPIRAMATE;TOPAMAX	ODE	AUG 28,	2004		
020505 006	TOPIRAMATE;TOPAMAX	ODE	AUG 28,	2008		
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	I-335	AUG 28,	2004		
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	I-335	AUG 28,	2004		
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	I-335	AUG 28,	2004		
020528 001	TRANDOLAPRIL;MAVIK	ODE	AUG 28,	2008		
020528 002	TRANDOLAPRIL;MAVIK	I-335	AUG 28,	2004		
		4933361	JUN 12, 2007			
		4933361	JUN 12, 2007			

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXPRES	EXCL USE CODE	EXCL CODE	EXCLUS EXPIRES
020528 003 020591 001 020591 002 020591 003 020591 004 021257 001	TRANDOLAPRIL;MAVIK TRANDOLAPRIL;TARKA TRANDOLAPRIL;TARKA TRANDOLAPRIL;TARKA TRANDOLAPRIL;TARKA TRAVOPROST;TRAVATAN	4933361 5721244 5721244 5721244 5721244 5611062	JUN 12, 2007 FEB 24, 2015 FEB 24, 2015 FEB 24, 2015 FEB 24, 2015 DEC 22, 2014	NCE	MAR 16, 2006	
		5631287 5849792 5889052 6235781	DEC 22, 2014 DEC 22, 2014 AUG 03, 2013 JUN 15, 2019	U-382 U-382 U-383 U-382		
019963 001 021108 001	TRETINOIN;RENOVA 'TRETINOIN;RENOVA	RE36068 RE36068 4603146 5955109 6143329 5225205 5192741 5776885 6187341 6187341 4830010 5140993	JUL 29, 2003 JUL 29, 2003 JUL 29, 2003 SEP 21, 2016 JUL 03, 2016 JUL 20, 2010 MAR 09, 2010 JUL 07, 2015 JAN 20, 2019 JAN 20, 2019 OCT 27, 2009 AUG 24, 2009	U-131 U-131 U-131 U-134 U-134 NP NCE	JUN 29, 2004 JUN 15, 2005	
020475 001 020468 001 021288 001	TRETINOIN;RETIN-A MICRO TRIAMCINOLONE ACETONIDE;NASACORT AQ TRIPTORELIN PAMOATE;TRELSTAR	4603146 5955109 6143329 5225205 5192741 5776885 6187341 6187341 4830010 5140993	JUL 29, 2003 SEP 21, 2016 JUL 03, 2016 JUL 20, 2010 MAR 09, 2010 JUL 07, 2015 JAN 20, 2019 JAN 20, 2019 OCT 27, 2009 AUG 24, 2009	U-131 U-134 U-134 NP NCE	JUN 29, 2004 JUN 15, 2005	
020715 001 020759 001 020759 002 020586 002	TRIPTORELIN PAMOATE;TRELSTAR DEPOT TROVAFLOXACIN MESYLATE;TROYAN TROVAFLOXACIN MESYLATE;TROYAN UREA, C-13;BREATHTEK UBT FOR H-	5767067 4845077 4725579 5767067 4845077 4725579	JUN 16, 2015 JUL 04, 2006 FEB 21, 2005 JUN 16, 2015 JUL 04, 2006 FEB 21, 2005	U-148 U-408 U-408 U-408 U-408 U-408		
019415 004	UROFOLLITROPIN;FERTINEX	5767067 4845077 4725579 5767067 4845077 4725579	JUN 16, 2015 JUL 04, 2006 FEB 21, 2005 JUN 16, 2015 JUL 04, 2006 FEB 21, 2005	U-148 U-408 U-408 U-408 U-408 U-408		
019415 005	UROFOLLITROPIN;FERTINEX					
020550 001 020550 002 021304 001 021283 001 021283 002 021283 003 020151 001 020151 002 020151 003 020151 004 020151 005 020151 006 020699 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX VALACYCLOVIR HYDROCHLORIDE;VALTREX VALGANCICLOVIR HYDROCHLORIDE;VALCYTE VALSARTAN;DIOVAN VALSARTAN;DIOVAN VALSARTAN;DIOVAN VENLAFAXINE HYDROCHLORIDE;EFFEXOR VENLAFAXINE HYDROCHLORIDE;EFFEXOR VENLAFAXINE HYDROCHLORIDE;EFFEXOR VENLAFAXINE HYDROCHLORIDE;EFFEXOR VENLAFAXINE HYDROCHLORIDE;EFFEXOR VENLAFAXINE HYDROCHLORIDE;EFFEXOR VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6083953 5399578 5399578 5399578 5399578 5399578 4845077 4725579	JUL 28, 2014 MAR 21, 2012 MAR 21, 2012 MAR 21, 2012 MAR 21, 2012 MAR 21, 2012 JUL 04, 2006 FEB 21, 2005	U-384 NE NCE NCE NCE NCE U-408	D-67 D-67 DEC 23, 2001 DEC 23, 2001 DEC 23, 2001 I-325 I-325 I-325 I-325 I-325 I-325	JUN 25, 2004 JUN 25, 2004 MAR 29, 2004 DEC 23, 2001 DEC 23, 2001 MAY 02, 2004 MAY 02, 2004 MAY 02, 2004 MAY 02, 2004 MAY 02, 2004 MAY 02, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES NEW DOSING SCHEDULE

- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

NEW INDICATION

- I-321 JUVENILE RHEUMATOID ARTHRITIS
- I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
- I-323 COLORECTAL CANCER
- I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
- I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
- I-326 GENERALIZED ANXIETY DISORDER
- I-327 SYMPTOMATIC RELIEF OF RHINOIRRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
- I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
- I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-330 MAINTENANCE OF HEALING OF EROSIONAL ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
- I-331 TREATMENT OF MODERATE ACNE VULGARIS
- I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
- I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
- I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
- I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS

	REFERENCES NEW INDICATION	
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS	U-384 U-385 U-386
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME	U-387
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA	U-388
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS	U-389
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5	U-390
I-341	BREAST CANCER COMBINATION THERAPY	U-390
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICITION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA	U-391
I-343	USE OF COREG FOR SEVERE HEART FAILURE	U-392
I-344	ACNE VULGARIS	U-393
MISCELLANEOUS EXCLUSIVITY CODES		
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN	U-394 U-395 U-396
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION	U-397 U-398 U-399
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING	U-400
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY	U-401
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING	U-402
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER	U-403
M-12	NEW LANGUAGE FOR PEDIATRIC USE	U-404 U-405 U-406 U-407 U-408
PATENT USE CODES		
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE	U-409 U-410
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...	U-411
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE	U-412 U-413
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX	U-414
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C	U-415
U-376	TREATMENT OF INFLUENZA	U-416
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS	U-417
U-378	METHOD FOR TREATING INCONTINENCE	U-418
U-379	METHOD OF TREATINGONYCHROMYCOSIS	U-419
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS	U-420
U-381	TREATMENT OF HYPERPHOSPHATEMIA	
U-382	METHOD OF STABILIZING PROSTAGLANDIN	
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION	

PATENT AND EXCLUSIVITY TERMS

REFERENCES PATENT USE CODES

- U-384 TREATMENT OF CMV RETINITIS
- U-385 TREATMENT OF PEPTIC ULCERS
- U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
- U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
- U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
- U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER
ABOUT 16 HOURS
- U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE
SCLEROSIS)
- U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE
CANCER
- U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
- U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF
INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH
PT
- U-394 METHOD OF USE OF ALPHAGAN
- U-395 METHOD OF USE OF ALPHAGAN P
- U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
- U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
- U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
- U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
- U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE
RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION
TO TREAT INFECTIONS AND INFESTATIONS
- U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV
INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
- U-402 TREATMENT OF ACTINIC KERATOSES
- U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
- U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
- U-405 METHOD OF USE OF LOTRONEX
- U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
- U-407 METHOD OF TREATING OTOPATHY
- U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR
ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
- U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
- U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A
DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA
(INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC
PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH
INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
- U-412 TREATMENT OF TYPE 2 DIABETES
- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND
TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN
SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC
PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE)
IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC
PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE)
IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL
COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION
WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN
SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES

PATENT AND EXCLUSIVITY TERMS

REFERENCES PATENT USE CODES

- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code

* 8392

**Charge your order.
It's easy!**



A

Yes, enter my subscription as follows:

Subscriptions of APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP, and the monthly Cumulative Supplements, for \$105.00 per year.

The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

Do not make my name available to other mailers.

Please choose method of payment:

Check payable to Superintendent of Documents
 GPO Deposit Account -

VISA or MasterCard

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(_____) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90038 2702

RM301.45 .A66 2001 Sept. suppl.

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY

ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, 63110

